Adrian Felipe Hernandez

Journal Article Am Heart J · January 2025 BACKGROUND: Although guidelines recommend low-density lipoprotein cholesterol (LDL-C) to be < 70 mg/dL in patients with atherosclerotic cardiovascular disease (ASCVD), the rate of achieving this goal remains suboptimal. We sought to understand real world c ... Full text Link to item Cite

Evaluating anchor variables and variation in meaningful score differences for PROMIS® Pediatric measures in children and adolescents living with a rheumatic disease.

Journal Article Qual Life Res · December 2024 PURPOSE: Meaningful score differences (MSDs), as defined by recent FDA guidance, can improve the interpretation of outcome measure scores and score changes. Well-accepted methods for estimating MSDs typically rely on external anchor variables, but the appl ... Full text Link to item Cite

Lipoprotein (a) Testing in Patients With Atherosclerotic Cardiovascular Disease in 5 Large US Health Systems.

Journal Article J Am Heart Assoc · November 5, 2024 BACKGROUND: Lipoprotein (a) is an independent risk factor for atherosclerotic cardiovascular disease. However, lipoprotein (a) testing remains variable and it is unclear what factors influence testing and if testing changes clinical management. METHODS AND ... Full text Link to item Cite

Remote Follow-up in a Heart Failure Pragmatic Trial: Insights From the CONNECT-HF.

Journal Article J Card Fail · November 2024 BACKGROUND: Randomized controlled trials typically require study-specific visits, which can burden participants and sites. Remote follow-up, such as centralized call centers for participant-reported or site-reported, holds promise for reducing costs and en ... Full text Link to item Cite

Optimal Medical Therapy and Outcomes Among Patients With Chronic Heart Failure With Reduced Ejection Fraction.

Journal Article JACC Heart Fail · November 2024 BACKGROUND: Optimal medical therapy (OMT) scoring may stratify clinical risk in real-world chronic heart failure with reduced ejection fraction (HFrEF) by integrating use and dosing of guideline-directed medical therapy (GDMT) for HFrEF. OBJECTIVES: The pu ... Full text Link to item Cite

Accelerating evidence generation: Addressing critical challenges and charting a path forward

Journal Article Journal of Clinical and Translational Science · October 31, 2024 Efficient evidence generation to assess the clinical and economic impact of medical therapies is critical amid rising healthcare costs and aging populations. However, drug development and clinical trials remain far too expensive and inefficient for all sta ... Full text Cite

Implications of trial eligibility in patients with heart failure with mildly reduced or preserved ejection fraction.

Journal Article ESC heart failure · October 2024 AimsClinical trials in heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) commonly have detailed eligibility criteria. This may contribute to challenges with efficient enrolment and questions regarding the generalizabi ... Full text Cite

Time to Sustained Recovery Among Outpatients With COVID-19 Receiving Montelukast vs Placebo: The ACTIV-6 Randomized Clinical Trial.

Journal Article JAMA Netw Open · October 1, 2024 IMPORTANCE: The effect of montelukast in reducing symptom duration among outpatients with mild to moderate COVID-19 is uncertain. OBJECTIVE: To assess the effectiveness of montelukast compared with placebo in treating outpatients with mild to moderate COVI ... Full text Link to item Cite

In-hospital course of patients with heart failure with improved ejection fraction in the DELIVER trial.

Journal Article Eur J Heart Fail · September 19, 2024 AIMS: Patients with heart failure (HF) with improved ejection fraction (HFimpEF) may face residual risks of clinical events that are comparable to those experienced by patients with HF whose left ventricular ejection fraction (LVEF) has consistently been a ... Full text Link to item Cite

Overcoming the barriers to better evidence generation from clinical trials.

Journal Article Trials · September 16, 2024 Clinical evidence generation from and for representative populations can be improved through increased research access and ease of trial participation. To improve access and participation, a modern trial infrastructure is needed that broadens research into ... Full text Link to item Cite

Comparing Analytical Methods for Composite End Points in Clinical Trials: Insights from the Vericiguat Global Study in Subjects with Heart Failure With Reduced Ejection Fraction Trial.

Journal Article J Card Fail · September 7, 2024 BACKGROUND: In VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction), participants with heart failure (HF) and reduced ejection fraction, vericiguat decreased the primary composite outcome (time to first HF hospit ... Full text Link to item Cite

Early Beta-Blocker Utilization in Critically Ill Patients With Moderate-Severe Traumatic Brain Injury: A Retrospective Cohort Study.

Journal Article J Intensive Care Med · September 2024 BACKGROUND: There is limited evidence that beta-blockers may provide benefit for patients with moderate-severe traumatic brain injury (TBI) during the acute injury period. Larger studies on utilization patterns and impact on outcomes in clinical practice a ... Full text Link to item Cite

Dapagliflozin and Timing of Prior Heart Failure Hospitalization: A Patient-Level Meta-Analysis of DAPA-HF and DELIVER.

Journal Article JACC Heart Fail · September 2024 BACKGROUND: Patients recently hospitalized for heart failure (HF) are at a higher risk of adverse clinical outcomes, but they may experience a greater absolute and relative benefit from effective therapies than individuals who are considered more "stable." ... Full text Link to item Cite

Framework of the strengths and challenges of clinically integrated trials: An expert panel report.

Journal Article Am Heart J · September 2024 The limitations of the explanatory clinical trial framework include the high expense of implementing explanatory trials, restrictive entry criteria for participants, and redundant logistical processes. These limitations can result in slow evidence generati ... Full text Link to item Cite

Characterization of peripheral artery disease and associations with traditional risk factors, mobility, and biomarkers in the project baseline health study.

Journal Article Am Heart J · September 2024 BACKGROUND: There is a dearth of research on immunophenotyping in peripheral artery disease (PAD). This study aimed to describe the baseline characteristics, immunophenotypic profile, and quality of life (QoL) of participants with PAD in the Project Baseli ... Full text Link to item Cite

Effects of dapagliflozin according to QRS duration across the spectrum of left ventricular ejection fraction: An analysis of DAPA-HF and DELIVER.

Journal Article Eur J Heart Fail · September 2024 AIMS: The primary aim was to evaluate the effect of dapagliflozin according to QRS duration across the spectrum of left ventricular ejection fraction (LVEF), given that prolongation of QRS duration is associated with less favourable ventricular remodelling ... Full text Link to item Cite

Association of Medication Adherence and Health Status in Heart Failure With Reduced Ejection Fraction: Insights From the CHAMP-HF Registry.

Journal Article Circ Cardiovasc Qual Outcomes · September 2024 BACKGROUND: The foundation for managing heart failure with reduced ejection fraction (HFrEF) is adherence to guideline-directed medical therapy. Finding an association between medication adherence and patients' health status (their symptoms, function, and ... Full text Link to item Cite

Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Male and Female Patients: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial.

Journal Article JAMA Cardiol · September 1, 2024 IMPORTANCE: Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of morbidity and mortality in the US. Although aspirin is recommended for secondary prevention of ASCVD, there was no difference in safety and effectiveness of aspirin dos ... Full text Link to item Cite

Contribution of Clinical Trial Event Data by Data Source: A Prespecified Analysis of the ADAPTABLE Randomized Clinical Trial.

Journal Article JAMA Cardiol · September 1, 2024 IMPORTANCE: Pragmatic randomized clinical trials (RCTs) often use multiple data sources to examine clinical events, but the relative contribution of data sources to clinical end-point rates is understudied. OBJECTIVE: To assess the contribution of data sou ... Full text Link to item Cite

Impact of aspirin dose according to race in secondary prevention of atherosclerotic cardiovascular disease: a secondary analysis of the ADAPTABLE randomised controlled trial.

Journal Article BMJ Open · August 7, 2024 OBJECTIVES: To evaluate whether the effectiveness and safety of low (81 mg daily) versus high-dose (325 mg daily) aspirin is consistent across races among patients with established atherosclerotic cardiovascular disease (ASCVD). DESIGN: A secondary analysi ... Full text Link to item Cite

Association of Early Dexmedetomidine Utilization With Clinical Outcomes After Moderate-Severe Traumatic Brain Injury: A Retrospective Cohort Study.

Journal Article Anesth Analg · August 1, 2024 BACKGROUND: Traumatic brain injury (TBI) is an expensive and common public health problem. Management of TBI oftentimes includes sedation to facilitate mechanical ventilation (MV) for airway protection. Dexmedetomidine has emerged as a potential candidate ... Full text Link to item Cite

Association of early dexmedetomidine exposure with brain injury biomarker levels following moderate - Severe traumatic brain injury: A TRACK-TBI study.

Journal Article J Clin Neurosci · August 2024 BACKGROUND: Traumatic brain injury (TBI) triggers autonomic dysfunction and inflammatory response that can result in secondary brain injuries. Dexmedetomidine is an alpha-2 agonist that may modulate autonomic function and inflammation and has been increasi ... Full text Link to item Cite

Interleukin-6 and Cardiovascular Events in Healthy Adults: MESA.

Journal Article JACC Adv · August 2024 BACKGROUND: Elevated interleukin (IL)-6 levels have been linked to adverse outcomes in patients with and without baseline cardiovascular disease (CVD). OBJECTIVES: The purpose of this study was to examine the association between circulating IL-6 levels and ... Full text Link to item Cite

Forecasting the Burden of Cardiovascular Disease and Stroke in the United States Through 2050-Prevalence of Risk Factors and Disease: A Presidential Advisory From the American Heart Association.

Journal Article Circulation · July 23, 2024 BACKGROUND: Cardiovascular disease and stroke are common and costly, and their prevalence is rising. Forecasts on the prevalence of risk factors and clinical events are crucial. METHODS: Using the 2015 to March 2020 National Health and Nutrition Examinatio ... Full text Link to item Cite

Effects of albiglutide on myocardial infarction and ischaemic heart disease outcomes in patients with type 2 diabetes and cardiovascular disease in the Harmony Outcomes trial.

Journal Article Eur Heart J Cardiovasc Pharmacother · July 16, 2024 AIMS: Large outcome trials have demonstrated cardiovascular benefits of selected glucagon-like peptide-1 (GLP-1) receptor agonists. We examined coronary disease outcomes in the Harmony Outcomes trial of the GLP-1 receptor agonist albiglutide. METHODS AND R ... Full text Link to item Cite

Dapagliflozin and quality of life measured using the EuroQol 5-dimension questionnaire in patients with heart failure with reduced and mildly reduced/preserved ejection fraction.

Journal Article Eur J Heart Fail · July 2024 AIMS: Although much is known about the usefulness of heart failure (HF)-specific instruments for assessing patient well-being, less is known about the value of generic instruments for the measurement of health-related quality of life (HRQL) in HF. The aim ... Full text Link to item Cite

Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose-lowering therapy: A pre-specified analysis of the DELIVER trial.

Journal Article European journal of heart failure · July 2024 AimsType 2 diabetes (T2D) and heart failure (HF) frequently coexist, but whether clinical outcomes and treatment effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) vary in relation to background glucose-lowering therapy (GLT) in this po ... Full text Cite

Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis.

Journal Article The lancet. Diabetes & endocrinology · July 2024 BackgroundSodium-glucose co-transporter-2 (SGLT2) inhibitors have been studied in patients with heart failure, type 2 diabetes, chronic kidney disease, atherosclerotic cardiovascular disease, and acute myocardial infarction. Individual trials were ... Full text Cite

Advancing Transthyretin Amyloidosis Drug Development in an Evolving Treatment Landscape: Amyloidosis Forum Meeting Proceedings.

Journal Article Adv Ther · July 2024 INTRODUCTION: Hereditary transthyretin amyloidosis (ATTRv, also referred to as hATTR; ORPHA 271861) and wild-type ATTR amyloidosis (ATTRwt; ORPHA 330001) are rare, progressive, systemic protein misfolding disorders with heterogeneous clinical presentations ... Full text Link to item Cite

Characterization of serum phosphate levels over time with intravenous ferric carboxymaltose versus placebo as treatment for heart failure with reduced ejection fraction and iron deficiency: An exploratory prospective substudy from HEART-FID.

Journal Article Eur J Heart Fail · June 19, 2024 AIMS: Ferric carboxymaltose (FCM) is guideline-recommended for iron deficiency (ID) in heart failure with reduced ejection fraction (HFrEF). Despite a well-established safety profile, the magnitude and clinical significance of FCM-induced hypophosphataemia ... Full text Link to item Cite

Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction.

Journal Article J Am Coll Cardiol · June 11, 2024 BACKGROUND: Empagliflozin reduces the risk of heart failure (HF) hospitalizations but not all-cause mortality when started within 14 days of acute myocardial infarction (AMI). OBJECTIVES: This study sought to evaluate the association of left ventricular ej ... Full text Link to item Cite

Sex Differences in Heart Failure With Improved Ejection Fraction: The DELIVER Trial.

Journal Article JACC Heart Fail · June 2024 Full text Link to item Cite

Effects of Sacubitril/Valsartan vs Valsartan in De Novo vs Acute on Chronic HFpEF and HFmrEF.

Journal Article JACC Adv · June 2024 BACKGROUND: Decompensated heart failure (HF) can be categorized as de novo or worsening of chronic HF. In PARAGLIDE-HF (Prospective comparison of ARNI with ARB Given following stabiLization In DEcompensated HFpEF), among patients with an ejection fraction ... Full text Link to item Cite

Everything, Everywhere All at Once: Evidence Generation and Implementation in the Digital Age.

Journal Article Circ Cardiovasc Qual Outcomes · June 2024 Full text Link to item Cite

Association of Sacubitril/Valsartan vs Valsartan With Blood Pressure Changes and Symptomatic Hypotension: the PARAGLIDE-HF Trial.

Journal Article J Card Fail · May 26, 2024 BACKGROUND: In PARAGLIDE-HF, in patients with ejection fraction (EF) > 40%, stabilized after worsening heart failure (WHF), sacubitril/valsartan led to greater reduction in plasma NT-proBNP levels and was associated with clinical benefit compared to valsar ... Full text Link to item Cite

Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial.

Journal Article Circulation · May 21, 2024 BACKGROUND: Empagliflozin reduces the risk of heart failure (HF) events in patients with type 2 diabetes at high cardiovascular risk, chronic kidney disease, or prevalent HF irrespective of ejection fraction. Whereas the EMPACT-MI trial (Effect of Empaglif ... Full text Link to item Cite

Winning or Losing Trials: Making Better Days Matter.

Journal Article J Am Coll Cardiol · May 21, 2024 Full text Link to item Cite

Effect of albiglutide on cardiovascular outcomes in older adults: A post hoc analysis of a randomized controlled trial.

Journal Article Diabetes Obes Metab · May 2024 AIM: To analyse the effects of albiglutide, a glucagon-like peptide 1 receptor agonist, on cardiovascular outcomes in older adults aged ≥65 years with type 2 diabetes and cardiovascular disease who participated in the Harmony Outcomes trial (NCT02465515). ... Full text Link to item Cite

Recurrent Hospitalizations and Response to Vericiguat in Heart Failure and Reduced Ejection Fraction.

Journal Article JACC Heart Fail · May 2024 BACKGROUND: In VICTORIA (Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction), vericiguat compared with placebo reduced cardiovascular death or heart failure (HF) hospitalization in patients with HF with reduced ejection f ... Full text Link to item Cite

Regional variation in cause of death in patients with type 2 diabetes: Insights from EXSCEL.

Journal Article Am Heart J · May 2024 AIMS: Type 2 diabetes (T2D) is a risk factor for cardiovascular and non-cardiovascular mortality. However, global distribution of cause-specific deaths in T2D is poorly understood. We characterized cause-specific deaths by geographic region among individua ... Full text Link to item Cite

Prognostic Models for Mortality and Morbidity in Heart Failure With Preserved Ejection Fraction.

Journal Article JAMA Cardiol · May 1, 2024 IMPORTANCE: Accurate risk prediction of morbidity and mortality in patients with heart failure with preserved ejection fraction (HFpEF) may help clinicians risk stratify and inform care decisions. OBJECTIVE: To develop and validate a novel prediction model ... Full text Link to item Cite

Empagliflozin after Acute Myocardial Infarction.

Journal Article N Engl J Med · April 25, 2024 BACKGROUND: Empagliflozin improves cardiovascular outcomes in patients with heart failure, patients with type 2 diabetes who are at high cardiovascular risk, and patients with chronic kidney disease. The safety and efficacy of empagliflozin in patients who ... Full text Link to item Cite

Contemporary Use and Implications of Beta-Blockers in Patients With HFmrEF or HFpEF: The DELIVER Trial.

Journal Article JACC Heart Fail · April 2024 BACKGROUND: Although beta-blockers are not recommended for the treatment of heart failure with preserved ejection fraction (HFpEF) according to the latest European Society of Cardiology and American Heart Association/American College of Cardiology/Heart Fa ... Full text Link to item Cite

Association of Early Dexmedetomidine Utilization With Clinical and Functional Outcomes Following Moderate-Severe Traumatic Brain Injury: A Transforming Clinical Research and Knowledge in Traumatic Brain Injury Study.

Journal Article Crit Care Med · April 1, 2024 OBJECTIVE: To examine early sedation patterns, as well as the association of dexmedetomidine exposure, with clinical and functional outcomes among mechanically ventilated patients with moderate-severe traumatic brain injury (msTBI). DESIGN: Retrospective c ... Full text Link to item Cite

Drug development for major chronic health conditions-aligning with growing public health needs: Proceedings from a multistakeholder think tank.

Journal Article Am Heart J · April 2024 The global pharmaceutical industry portfolio is skewed towards cancer and rare diseases due to more predictable development pathways and financial incentives. In contrast, drug development for major chronic health conditions that are responsible for a larg ... Full text Link to item Cite

Dapagliflozin in patients with heart failure and previous myocardial infarction: A participant-level pooled analysis of DAPA-HF and DELIVER.

Journal Article Eur J Heart Fail · April 2024 AIMS: Patients with heart failure (HF) and history of myocardial infarction (MI) face a higher risk of disease progression and clinical events. Whether sodium-glucose cotransporter 2 inhibitors may modify clinical trajectory in such individuals remains inc ... Full text Link to item Cite

Sacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure.

Journal Article J Am Coll Cardiol · March 26, 2024 BACKGROUND: The efficacy and safety of sacubitril/valsartan in patients hospitalized with heart failure (HF) across the spectrum of left ventricular ejection fraction (EF) has not been described. OBJECTIVES: Data from randomized trials of sacubitril/valsar ... Full text Link to item Cite

Cost Effectiveness of Dapagliflozin for Heart Failure Across the Spectrum of Ejection Fraction: An Economic Evaluation Based on Pooled, Individual Participant Data From the DELIVER and DAPA-HF Trials.

Journal Article J Am Heart Assoc · March 5, 2024 BACKGROUND: The sodium glucose cotransporter-2 inhibitors are guideline-recommended to treat heart failure across the spectrum of left ventricular ejection fraction; however, economic evaluations of adding sodium glucose cotransporter-2 inhibitors to stand ... Full text Link to item Cite

Heart Failure, Investigator-Reported Sleep Apnea and Dapagliflozin: A Patient-Level Pooled Meta-Analysis of DAPA-HF and DELIVER.

Journal Article J Card Fail · March 2024 BACKGROUND: Sleep apnea is more common in patients with heart failure (HF) than in the general population, but little is known about its association with clinical outcomes in various HF phenotypes or how it might modify the effect of HF therapy. OBJECTIVES ... Full text Link to item Cite

Identifying a stable and generalizable factor structure of major depressive disorder across three large longitudinal cohorts.

Journal Article Psychiatry Res · March 2024 The Patient Health Questionnaire 9 (PHQ-9) is the current standard outpatient screening tool for measuring and tracking the nine symptoms of major depressive disorder (MDD). While the PHQ-9 was originally conceptualized as a unidimensional measure, it has ... Full text Link to item Cite

Dapagliflozin and Mode of Death in Heart Failure With Improved Ejection Fraction: A Post Hoc Analysis of the DELIVER Trial.

Journal Article JAMA Cardiol · March 1, 2024 IMPORTANCE: Heart failure with improved ejection fraction (HFimpEF), defined as prior left ventricular ejection fraction (LVEF) 40% or lower that has increased to greater than 40%, is understudied. OBJECTIVE: To examine mode of death and the association of ... Full text Link to item Cite

Iron replacement therapy in heart failure: Contextualizing the results of the HEART-FID trial.

Journal Article Eur J Heart Fail · March 2024 Full text Link to item Cite

Age and Aspirin Dosing in Secondary Prevention of Atherosclerotic Cardiovascular Disease.

Journal Article J Am Heart Assoc · February 20, 2024 BACKGROUND: In patients with atherosclerotic cardiovascular disease, increasing age is concurrently associated with higher risks of ischemic and bleeding events. The objectives are to determine the impact of aspirin dose on clinical outcomes according to a ... Full text Link to item Cite

Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial.

Journal Article JAMA Cardiol · February 1, 2024 IMPORTANCE: An initial decline in estimated glomerular filtration rate (eGFR) is expected after initiating a sodium-glucose cotransporter-2 inhibitor (SGLT2i) and has been observed across patients with diabetes, chronic kidney disease, and heart failure. O ... Full text Link to item Cite

Access to Mobile Health Interventions Among Patients Hospitalized With Heart Failure: Insights Into the Digital Divide From the CONNECT-HF mHealth Substudy.

Journal Article Circ Heart Fail · February 2024 Full text Link to item Cite

Hierarchical End Points in Prior Heart Failure Trials and the HEART-FID Trial.

Journal Article Circ Heart Fail · February 2024 BACKGROUND: Clinical trials in heart failure (HF) traditionally use time-to-event analyses focusing on death and hospitalization for HF. These time-to-first event analyses may have more limited abilities to assess the probability of benefiting from a thera ... Full text Link to item Cite

Effects of Dapagliflozin in Patients in Asia: A Post Hoc Subgroup Analysis From the DELIVER Trial.

Journal Article JACC Asia · February 2024 BACKGROUND: Patients with heart failure (HF) with mildly reduced or preserved ejection fraction in Asia may have different clinical characteristics and outcomes compared with patients from other parts of the world. OBJECTIVES: The purpose of this study was ... Full text Link to item Cite

Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease and Diabetes Mellitus: A Subgroup Analysis of the ADAPTABLE Trial.

Journal Article Diabetes Care · January 1, 2024 OBJECTIVE: Patients with diabetes mellitus (DM) and concomitant atherosclerotic cardiovascular disease (ASCVD) must be on the most effective dose of aspirin to mitigate risk of future adverse cardiovascular events. RESEARCH DESIGN AND METHODS: ADAPTABLE, a ... Full text Link to item Cite

Clinical trial site readiness for decentralized trials - fitting trials into today's world.

Journal Article J Clin Transl Sci · 2024 Full text Link to item Cite

Lipoprotein(a) testing in Patients with Atherosclerotic Cardiovascular Disease in Five Large U.S. Health Systems

Preprint · 2024 Full text Cite

Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19: The ACTIV-6 Randomized Clinical Trial.

Journal Article JAMA · December 26, 2023 IMPORTANCE: The effect of higher-dose fluvoxamine in reducing symptom duration among outpatients with mild to moderate COVID-19 remains uncertain. OBJECTIVE: To assess the effectiveness of fluvoxamine, 100 mg twice daily, compared with placebo, for treatin ... Full text Link to item Cite

Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis.

Journal Article Eur Heart J · December 21, 2023 BACKGROUND AND AIMS: Whereas a beneficial effect of intravenous ferric carboxymaltose (FCM) on symptoms and exercise capacity among patients with iron deficiency and heart failure (HF) has been consistently demonstrated, the effects of treatment on clinica ... Full text Link to item Cite

Lessons From COVID-19 for Pandemic Preparedness: Proceedings From a Multistakeholder Think Tank.

Journal Article Clin Infect Dis · December 15, 2023 While the coronavirus disease 2019 (COVID-19) pandemic continues to present global challenges, sufficient time has passed to reflect on lessons learned and use those insights to inform policy and approaches to prepare for the next pandemic. In May 2022, th ... Full text Link to item Cite

Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial.

Journal Article Circulation · December 12, 2023 BACKGROUND: Apparent treatment-resistant hypertension (aTRH) is prevalent and associated with adverse outcomes in heart failure with mildly reduced or preserved ejection fraction. Less is known about the potential role of sodium-glucose co-transporter 2 in ... Full text Link to item Cite

The Future of Clinical Trials: Artificial to Augmented to Applied Intelligence.

Journal Article JAMA · December 5, 2023 Full text Link to item Cite

Author Correction: Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial.

Journal Article Nat Med · December 2023 Full text Link to item Cite

Morbidity and Mortality Associated With Heart Failure in Acute Coronary Syndrome: A Pooled Analysis of 4 Clinical Trials.

Journal Article J Card Fail · December 2023 BACKGROUND: Heart failure (HF) may complicate acute coronary syndrome (ACS) and is associated with a high burden of short- and long-term morbidity and mortality. Only limited data regarding future ischemic events and rehospitalization are available for pat ... Full text Link to item Cite

Baseline characteristics of patients in the randomized study to investigate the efficacy and safety of ferric carboxymaltose as treatment for heart failure with iron deficiency: HEART-FID trial.

Journal Article Am Heart J · December 2023 BACKGROUND: Prior clinical trials have investigated intravenous iron in patients with heart failure (HF) and iron deficiency, but the safety and efficacy of this therapy remains unclear. METHODS: We report the baseline demographics and clinical characteris ... Full text Link to item Cite

Impact of COVID-19 in patients with heart failure with mildly reduced or preserved ejection fraction enrolled in the DELIVER trial.

Journal Article Eur J Heart Fail · December 2023 AIM: COVID-19 may affect clinical risk in patients with heart failure. DELIVER began before and was conducted during the COVID-19 pandemic. This study aimed to evaluate the association between COVID-19 and clinical outcomes among DELIVER participants. METH ... Full text Link to item Cite

Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER.

Journal Article Circ Heart Fail · December 2023 BACKGROUND: Although elevated resting heart rate (HR) is associated with a higher risk of cardiovascular events in patients with heart failure with reduced ejection fraction in sinus rhythm (SR), the relationship between HR and outcomes among patients with ... Full text Link to item Cite

Proactive Algorithm Monitoring to Ensure Health Equity.

Journal Article JAMA Netw Open · December 1, 2023 Full text Link to item Cite

Ferric Carboxymaltose in Heart Failure with Iron Deficiency. Reply.

Journal Article N Engl J Med · November 30, 2023 Full text Link to item Cite

Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial.

Journal Article Circulation · November 28, 2023 BACKGROUND: Hospitalization is recognized as a sentinel event in the disease trajectory of patients with heart failure (HF), but not all patients experiencing clinical decompensation are ultimately hospitalized. Outpatient intensification of diuretics is c ... Full text Link to item Cite

Dapagliflozin in Patients With Heart Failure and Deterioration in Renal Function.

Journal Article J Am Coll Cardiol · November 7, 2023 BACKGROUND: Sodium-glucose cotransporter-2 (SGLT2) inhibitors are guideline recommended in the management of heart failure (HF). Although these therapies can be initiated even in patients with comorbid chronic kidney disease, some patients may face deterio ... Full text Link to item Cite

Clinical and Echocardiographic Diversity Associated With Physical Fitness in the Project Baseline Health Study: Implications for Heart Failure Staging.

Journal Article J Card Fail · November 2023 BACKGROUND: Clinical and echocardiographic features may carry diverse information about the development of heart failure (HF). Therefore, we determined heterogeneity in clinical and echocardiographic phenotypes and its association with exercise capacity. M ... Full text Link to item Cite

Cardio-Renal-Metabolic Overlap, Outcomes, and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction.

Journal Article JACC Heart Fail · November 2023 BACKGROUND: Cardio-renal-metabolic (CRM) conditions are individually common among patients with heart failure (HF), but the prevalence and influence of overlapping CRM conditions in this population have not been well-studied. OBJECTIVES: This study aims to ... Full text Link to item Cite

2022 ACC/AHA guideline for the diagnosis and management of aortic disease: A report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.

Journal Article J Thorac Cardiovasc Surg · November 2023 AIM: The "2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease" provides recommendations to guide clinicians in the diagnosis, genetic evaluation and family screening, medical therapy, endovascular and surgical treatment, and long-term ... Full text Link to item Cite

Effectiveness and Safety of Enteric-Coated vs Uncoated Aspirin in Patients With Cardiovascular Disease: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial.

Journal Article JAMA Cardiol · November 1, 2023 IMPORTANCE: Clinicians recommend enteric-coated aspirin to decrease gastrointestinal bleeding in secondary prevention of coronary artery disease even though studies suggest platelet inhibition is decreased with enteric-coated vs uncoated aspirin formulatio ... Full text Link to item Cite

Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Patients Treated With P2Y12 Inhibitors.

Journal Article J Am Heart Assoc · October 17, 2023 Background The ADAPTABLE (Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness) was a large, pragmatic, randomized controlled trial that found no difference between high- versus low-dose aspirin for secondary prevention of ... Full text Link to item Cite

Cost-Effectiveness of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: The VICTORIA Randomized Clinical Trial.

Conference Circulation · October 3, 2023 BACKGROUND: The VICTORIA trial (Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction) demonstrated that, in patients with high-risk heart failure, vericiguat reduced the primary composite outcome of cardiovascular death or ... Full text Link to item Cite

Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Polypharmacy Status.

Journal Article JACC Heart Fail · October 2023 BACKGROUND: Patients with heart failure (HF) have a high burden of multimorbidity, often necessitating numerous medications. There may be clinical concern about introducing another medication, especially among individuals with polypharmacy. OBJECTIVES: Thi ... Full text Link to item Cite

Comparison of the effectiveness and safety of 2 aspirin doses in secondary prevention of cardiovascular outcomes in patients with chronic kidney disease: A subgroup analysis of ADAPTABLE.

Journal Article Am Heart J · October 2023 BACKGROUND: Among patients with established cardiovascular disease, the ADAPTABLE trial found no significant differences in cardiovascular events and bleeding rates between 81 mg and 325 mg of aspirin (ASA) daily. In this secondary analysis from the ADAPTA ... Full text Link to item Cite

Inhaled Fluticasone Furoate for Outpatient Treatment of Covid-19.

Journal Article N Engl J Med · September 21, 2023 BACKGROUND: The effectiveness of inhaled glucocorticoids in shortening the time to symptom resolution or preventing hospitalization or death among outpatients with mild-to-moderate coronavirus disease 2019 (Covid-19) is unclear. METHODS: We conducted a dec ... Full text Link to item Cite

Ferric Carboxymaltose in Heart Failure with Iron Deficiency.

Journal Article N Engl J Med · September 14, 2023 BACKGROUND: Ferric carboxymaltose therapy reduces symptoms and improves quality of life in patients who have heart failure with a reduced ejection fraction and iron deficiency. Additional evidence about the effects of ferric carboxymaltose on clinical even ... Full text Link to item Cite

Mitochondrial metabolites predict adverse cardiovascular events in individuals with diabetes.

Journal Article JCI Insight · September 8, 2023 Metabolic mechanisms underlying the heterogeneity of major adverse cardiovascular (CV) event (MACE) risk in individuals with type 2 diabetes mellitus (T2D) remain unclear. We hypothesized that circulating metabolites reflecting mitochondrial dysfunction pr ... Full text Link to item Cite

Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart Failure.

Journal Article J Am Coll Cardiol · September 5, 2023 BACKGROUND: Because clinical characteristics and prognosis vary by geographic region in patients with heart failure (HF), the response to treatment may also vary. A previous report suggested that the efficacy of sodium-glucose cotransporter-2 inhibitor eff ... Full text Link to item Cite

Operational challenges and mitigation measures during the COVID-19 pandemic-Lessons from DELIVER.

Journal Article Am Heart J · September 2023 BACKGROUND: Catastrophic disruptions in care delivery threaten the operational efficiency and potentially the validity of clinical research efforts, in particular randomized clinical trials. Most recently, the COVID-19 pandemic affected essentially all asp ... Full text Link to item Cite

Background Medical Therapy and Clinical Outcomes From the VICTORIA Trial.

Journal Article Circ Heart Fail · September 2023 BACKGROUND: We examined whether the primary composite outcome (cardiovascular death or heart failure hospitalization) was related to differences in background use and dosing of guideline-directed medical therapy in patients with heart failure with reduced ... Full text Link to item Cite

"Click and mortar" opportunities for digitization and consumerism in trials.

Journal Article Contemp Clin Trials · September 2023 BACKGROUND: Digitization (using novel digital tools and strategies) and consumerism (taking a consumer-oriented approach) are increasingly commonplace in clinical trials, but the implications of these changes are not well described. METHODS: We assembled a ... Full text Link to item Cite

Baseline characteristics of patients enrolled in the EMPACT-MI trial.

Journal Article Eur J Heart Fail · September 2023 AIMS: Empagliflozin has been shown to reduce the risk of adverse cardiovascular outcomes in patients with type 2 diabetes and in those with heart failure. The impact of empagliflozin in post-acute myocardial infarction (AMI) patients is unknown. METHODS AN ... Full text Link to item Cite

Influence of background medical therapy on efficacy and safety of dapagliflozin in patients with heart failure with improved ejection fraction in the DELIVER trial.

Journal Article Eur J Heart Fail · September 2023 AIMS: The Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure (DELIVER) trial demonstrated the sodium-glucose cotransporter 2 inhibitor dapagliflozin to be beneficial in patients with symptomatic heart f ... Full text Link to item Cite

Association of Early Beta-Blocker Exposure and Functional Outcomes in Critically Ill Patients With Moderate to Severe Traumatic Brain Injury: A Transforming Clinical Research and Knowledge in Traumatic Brain Injury Study.

Journal Article Crit Care Explor · September 2023 OBJECTIVES: We aimed to 1) describe patterns of beta-blocker utilization among critically ill patients following moderate-severe traumatic brain injury (TBI) and 2) examine the association of early beta-blocker exposure with functional and clinical outcome ... Full text Open Access Link to item Cite

Common Variants on FGD5 Increase Hazard of Mortality or Rehospitalization in Patients With Heart Failure From the ASCEND-HF Trial.

Journal Article Circ Heart Fail · September 2023 BACKGROUND: Heart failure remains a global health burden, and patients hospitalized are particularly at risk, but genetic associates for subsequent death or rehospitalization are still lacking. METHODS: The genetic substudy of the ASCEND-HF trial (Acute St ... Full text Link to item Cite

Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF.

Journal Article Eur Heart J · August 14, 2023 AIMS: The PARAGLIDE-HF trial demonstrated reductions in natriuretic peptides with sacubitril/valsartan compared with valsartan in patients with heart failure (HF) with mildly reduced or preserved ejection fraction who had a recent worsening HF event, but w ... Full text Link to item Cite

Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial.

Journal Article Eur Heart J · August 14, 2023 AIMS: Dapagliflozin reduced the combined risk of worsening heart failure or cardiovascular death among patients with heart failure with mildly reduced or preserved ejection fraction. In this study, the safety and efficacy of dapagliflozin according to back ... Full text Link to item Cite

GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes.

Journal Article J Am Coll Cardiol · August 8, 2023 BACKGROUND: Sodium-glucose cotransporter-2 (SGLT2) inhibitors and GLP-1 receptor agonists (GLP-1 RAs) reduce adverse cardiovascular outcomes in type 2 diabetes (T2D). However, the efficacy of combination therapy is unclear. OBJECTIVES: The aim of this stud ... Full text Link to item Cite

Effects of dapagliflozin on heart failure hospitalizations according to severity of inpatient course: Insights from DELIVER and DAPA-HF.

Journal Article Eur J Heart Fail · August 2023 AIMS: Dapagliflozin resulted in significant and sustained reductions in first and recurrent heart failure (HF) hospitalizations among patients with HF across the spectrum of ejection fraction. How treatment with dapagliflozin differentially impacts hospita ... Full text Link to item Cite

Classification of Heart Failure Events by Severity: Insights From the VICTORIA Trial.

Journal Article J Card Fail · August 2023 BACKGROUND: Hospitalization due to heart failure (HFH) is a major source of morbidity, consumes significant economic resources and is a key endpoint in HF clinical trials. HFH events vary in severity and implications, but they are typically considered equi ... Full text Link to item Cite

Opportunities and Achievement of Medication Initiation Among Inpatients With Heart Failure With Reduced Ejection Fraction.

Journal Article JACC Heart Fail · August 2023 BACKGROUND: Initiation of evidence-based medications for patients with heart failure with reduced ejection fraction (HFrEF) during hospitalization in contemporary practice is unknown. OBJECTIVES: This study characterized opportunities for and achievement o ... Full text Link to item Cite

Splanchnic Nerve Modulation Effects on Surrogate Measures of Venous Capacitance.

Journal Article J Am Heart Assoc · July 18, 2023 Background Splanchnic nerve modulation (SNM) is an emerging procedure to reduce cardiac filling pressures in heart failure. Although the main contributor to reduction in cardiac preload is thought to be increased venous capacitance in the splanchnic circul ... Full text Link to item Cite

Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure.

Journal Article J Am Coll Cardiol · July 4, 2023 BACKGROUND: U.S. guidelines recommend consideration of sacubitril/valsartan in chronic heart failure (HF) and mildly reduced or preserved ejection fraction (EF). Whether initiation is safe and effective in EF >40% after a worsening heart failure (WHF) even ... Full text Link to item Cite

Internet Versus Noninternet Participation in a Decentralized Clinical Trial: Lessons From the ADAPTABLE Study.

Journal Article J Am Heart Assoc · July 4, 2023 Background Internet-based participation has the potential to enhance pragmatic and decentralized trials, where representative study populations and generalizability to clinical practice are key. We aimed to study the differences between internet and nonint ... Full text Link to item Cite

Association of Brain Injury Biomarkers and Circulatory Shock Following Moderate-Severe Traumatic Brain Injury: A TRACK-TBI Study.

Journal Article J Neurosurg Anesthesiol · July 1, 2023 INTRODUCTION: Early circulatory shock following traumatic brain injury (TBI) is a multifactorial process; however, the impact of brain injury biomarkers on the risk of shock has not been evaluated. We examined the association between neuronal injury biomar ... Full text Open Access Link to item Cite

Renal and blood pressure effects of dapagliflozin in recently hospitalized patients with heart failure with mildly reduced or preserved ejection fraction: Insights from the DELIVER trial.

Journal Article European journal of heart failure · July 2023 AimsPatients recently hospitalized for heart failure (HF) often have unstable haemodynamics and experience worsening renal failure, and are at elevated risk for recurrent HF events. In DELIVER, dapagliflozin reduced HF events or cardiovascular dea ... Full text Cite

Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: Participant-level pooled analysis from the DAPA-HF and DELIVER trials.

Journal Article Eur J Heart Fail · July 2023 AIMS: Patients with heart failure experience a high burden of symptoms and physical limitations, and poor quality of life. Dapagliflozin reduces heart failure hospitalization and cardiovascular death in patients with reduced, mildly reduced, and preserved ... Full text Link to item Cite

Association of Dapagliflozin vs Placebo With Individual Kansas City Cardiomyopathy Questionnaire Components in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the DELIVER Trial.

Journal Article JAMA cardiology · July 2023 ImportanceDapagliflozin has been shown to improve overall health status based on aggregate summary scores of the Kansas City Cardiomyopathy Questionnaire (KCCQ) in patients with heart failure (HF) with mildly reduced or preserved ejection fraction ... Full text Cite

Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER.

Journal Article Eur Heart J · June 25, 2023 AIMS: Because an increased risk of amputation with canagliflozin was reported in the CANVAS trials, there has been a concern about the safety of sodium-glucose cotransporter 2 inhibitors in patients with peripheral artery disease (PAD) who are at higher ri ... Full text Link to item Cite

Recent Vitamin K Antagonist Use and Intracranial Hemorrhage After Endovascular Thrombectomy for Acute Ischemic Stroke.

Journal Article JAMA · June 20, 2023 IMPORTANCE: Use of oral vitamin K antagonists (VKAs) may place patients undergoing endovascular thrombectomy (EVT) for acute ischemic stroke caused by large vessel occlusion at increased risk of complications. OBJECTIVE: To determine the association betwee ... Full text Link to item Cite

Safety and efficacy of hydroxychloroquine as prophylactic against COVID-19 in healthcare workers: a meta-analysis of randomised clinical trials.

Journal Article BMJ Open · June 16, 2023 OBJECTIVE: We studied the safety and efficacy of hydroxychloroquine (HCQ) as pre-exposure prophylaxis for COVID-19 in healthcare workers (HCWs), using a meta-analysis of randomised controlled trials (RCTs). DATA SOURCES: PubMed and EMBASE databases were se ... Full text Link to item Cite

Rationale, Design and Baseline Characteristics of the PARAGLIDE-HF Trial: Sacubitril/Valsartan vs Valsartan in HFmrEF and HFpEF With a Worsening Heart Failure Event.

Journal Article J Card Fail · June 2023 BACKGROUND: The PARAGON-HF trial studied the effect of sacubitril/valsartan (Sac/Val) compared with valsartan (Val) on clinical outcomes in patients with chronic heart failure with preserved ejection fraction (HFpEF) or mildly reduced EF (HFmrEF). Further ... Full text Link to item Cite

Accelerated Epigenetic Aging Is Associated With Multiple Cardiometabolic, Hematologic, and Renal Abnormalities: A Project Baseline Health Substudy.

Journal Article Circ Genom Precis Med · June 2023 BACKGROUND: Epigenetic clocks estimate chronologic age using methylation levels at specific loci. We tested the hypothesis that accelerated epigenetic aging is associated with abnormal values in a range of clinical, imaging, and laboratory characteristics. ... Full text Link to item Cite

Pragmatic evaluation of events and benefits of lipid lowering in older adults (PREVENTABLE): Trial design and rationale.

Journal Article Journal of the American Geriatrics Society · June 2023 Whether initiation of statins could increase survival free of dementia and disability in adults aged ≥75 years is unknown. PREVENTABLE, a double-blind, placebo-controlled randomized pragmatic clinical trial, will compare high-intensity statin therapy (ator ... Full text Cite

Effect of Dapagliflozin on Total Heart Failure Events in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Trial.

Journal Article JAMA Cardiol · June 1, 2023 IMPORTANCE: In the Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure (DELIVER) trial, dapagliflozin reduced the risk of time to first worsening heart failure (HF) event or cardiovascular death in patie ... Full text Link to item Cite

Utilization and Outcomes of Extracorporeal Membrane Oxygenation Following Traumatic Brain Injury in the United States.

Journal Article J Intensive Care Med · May 2023 Objectives: Describe contemporary ECMO utilization patterns among patients with traumatic brain injury (TBI) and examine clinical outcomes among TBI patients requiring ECMO. Design: Retrospective cohort study. Setting: Premier Healthcare Database (PHD) bet ... Full text Link to item Cite

Omecamtiv Mecarbil: Decisional Dilemmas and Regulatory Science - Opportunities for Improvement?

Journal Article J Card Fail · May 2023 Full text Link to item Cite

Ejection Fraction, Biomarkers, and Outcomes and Impact of Vericiguat on Outcomes Across EF in VICTORIA.

Journal Article JACC Heart Fail · May 2023 BACKGROUND: Vericiguat reduced the risk of cardiovascular death (CVD) or hospitalization for heart failure (HF) in patients with worsening HF and reduced left ventricular ejection fraction (LVEF). OBJECTIVES: The authors assessed the association of LVEF wi ... Full text Link to item Cite

Splanchnic nerve block with botulinum toxin for therapy of chronic heart failure - mechanism of action (SPONGE-HF).

Conference Eur J Heart Fail · April 2023 Full text Link to item Cite

Hydroxychloroquine for pre-exposure prophylaxis of COVID-19 in health care workers: a randomized, multicenter, placebo-controlled trial Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine (HERO-HCQ).

Conference Int J Infect Dis · April 2023 OBJECTIVES: To determine whether hydroxychloroquine (HCQ) is safe and effective at preventing COVID-19 infections among health care workers (HCWs). METHODS: In a 1: 1 randomized, placebo-controlled, double-blind, parallel-group, superiority trial at 34 US ... Full text Link to item Cite

Assessment of Biomarkers of Myocardial injury, Inflammation, and Renal Function in Heart Failure With Reduced Ejection Fraction: The VICTORIA Biomarker Substudy.

Journal Article J Card Fail · April 2023 BACKGROUND: Circulating biomarkers may be useful in understanding prognosis and treatment efficacy in heart failure with reduced ejection fraction. In the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) tria ... Full text Link to item Cite

Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid-Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout: A Patient-Level Pooled Meta-analysis of DAPA-HF and DELIVER.

Journal Article JAMA Cardiol · April 1, 2023 IMPORTANCE: Gout is common in patients with heart failure (HF), and sodium-glucose cotransporter 2 inhibitors, a foundational treatment for HF, reduce uric acid levels. OBJECTIVE: To examine the reported prevalence of gout at baseline, the association betw ... Full text Link to item Cite

Medication-Attributable Adverse Events in Heart Failure Trials.

Journal Article JACC Heart Fail · April 2023 BACKGROUND: Initiation and up-titration of guideline-directed medical therapies (GDMTs) for heart failure with reduced ejection fraction (HFrEF) remains suboptimal, in part because of concerns regarding tolerability and adverse events (AEs). OBJECTIVES: Th ... Full text Link to item Cite

Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum.

Journal Article JACC Heart Fail · April 2023 BACKGROUND: Black people have a higher incidence and prevalence of heart failure (HF) than White people, and once HF has developed, they may have worse outcomes. There is also evidence that the response to several pharmacologic therapies may differ between ... Full text Link to item Cite

Patient Characteristics, Outcomes, and Effects of Dapagliflozin According to the Duration of Heart Failure: A Prespecified Analysis of the DELIVER Trial.

Journal Article Circulation · April 2023 BackgroundHow patient characteristics and outcomes vary according to the duration of heart failure (HF) is unknown in individuals with mildly reduced or preserved ejection fraction. We compared these, and the efficacy and safety of dapagliflozin, ... Full text Cite

Outcomes among patients with peripheral artery disease in the Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness (ADAPTABLE) study.

Journal Article Vasc Med · April 2023 BACKGROUND: We aimed to understand the effects of aspirin dose on outcomes in patients with peripheral artery disease (PAD) as well as their participation in a pragmatic randomized controlled trial. METHODS: In a subanalysis of the Aspirin Dosing: A Patien ... Full text Link to item Cite

Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19: A Randomized Clinical Trial.

Journal Article JAMA · March 21, 2023 IMPORTANCE: It is unknown whether ivermectin, with a maximum targeted dose of 600 μg/kg, shortens symptom duration or prevents hospitalization among outpatients with mild to moderate COVID-19. OBJECTIVE: To evaluate the effectiveness of ivermectin at a max ... Full text Link to item Cite

Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER.

Journal Article Circulation · February 21, 2023 BACKGROUND: Sodium-glucose cotransporter-2 inhibitors have emerged as a key pharmacotherapy in heart failure (HF) with both reduced and preserved ejection fraction. The benefit of other HF therapies may be modified by sex, but whether sex modifies the trea ... Full text Link to item Cite

Clinical Implications of Negatively Adjudicated Heart Failure Events: Data From the VICTORIA Study.

Journal Article Circulation · February 21, 2023 Full text Link to item Cite

Association of post-vaccination adverse reactions after influenza vaccine with mortality and cardiopulmonary outcomes in patients with high-risk cardiovascular disease: the INVESTED trial.

Journal Article Eur J Heart Fail · February 2023 AIMS: Influenza vaccination is associated with reduced cardiopulmonary morbidity and mortality among patients with heart failure or recent myocardial infarction. The immune response to vaccination frequently results in mild adverse reactions (AR), which le ... Full text Link to item Cite

Assessing Heuristic Bias During Care for Patients Hospitalized for Heart Failure: Get With The Guidelines-Heart Failure.

Journal Article Circ Heart Fail · February 2023 BACKGROUND: Heuristic biases are increasingly recognized, and potentially modifiable, contributors to patient care and outcomes. Left digit bias is a cognitive bias where continuous variables are categorized by their left-most digit. The impact of this heu ... Full text Link to item Cite

Effect of Dapagliflozin on Health Status in Patients With Preserved or Mildly Reduced Ejection Fraction.

Journal Article Journal of the American College of Cardiology · February 2023 BackgroundPatients with heart failure with mildly reduced ejection fraction (HFmrEF) and heart failure with preserved ejection fraction (HFpEF) experience a high burden of symptoms, physical limitations, and poor quality of life; improving health ... Full text Cite

External validation of the ADA score for predicting thrombosis among acutely ill hospitalized medical patients from the APEX Trial.

Journal Article J Thromb Thrombolysis · February 2023 The ADA (Age-D-dimer-Albumin) score was developed to identify hospitalized patients at an increased risk for thrombosis in the coronavirus infectious disease-19 (COVID-19) setting. The study aimed to validate the ADA score for predicting thrombosis in a no ... Full text Link to item Cite

Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial.

Journal Article JAMA · January 24, 2023 IMPORTANCE: The effectiveness of fluvoxamine to shorten symptom duration or prevent hospitalization among outpatients with mild to moderate symptomatic COVID-19 is unclear. OBJECTIVE: To evaluate the efficacy of low-dose fluvoxamine (50 mg twice daily) for ... Full text Link to item Cite

Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Randomized Clinical Trial.

Journal Article JAMA Cardiol · January 1, 2023 IMPORTANCE: Sodium-glucose cotransporter 2 inhibitors are known to reduce heart failure events and slow progression of kidney disease among patients with heart failure and a reduced ejection fraction. OBJECTIVE: To determine the effect of dapagliflozin on ... Full text Link to item Cite

Albuminuria and Heart Failure: JACC State-of-the-Art Review.

Journal Article Journal of the American College of Cardiology · January 2023 Although chronic kidney disease is characterized by low glomerular filtration rate (GFR) or albuminuria, estimated GFR (eGFR) is more widely utilized as a marker of risk profile in cardiovascular diseases, including heart failure (HF). The presence and mag ... Full text Cite

Early Vasopressor Utilization Strategies and Outcomes in Critically Ill Patients With Severe Traumatic Brain Injury.

Journal Article Anesth Analg · December 1, 2022 BACKGROUND: Early hypotension after severe traumatic brain injury (sTBI) is associated with increased mortality and poor long-term outcomes. Current guidelines suggest the use of intravenous vasopressors, commonly norepinephrine and phenylephrine, to suppo ... Full text Link to item Cite

Patient-reported and Clinical Outcomes Among Patients Hospitalized for Heart Failure With Reduced Versus Preserved Ejection Fraction.

Journal Article J Card Fail · December 2022 BACKGROUND: Differences between patients hospitalized for heart failure with reduced ejection fraction (HFrEF) vs HF with preserved EF (HFpEF) are not well-characterized, particularly as pertains to in-hospital decongestion and longitudinal patient-reporte ... Full text Link to item Cite

Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction.

Journal Article JACC Heart Fail · December 2022 BACKGROUND: N-terminal pro-B-type natriuretic peptide (NT-proBNP) is used for diagnostic and prognostic evaluation in heart failure (HF). Previous clinical trials in heart failure with mildly reduced ejection fraction (HFmrEF) or heart failure with preserv ... Full text Link to item Cite

Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial.

Journal Article JAMA Cardiol · December 1, 2022 IMPORTANCE: Dapagliflozin was recently shown to reduce cardiovascular death or worsening heart failure (HF) events in patients with HF with mildly reduced or preserved ejection fraction in the Dapagliflozin Evaluation to Improve the Lives of Patients With ... Full text Link to item Cite

Concordance Between Patient-Reported Health Data and Electronic Health Data in the ADAPTABLE Trial.

Journal Article JAMA Cardiol · December 1, 2022 IMPORTANCE: Patient-reported health data can facilitate clinical event capture in pragmatic clinical trials. However, few data are available on the fitness for use of patient-reported data in large-scale health research. OBJECTIVE: To evaluate the concorda ... Full text Link to item Cite

Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan.

Journal Article Eur J Heart Fail · December 2022 AIMS: The effects of adding a sodium-glucose cotransporter 2 (SGLT2) inhibitor to a mineralocorticoid receptor antagonist (MRA) or an angiotensin receptor-neprilysin inhibitor (ARNI) in patients with heart failure (HF) and mildly reduced ejection fraction ... Full text Link to item Cite

Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial.

Journal Article Lancet Diabetes Endocrinol · December 2022 BACKGROUND: Type 2 diabetes and prediabetes are risk factors for heart failure and adverse heart failure outcomes. The Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure (DELIVER) trial showed that dapa ... Full text Link to item Cite

Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial.

Journal Article Nature medicine · December 2022 With modern treatments for heart failure with reduced ejection fraction (EF), indicative of impaired cardiac systolic function, patients may exhibit an increase in EF. Limited data are available regarding the clinical management of this growing population, ... Full text Cite

Protein biomarkers of cardiac remodeling and inflammation associated with HFpEF and incident events.

Journal Article Sci Rep · November 22, 2022 There is increasing evidence that HFpEF is a heterogeneous clinical entity and distinct molecular pathways may contribute to pathophysiology. Leveraging unbiased proteomics to identify novel biomarkers, this study seeks to understand the underlying molecul ... Full text Link to item Cite

General Anxiety Disorder-7 Questionnaire as a marker of low socioeconomic status and inequity.

Journal Article J Affect Disord · November 15, 2022 BACKGROUND: The General Anxiety Disorder-7 (GAD-7) questionnaire is a standard tool used for screening and follow-up of patients with Generalized Anxiety Disorder (GAD). Although it is generally accepted that anxiety correlates with clinical and psychosoci ... Full text Link to item Cite

Estimated Long-Term Benefit of Dapagliflozin in Patients With Heart Failure.

Journal Article J Am Coll Cardiol · November 8, 2022 BACKGROUND: Recent guidelines support consideration of sodium-glucose cotransporter-2 inhibitors in the long-term management of heart failure (HF) with mildly reduced or preserved ejection fraction. Patients and clinicians may be interested in the expected ... Full text Link to item Cite

Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial.

Journal Article Am Heart J · November 2022 BACKGROUND: Patients with acute myocardial infarction (MI) are at risk for developing heart failure (HF) and subsequently are at an increased risk of mortality. Sodium-glucose cotransporter-2 inhibitors have been proven to improve outcomes in patients with ... Full text Link to item Cite

Dapagliflozin for heart failure according to body mass index: the DELIVER trial.

Journal Article European heart journal · November 2022 AimsObesity is common and associated with unique phenotypic features in heart failure with preserved ejection fraction (HFpEF). Therefore, understanding the efficacy and safety of new therapies in HFpEF patients with obesity is important. The effe ... Full text Cite

Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection Fraction.

Journal Article J Am Coll Cardiol · November 1, 2022 BACKGROUND: Atrial fibrillation (AF) is common in heart failure (HF), is associated with worse outcomes compared with sinus rhythm, and may modify the effects of therapy. OBJECTIVES: This study examined the effects of dapagliflozin according to the presenc ... Full text Link to item Cite

Assessing the Impact of the American Heart Association's Research Portfolio: A Scientific Statement From the American Heart Association.

Journal Article Circulation · November 2022 A task force composed of American Heart Association (AHA) Research Committee members established processes to measure the performance of the AHA's research portfolio and evaluated key outcomes that are fundamental to the overall success of the program. Thi ... Full text Link to item Cite

Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction.

Journal Article J Am Coll Cardiol · October 4, 2022 BACKGROUND: Patients recently hospitalized for heart failure (HF) are at high risk for rehospitalization and death. OBJECTIVES: The purpose of this study was to investigate clinical outcomes and response to dapagliflozin in patients with HF with mildly red ... Full text Link to item Cite

Landscape of coronavirus disease 2019 clinical trials: New frontiers and challenges.

Journal Article Clin Trials · October 2022 BACKGROUND/AIM: The number of coronavirus disease 2019 deaths and cases continues to increase globally. Novel therapies are urgently needed to treat patients with coronavirus disease 2019. We sought to provide a critical review of trials designed during th ... Full text Link to item Cite

The Association of Digital Health Application Use With Heart Failure Care and Outcomes: Insights From CONNECT-HF.

Journal Article J Card Fail · October 2022 BACKGROUND: It is unknown whether digital applications can improve guideline-directed medical therapy (GDMT) and outcomes in heart failure with reduced ejection fraction (HFrEF). METHODS AND RESULTS: Care Optimization Through Patient and Hospital Engagemen ... Full text Link to item Cite

Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial.

Journal Article Circulation · October 2022 BackgroundFrailty is increasing in prevalence. Because patients with frailty are often perceived to have a less favorable risk/benefit profile, they may be less likely to receive new pharmacologic treatments. We investigated the efficacy and toler ... Full text Cite

Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial.

Journal Article Eur J Heart Fail · October 2022 AIMS: This pre-specified analysis of the DELIVER trial examined whether clinical benefits of dapagliflozin in heart failure (HF) with left ventricular ejection fraction (LVEF) >40% varied by baseline New York Heart Association (NYHA) class and examined the ... Full text Link to item Cite

Evaluating the Application of Chronic Heart Failure Therapies and Developing Treatments in Individuals With Recent Myocardial Infarction: A Review.

Journal Article JAMA Cardiol · October 1, 2022 IMPORTANCE: Despite advances in cardiac care, patients remain at a high risk of death and the development of heart failure (HF) following myocardial infarction (MI). These risks are highest in patients with reduced ejection fraction (EF) or signs of HF imm ... Full text Link to item Cite

A multicenter program for electronic health record screening for patients with heart failure with preserved ejection fraction: Lessons from the DELIVER-EHR initiative.

Journal Article Contemp Clin Trials · October 2022 Efficiency in clinical trial recruitment and enrollment remains a major challenge in many areas of clinical medicine. In particular, despite the prevalence of heart failure with preserved ejection fraction (HFpEF), identifying patients with HFpEF for clini ... Full text Link to item Cite

Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial.

Journal Article JAMA · October 2022 ImportanceThe effectiveness of ivermectin to shorten symptom duration or prevent hospitalization among outpatients in the US with mild to moderate symptomatic COVID-19 is unknown.ObjectiveTo evaluate the efficacy of ivermectin, 400 μg/kg, ... Full text Cite

Efficacy and Safety of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Age: The DELIVER Trial.

Journal Article Circulation. Heart failure · October 2022 BackgroundThe prevalence of heart failure with mildly reduced or preserved ejection fraction markedly increases with age, with older individuals disproportionately facing excess risk for mortality and hospitalization.MethodsThe DELIVER tr ... Full text Cite

Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.

Journal Article N Engl J Med · September 22, 2022 BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure and cardiovascular death among patients with chronic heart failure and a left ventricular ejection fraction of 40% or less. Whether SGLT2 inh ... Full text Link to item Cite

Heart Failure Strategically Focused Research Network: Summary of Results and Future Directions.

Journal Article J Am Heart Assoc · September 20, 2022 Heart failure remains among the most common and morbid health conditions. The Heart Failure Strategically Focused Research Network (HF SFRN) was funded by the American Heart Association to facilitate collaborative, high-impact research in the field of hear ... Full text Link to item Cite

SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials.

Journal Article Lancet · September 3, 2022 BACKGROUND: SGLT2 inhibitors are strongly recommended in guidelines to treat patients with heart failure with reduced ejection fraction, but their clinical benefits at higher ejection fractions are less well established. Two large-scale trials, DELIVER and ... Full text Link to item Cite

Quantitative Blood Volume Analysis and Hemodynamic Measures of Vascular Compliance in Patients With Worsening Heart Failure.

Journal Article J Card Fail · September 2022 BACKGROUND: The role of blood volume (BV) expansion vs a change in vascular compliance in worsening heart failure (HF) remains under debate. We aimed to assess the relationship between BV and resting and stress hemodynamics in worsening HF and to further e ... Full text Link to item Cite

Risk Factors and Neurological Outcomes Associated With Circulatory Shock After Moderate-Severe Traumatic Brain Injury: A TRACK-TBI Study.

Journal Article Neurosurgery · September 1, 2022 BACKGROUND: Extracranial multisystem organ failure is a common sequela of severe traumatic brain injury (TBI). Risk factors for developing circulatory shock and long-term functional outcomes of this patient subset are poorly understood. OBJECTIVE: To ident ... Full text Link to item Cite

Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial.

Journal Article Eur J Heart Fail · September 2022 AIM: We assessed a subset of the 5040 patients in VICTORIA receiving sacubitril/valsartan, either at randomization (n = 731) or post-randomization drop-in use (n = 425), to evaluate the relationship between the efficacy and safety of combination therapy wi ... Full text Link to item Cite

Outcomes After Acute Coronary Syndrome in Patients With Diabetes Mellitus and Peripheral Artery Disease (from the TRACER, TRILOGY-ACS, APPRAISE-2, and PLATO Clinical Trials).

Journal Article Am J Cardiol · September 1, 2022 Patients with acute coronary syndrome (ACS) are at risk for recurrent adverse events, and multiple reports suggest that this risk is increased in patients with concomitant diabetes mellitus (DM) and peripheral artery disease (PAD). The aim of this article ... Full text Link to item Cite

Sequential Evaluation of NT-proBNP in Heart Failure: Insights Into Clinical Outcomes and Efficacy of Vericiguat.

Journal Article JACC Heart Fail · September 2022 BACKGROUND: The effect of vericiguat on sequential N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels and influence of this relationship on clinical outcomes is unknown. OBJECTIVES: This study assessed the relationship between changes in NT-proBN ... Full text Link to item Cite

Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER.

Journal Article Nat Med · September 2022 Whether the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduces the risk of a range of morbidity and mortality outcomes in patients with heart failure regardless of ejection fraction is unknown. A patient-level pooled meta-analysis of two trials ... Full text Link to item Cite

Health System-Level Performance in Prescribing Guideline-Directed Medical Therapy for Patients With Heart Failure With Reduced Ejection Fraction: Results From the CONNECT-HF Trial.

Journal Article J Card Fail · August 2022 BACKGROUND: Health system-level interventions to improve use of guideline-directed medical therapy (GDMT) often fail in the acute care setting. We sought to identify factors associated with high performance in adoption of GDMT among health systems in CONNE ... Full text Link to item Cite

Multiple cArdiac seNsors for mAnaGEment of Heart Failure (MANAGE-HF) - Phase I Evaluation of the Integration and Safety of the HeartLogic Multisensor Algorithm in Patients With Heart Failure.

Journal Article J Card Fail · August 2022 BACKGROUND: Patients with heart failure (HF) and reduced ejection fraction suffer from a relapsing and remitting disease course, where early treatment changes may improve outcomes. We assessed the clinical integration and safety of the HeartLogic multisens ... Full text Link to item Cite

Preface to theme issue on pragmatic and virtual trials: Progress and challenges.

Journal Article Contemp Clin Trials · August 2022 Full text Link to item Cite

Multi-dimensional characterization of prediabetes in the Project Baseline Health Study.

Journal Article Cardiovasc Diabetol · July 18, 2022 BACKGROUND: We examined multi-dimensional clinical and laboratory data in participants with normoglycemia, prediabetes, and diabetes to identify characteristics of prediabetes and predictors of progression from prediabetes to diabetes or reversion to no di ... Full text Link to item Cite

Medical Therapy During Hospitalization for Heart Failure With Reduced Ejection Fraction: The VICTORIA Registry.

Journal Article J Card Fail · July 2022 BACKGROUND: For patients hospitalized for heart failure with reduced ejection fraction (HFrEF), guidelines recommend optimization of medical therapy prior to discharge. The degree to which changes in medical therapy occur during hospitalizations for HFrEF ... Full text Link to item Cite

Tolerability of Sacubitril/Valsartan in Patients With Advanced Heart Failure: Analysis of the LIFE Trial Run-In.

Journal Article JACC Heart Fail · July 2022 BACKGROUND: The LIFE (LCZ696 In Hospitalized Advanced Heart FailurE) trial, which evaluated sacubitril/valsartan in patients with advanced heart failure (HF) with reduced ejection fraction and recent New York Heart Association functional class IV symptomat ... Full text Link to item Cite

Angiotensin Receptor Neprilysin Inhibition and Associated Outcomes by Race and Ethnicity in Patients With Heart Failure With Reduced Ejection Fraction: Data From CHAMP-HF.

Journal Article J Am Heart Assoc · June 20, 2022 Background There are limited data on the use of angiotensin receptor neprilysin inhibitors (ARNIs) in minority populations with heart failure (HF) with reduced ejection fraction. We used data from the CHAMP-HF (Change the Management of Patients With Heart ... Full text Link to item Cite

Plasma metabolites associated with functional and clinical outcomes in heart failure with reduced ejection fraction with and without type 2 diabetes.

Journal Article Sci Rep · June 2, 2022 Heart failure with reduced ejection fraction (HFrEF) is increasingly treated with medications for type 2 diabetes mellitus (T2DM). Whether metabolic derangements in HFrEF and T2DM are associated with differential outcomes remains unclear. Therefore, unders ... Full text Link to item Cite

Iterative approaches to the use of electronic health records data for large pragmatic studies.

Journal Article Contemp Clin Trials · June 2022 Randomized controlled trials (RCT) are the gold standard for evaluating the effectiveness and safety of interventions and treatments, yet traditional clinical trials have relied on cumbersome and redundant processes such as electronic data entry which invo ... Full text Link to item Cite

Could Neprilysin Be Already Inhibited by BNP in the LIFE Trial?-Reply.

Journal Article JAMA Cardiol · June 1, 2022 Full text Link to item Cite

Acute Decompensated Heart Failure in the Setting of Acute Coronary Syndrome.

Journal Article JACC Heart Fail · June 2022 Acute coronary syndrome (ACS) is frequently complicated by evidence of heart failure (HF). Those at highest risk for acute decompensated HF in the setting of ACS (ACS-HF) are older, female, and have preexisting heart disease, type 2 diabetes mellitus, hype ... Full text Link to item Cite

Vericiguat and Health-Related Quality of Life in Patients With Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial.

Journal Article Circ Heart Fail · June 2022 BACKGROUND: We examined the effects of vericiguat compared with placebo in patients with heart failure with reduced ejection fraction enrolled in VICTORIA (Vericiguat Global Study in Patients With Heart Failure With Reduced Ejection Fraction) on health sta ... Full text Link to item Cite

The impact of COVID-19 on pragmatic clinical trials: lessons learned from the NIH Health Care Systems Research Collaboratory.

Journal Article Trials · May 21, 2022 BACKGROUND: The COVID-19 pandemic has considerably disrupted nearly all aspects of daily life, including healthcare delivery and clinical research. Because pragmatic clinical trials are often embedded within healthcare delivery systems, they may be at high ... Full text Link to item Cite

2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Journal Article Circulation · May 3, 2022 AIM: The "2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure" replaces the "2013 ACCF/AHA Guideline for the Management of Heart Failure" and the "2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failu ... Full text Link to item Cite

2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Journal Article J Am Coll Cardiol · May 3, 2022 AIM: The "2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure" replaces the "2013 ACCF/AHA Guideline for the Management of Heart Failure" and the "2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failu ... Full text Link to item Cite

2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction.

Journal Article Eur J Heart Fail · May 2022 AIMS: Coronary artery disease (CAD) portends worse outcomes in heart failure (HF). We aimed to characterize patients with CAD and worsening HF with reduced ejection fraction (HFrEF) and evaluate post hoc whether vericiguat treatment effect varied according ... Full text Link to item Cite

The association of improvement in left ventricular ejection fraction with outcomes in patients with heart failure with reduced ejection fraction: data from CHAMP-HF.

Journal Article Eur J Heart Fail · May 2022 AIMS: We assessed for an association between improvements in left ventricular ejection fraction (LVEF) and future outcomes, including health status, in routine clinical practice. METHODS AND RESULTS: CHAMP-HF was a registry of outpatients with heart failur ... Full text Link to item Cite

2022 American College of Cardiology/American Heart Association/Heart Failure Society of America Guideline for the Management of Heart Failure: Executive Summary.

Journal Article J Card Fail · May 2022 BACKGROUND: The 2022 American College of Cardiology/American Heart Association/Heart Failure Society of America (AHA/ACC/HFSA) Guideline for the Management of Heart Failure replaces the 2013 ACCF/AHA Guideline for the Management of Heart Failure and the 20 ... Full text Link to item Cite

2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure.

Journal Article J Card Fail · May 2022 AIM: The "2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure" replaces the "2013 ACCF/AHA Guideline for the Management of Heart Failure" and the "2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failu ... Full text Link to item Cite

Sodium Glucose Cotransporter-2 Inhibition for Acute Myocardial Infarction: JACC Review Topic of the Week.

Journal Article Journal of the American College of Cardiology · May 2022 Sodium glucose cotransporter-2 (SGLT2) inhibitors improve cardiorenal outcomes in patients with type 2 diabetes mellitus, chronic kidney disease, and chronic heart failure. SGLT2 inhibitors also reduce the risk of cardiovascular mortality and hospitalizati ... Full text Cite

Patient partnership in cardiovascular clinical trials.

Journal Article Eur Heart J · April 6, 2022 Patients are ultimately the end-users of medical therapies and need to be actively integrated as contributors and decision-makers in the process of product development throughout product lifecycles. This is increasingly being recognized by patients, invest ... Full text Link to item Cite

Incidence and Clinical Impact of Myocardial Injury Following Traumatic Brain Injury: A Pilot TRACK-TBI Study.

Journal Article J Neurosurg Anesthesiol · April 1, 2022 BACKGROUND: Traumatic brain injury (TBI) is a major global health problem. Little research has addressed extracranial organ dysfunction following TBI, particularly myocardial injury. Using a sensitive marker of myocardial injury-high sensitivity troponin ( ... Full text Link to item Cite

Achieving More Rapid Door-to-Needle Times and Improved Outcomes in Acute Ischemic Stroke in a Nationwide Quality Improvement Intervention.

Journal Article Stroke · April 2022 BACKGROUND: The benefits of tPA (tissue-type plasminogen activator) in acute ischemic stroke are time-dependent. However, delivery of thrombolytic therapy rapidly after hospital arrival was initially occurring infrequently in hospitals in the United States ... Full text Link to item Cite

Utilization of Brain Tissue Oxygenation Monitoring and Association with Mortality Following Severe Traumatic Brain Injury.

Journal Article Neurocrit Care · April 2022 BACKGROUND: The aim of this study was to describe the utilization patterns of brain tissue oxygen (PbtO2) monitoring following severe traumatic brain injury (TBI) and determine associations with mortality, health care use, and pulmonary toxicity. METHODS: ... Full text Open Access Link to item Cite

The challenges of data safety monitoring for a pragmatic study: Lessons from the ADAPTABLE study.

Journal Article Contemp Clin Trials · April 2022 Data monitoring committees (DMCs) play a critical role in protecting the safety of participants and integrity of clinical studies. While there are well-established DMC guidelines for traditional, randomized controlled trials, the clinical trial community i ... Full text Link to item Cite

Comparative Effectiveness of Dosing of Medical Therapy for Heart Failure: From the CHAMP-HF Registry.

Journal Article J Card Fail · March 2022 BACKGROUND: The comparative effectiveness of differing dosages of guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) on clinical and patient-reported outcomes in clinical practice in the United States is unkn ... Full text Link to item Cite

Dysglycemia and incident heart failure among blacks: The jackson heart study.

Journal Article Am Heart J · March 2022 BACKGROUND: We aimed to investigate the associations of glycemic markers (hemoglobin A1C [HbA1C], fasting plasma glucose [FPG] and glycemic status [normoglycemia, prediabetes and diabetes]) with incident heart failure (HF) and its subtypes, among Blacks. M ... Full text Link to item Cite

Clinical Outcomes With Metformin and Sulfonylurea Therapies Among Patients With Heart Failure and Diabetes.

Journal Article JACC Heart Fail · March 2022 OBJECTIVES: The authors sought to characterize associations between initiation of metformin and sulfonylurea therapy and clinical outcomes among patients with comorbid heart failure (HF) and diabetes (overall and by ejection fraction [EF] phenotype). BACKG ... Full text Open Access Link to item Cite

Inverse relationship between body mass index and risk of venous thromboembolism among medically ill hospitalized patients: Observations from the APEX trial.

Journal Article Thromb Res · March 2022 Obesity is associated with cardiovascular complications such as diabetes and hypertension. However, obesity and high body mass index (BMI) can also be linked to improved clinical outcomes in certain patient populations. This counterintuitive observation is ... Full text Link to item Cite

Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial.

Journal Article JACC Heart Fail · March 2022 OBJECTIVES: This report describes the baseline clinical profiles and management of DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure) trial participants and how these compare with those in oth ... Full text Link to item Cite

Racial/Ethnic Disparities in Healthcare Worker Experiences During the COVID-19 Pandemic: An Analysis of the HERO Registry.

Journal Article EClinicalMedicine · March 2022 BACKGROUND: The extent to which healthcare worker (HCWs) experiences during the COVID-19 pandemic vary by race or ethnicity after adjustment for confounding factors is not currently known. METHODS: We performed an observational prospective cohort study of ... Full text Link to item Cite

Association of Recent Use of Non-Vitamin K Antagonist Oral Anticoagulants With Intracranial Hemorrhage Among Patients With Acute Ischemic Stroke Treated With Alteplase.

Journal Article JAMA · February 22, 2022 IMPORTANCE: Current guidelines recommend against use of intravenous alteplase in patients with acute ischemic stroke who are taking non-vitamin K antagonist oral anticoagulants (NOACs). OBJECTIVE: To evaluate the safety and functional outcomes of intraveno ... Full text Link to item Cite

Research Goes Red: Early Experience With a Participant-Centric Registry.

Journal Article Circ Res · February 4, 2022 RATIONALE: Cardiovascular disease remains the leading cause of death in women. To address its determinants including persisting cardiovascular risk factors amplified by sex and race inequities, novel personalized approaches are needed grounded in the engag ... Full text Link to item Cite

Association of Vasopressor Choice with Clinical and Functional Outcomes Following Moderate to Severe Traumatic Brain Injury: A TRACK-TBI Study.

Journal Article Neurocrit Care · February 2022 BACKGROUND: Early hypotension following moderate to severe traumatic brain injury (TBI) is associated with increased mortality and poor long-term outcomes. Current guidelines suggest the use of intravenous vasopressors to support blood pressure following T ... Full text Link to item Cite

Treatment Persistence of Renin-Angiotensin-Aldosterone-System Inhibitors Over Time in Heart Failure with Reduced Ejection Fraction.

Journal Article J Card Fail · February 2022 BACKGROUND: Clinical practice guidelines support sustained use of renin-angiotensin-aldosterone-system (RAAS) inhibitors over time in heart failure with reduced ejection fraction, yet few data are available regarding the frequency, timing or predictors of ... Full text Link to item Cite

Identifying patients at increased risk for poor outcomes from heart failure with reduced ejection fraction: the PROMPT-HF risk model.

Journal Article ESC Heart Fail · February 2022 AIMS: We aimed to develop a risk prediction tool that incorporated both clinical events and worsening health status for patients with heart failure (HF) with reduced ejection fraction (HFrEF). Identifying patients with HFrEF at increased risk of a poor out ... Full text Link to item Cite

When Are Treatment Blinding and Treatment Standardization Necessary in Real-World Clinical Trials?

Journal Article Clin Pharmacol Ther · January 2022 Concerns regarding both the limited generalizability and the slow pace of traditional randomized trials have led to calls for greater use of real-world evidence in the evaluation of new treatments or products. Real-world clinical trials or pragmatic trials ... Full text Link to item Cite

When Can Nonrandomized Studies Support Valid Inference Regarding Effectiveness or Safety of New Medical Treatments?

Journal Article Clin Pharmacol Ther · January 2022 The randomized controlled trial (RCT) is the gold standard for evaluating the causal effects of medications. Limitations of RCTs have led to increasing interest in using real-world evidence (RWE) to augment RCT evidence and inform decision making on medica ... Full text Link to item Cite

When Can We Rely on Real-World Evidence to Evaluate New Medical Treatments?

Journal Article Clin Pharmacol Ther · January 2022 Concerns regarding both the limited generalizability and the slow pace of traditional randomized trials have led to calls for greater use of real-world evidence (RWE) in the evaluation of new treatments or products. The RWE label has been used to refer to ... Full text Link to item Cite

When Can We Trust Real-World Data To Evaluate New Medical Treatments?

Journal Article Clin Pharmacol Ther · January 2022 Concerns regarding both the limited generalizability and the slow pace of traditional randomized trials have led to calls for greater use of real-world evidence (RWE) in the evaluation of new treatments or products. RWE studies often rely on real-world dat ... Full text Link to item Cite

Identifying Treatments for Stage C2 Heart Failure.

Journal Article JAMA Cardiol · January 1, 2022 Full text Link to item Cite

Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.

Journal Article JAMA Cardiol · January 1, 2022 IMPORTANCE: The use of sacubitril/valsartan is not endorsed by practice guidelines for use in patients with New York Heart Association class IV heart failure with a reduced ejection fraction because of limited clinical experience in this population. OBJECT ... Full text Link to item Cite

Lifetime cost-effectiveness simulation of once-weekly exenatide in type 2 diabetes: A cost-utility analysis based on the EXSCEL trial.

Journal Article Diabetes Res Clin Pract · January 2022 AIMS: The Exenatide Study of Cardiovascular Event Lowering (EXSCEL) trial assessed once-weekly exenatide (EQW) vs. placebo, added to usual care in 14,752 patients with type 2 diabetes mellitus (Clinicaltrials.gov: NCT01144338). We assessed the lifetime cos ... Full text Link to item Cite

Association of left ventricular diastolic function with coronary artery calcium score: A Project Baseline Health Study.

Journal Article J Cardiovasc Comput Tomogr · 2022 BACKGROUND: Coronary artery calcium (CAC) and left ventricular diastolic dysfunction (LVDD) are strong predictors of cardiovascular events and share common risk factors. However, their independent association remains unclear. METHODS: In the Project Baseli ... Full text Link to item Cite

Leveraging “Big Data” for the Design and Execution of Clinical Trials

Chapter · January 1, 2022 Randomized clinical trials form the cornerstone of evidence-based medicine and are required to accurately determine cause-effect relationships and treatment effects of medical interventions. Nonetheless, contemporary clinical trials are becoming increasing ... Full text Cite

Impact of the COVID-19 Pandemic on Cardiovascular Science: Anticipating Problems and Potential Solutions: A Presidential Advisory From the American Heart Association.

Journal Article Circulation · December 7, 2021 The coronavirus disease 2019 (COVID-19) pandemic has had worldwide repercussions for health care and research. In spring 2020, most non-COVID-19 research was halted, hindering research across the spectrum from laboratory-based experimental science to clini ... Full text Link to item Cite

Polyvascular disease and increased risk of cardiovascular events in patients with type 2 diabetes: Insights from the EXSCEL trial.

Journal Article Atherosclerosis · December 2021 BACKGROUND AND AIMS: Polyvascular disease is an independent predictor of major adverse cardiovascular events (MACE). The relationship between the number of diseased arterial beds and MACE is unknown. How MACE risk changes in individuals with type 2 diabete ... Full text Link to item Cite

Validation of Cardiovascular End Points Ascertainment Leveraging Multisource Electronic Health Records Harmonized Into a Common Data Model in the ADAPTABLE Randomized Clinical Trial.

Journal Article Circ Cardiovasc Qual Outcomes · December 2021 BACKGROUND: The ADAPTABLE trial (Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness) is the first randomized trial conducted within the National Patient-Centered Clinical Research Network to use the electronic health rec ... Full text Link to item Cite

Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial.

Journal Article J Am Heart Assoc · November 16, 2021 Background Although safety and tolerability of vericiguat were established in the VICTORIA (Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction) trial in patients with heart failure with reduced ejection fraction, some sub ... Full text Link to item Cite

A Hospital and Postdischarge Quality Improvement Intervention and Outcomes and Care for Patients With Heart Failure With Reduced Ejection Fraction-Reply.

Journal Article JAMA · November 16, 2021 Full text Link to item Cite

Hemoglobin and Clinical Outcomes in the Vericiguat Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA).

Journal Article Circulation · November 2, 2021 BACKGROUND: In the VICTORIA trial (Vericiguat Global Study in Patients with Heart Failure with Reduced Ejection Fraction), anemia occurred more often in patients treated with vericiguat (7.6%) than with placebo (5.7%). We explored the association between v ... Full text Link to item Cite

Racial and Ethnic Differences in Health Care Utilization Following Severe Acute Brain Injury in the United States.

Conference J Intensive Care Med · November 2021 OBJECTIVE: To examine racial and ethnic differences in the utilization of 3 interventions (tracheostomy placement, gastrostomy tube placement, and hospice utilization) among patients with severe acute brain injury (SABI). DESIGN: Retrospective cohort study ... Full text Link to item Cite

Diuretic Changes, Health Care Resource Utilization, and Clinical Outcomes for Heart Failure With Reduced Ejection Fraction: From the Change the Management of Patients With Heart Failure Registry.

Journal Article Circ Heart Fail · November 2021 BACKGROUND: Diuretics are a mainstay therapy for the symptomatic treatment of heart failure. However, in contemporary US outpatient practice, the degree to which diuretic dosing changes over time and the associations with clinical outcomes and health care ... Full text Link to item Cite

Relationship of Nonalcoholic Fatty Liver Disease and Heart Failure With Preserved Ejection Fraction.

Journal Article JACC Basic Transl Sci · November 2021 Although there is an established bidirectional relationship between heart failure with reduced ejection fraction and liver disease, the association between heart failure with preserved ejection fraction (HFpEF) and liver diseases, such as nonalcoholic fatt ... Full text Link to item Cite

Association of Severe Acute Kidney Injury with Mortality and Healthcare Utilization Following Isolated Traumatic Brain Injury.

Journal Article Neurocrit Care · October 2021 BACKGROUND/OBJECTIVE: Traumatic brain injury (TBI) is a leading cause of morbidity, mortality, and disability in the USA. While cardiopulmonary dysfunction can result in poor outcomes following severe TBI, the impact of acute kidney injury (AKI) is poorly ... Full text Open Access Link to item Cite

Predicting major adverse limb events in individuals with type 2 diabetes: Insights from the EXSCEL trial.

Journal Article Diabet Med · October 2021 AIMS: Although models exist to predict amputation among people with type 2 diabetes with foot ulceration or infection, we aimed to develop a prediction model for a broader range of major adverse limb events (MALE)-including gangrene, revascularization and ... Full text Link to item Cite

Association of Early Multiple Organ Dysfunction With Clinical and Functional Outcomes Over the Year Following Traumatic Brain Injury: A Transforming Research and Clinical Knowledge in Traumatic Brain Injury Study.

Journal Article Crit Care Med · October 1, 2021 OBJECTIVES: Traumatic brain injury is a leading cause of death and disability in the United States. While the impact of early multiple organ dysfunction syndrome has been studied in many critical care paradigms, the clinical impact of early multiple organ ... Full text Link to item Cite

Multiparameter diagnostic sensor measurements in heart failure patients presenting with SARS-CoV-2 infection.

Journal Article ESC Heart Fail · October 2021 AIMS: Implantable device-based sensor measurements including heart sounds, markers of ventilation, and thoracic impedance have been shown to predict heart failure (HF) hospitalizations. We sought to assess how these parameters changed prior to COVID-19 (Co ... Full text Link to item Cite

Design of the Healthcare Worker Exposure Response and Outcomes (HERO) research platform.

Journal Article Contemp Clin Trials · October 2021 BACKGROUND: The SARS CoV-2 virus has caused one of the deadliest pandemics in recent history, resulting in over 170 million deaths and global economic disruption. There remains an urgent need for clinical trials to test therapies for treatment and preventi ... Full text Open Access Link to item Cite

Patterns of antidepressant therapy and clinical outcomes among ischaemic stroke survivors.

Journal Article Stroke Vasc Neurol · September 2021 BACKGROUND AND PURPOSE: Depression is common after stroke and is often treated with antidepressant medications (AD). ADs have also been hypothesised to improve stroke recovery, although recent randomised trials were neutral. We investigated the patterns of ... Full text Link to item Cite

Effect of once-weekly exenatide on hospitalization for acute coronary syndrome or coronary revascularization in patients with type 2 diabetes mellitus.

Journal Article Am Heart J · September 2021 Cardiovascular (CV) outcome studies of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shifted the paradigm of type 2 diabetes management given their benefits regarding a reduction in major adverse CV events. However, the relationship between GL ... Full text Link to item Cite

Early diuretic strategies and the association with In-hospital and Post-discharge outcomes in acute heart failure.

Journal Article Am Heart J · September 2021 BACKGROUND: Decongestion is a primary goal during hospitalizations for decompensated heart failure (HF). However, data surrounding the preferred route and strategy of diuretic administration are limited with varying results in prior studies. METHODS: This ... Full text Link to item Cite

Participation in a Heart Failure Clinical Trial: Perspectives and Opportunities From the VICTORIA Trial and VICTORIA Simultaneous Registry.

Journal Article Circ Heart Fail · September 2021 BACKGROUND: Randomized controlled trials (RCTs) often target enrollment of patients with demographics and outcomes less representative of the broader population of interest. To provide context for the VICTORIA trial (Vericiguat Global Study in Subjects Wit ... Full text Link to item Cite

Aspirin Dosing in Cardiovascular Disease. Reply.

Journal Article N Engl J Med · August 19, 2021 Full text Link to item Cite

Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction.

Journal Article J Am Heart Assoc · August 17, 2021 Background Sacubitril/Valsartan has been highly efficacious in randomized trials of heart failure with reduced ejection fraction (HFrEF). However, the effectiveness of sacubitril/valsartan in older patients hospitalized for HFrEF in real-world US practice ... Full text Link to item Cite

Transmethylamine-N-Oxide Is Associated With Diffuse Cardiac Fibrosis in People Living With HIV.

Journal Article J Am Heart Assoc · August 17, 2021 Background People living with HIV are at increased risk of developing diastolic dysfunction, heart failure, and sudden cardiac death, all of which have been characterized by higher levels of myocardial fibrosis. Transmethylamine-N-oxide (TMAO), a dietary g ... Full text Link to item Cite

Association between sacubitril/valsartan initiation and real-world health status trajectories over 18 months in heart failure with reduced ejection fraction

Conference ESC Heart Failure · August 1, 2021 Aims: Improving the health status (symptoms, function, and quality of life) of patients with heart failure with reduced ejection fraction (HFrEF) is a primary treatment goal. Angiotensin receptor neprilysin inhibitors (ARNI) improve short-term health statu ... Full text Cite

2020 ACC/AHA guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Journal Article The Journal of thoracic and cardiovascular surgery · August 2021 Full text Cite

Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial.

Journal Article Eur J Heart Fail · August 2021 AIMS: Vericiguat reduced the primary composite outcome of cardiovascular death or heart failure (HF) hospitalization in patients with worsening HF with reduced ejection fraction (HFrEF) and a lower limit of baseline estimated glomerular filtration rate (eG ... Full text Link to item Cite

Growth differentiation factor-15, treatment with liraglutide, and clinical outcomes among patients with heart failure.

Journal Article ESC Heart Fail · August 2021 AIMS: Associations between growth differentiation factor-15 (GDF-15), cardiovascular outcomes, and exercise capacity among patients with a recent hospitalization for heart failure (HHF) and heart failure with reduced ejection fraction (HFrEF) are unknown. ... Full text Link to item Cite

Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the VICTORIA trial.

Journal Article Eur J Heart Fail · August 2021 AIMS: We evaluated the relation between baseline and new-onset atrial fibrillation (AF) and outcomes, and assessed whether vericiguat modified the likelihood of new-onset AF in patients with worsening heart failure (HF) with reduced ejection fraction in VI ... Full text Link to item Cite

Effect of a Hospital and Postdischarge Quality Improvement Intervention on Clinical Outcomes and Quality of Care for Patients With Heart Failure With Reduced Ejection Fraction: The CONNECT-HF Randomized Clinical Trial.

Journal Article JAMA · July 27, 2021 IMPORTANCE: Adoption of guideline-directed medical therapy for patients with heart failure is variable. Interventions to improve guideline-directed medical therapy have failed to consistently achieve target metrics, and limited data exist to inform efforts ... Full text Link to item Cite

The use of electronic health records for recruitment in clinical trials: a mixed methods analysis of the Harmony Outcomes Electronic Health Record Ancillary Study.

Journal Article Trials · July 19, 2021 BACKGROUND: The electronic health record (EHR) contains a wealth of clinical data that may be used to streamline the identification of potential clinical trial participants. However, there is little empirical information on site-level facilitators of and b ... Full text Link to item Cite

Splanchnic nerve modulation in heart failure: mechanistic overview, initial clinical experience, and safety considerations.

Journal Article Eur J Heart Fail · July 2021 Volume recruitment from the splanchnic compartment is an important physiological response to stressors such as physical activity and blood loss. In the setting of heart failure (HF), excess fluid redistribution from this compartment leads to increased card ... Full text Link to item Cite

2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Journal Article J Thorac Cardiovasc Surg · July 2021 Full text Link to item Cite

Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial.

Journal Article European journal of heart failure · July 2021 AimsSodium-glucose co-transporter 2 (SGLT2) inhibitors, originally developed as glucose-lowering agents, have been shown to reduce heart failure hospitalizations in patients with type 2 diabetes without established heart failure, and in patients w ... Full text Cite

Is Learning Worth the Trouble? - Improving Health Care System Participation in Embedded Research.

Journal Article N Engl J Med · July 1, 2021 Full text Link to item Cite

Assessment of North American Clinical Research Site Performance During the Start-up of Large Cardiovascular Clinical Trials.

Journal Article JAMA Netw Open · July 1, 2021 IMPORTANCE: Randomized clinical trials (RCTs) are critical in advancing patient care, yet conducting such large-scale trials requires tremendous resources and coordination. Clinical site start-up performance metrics can provide insight into opportunities f ... Full text Link to item Cite

Correction: Data Sharing Goals for Nonprofit Funders of Clinical Trials.

Journal Article J Particip Med · June 30, 2021 [This corrects the article DOI: 10.2196/23011.]. ... Full text Link to item Cite

Clinical Outcome Predictions for the VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial.

Journal Article J Card Fail · June 24, 2021 BACKGROUND: The prediction of outcomes in patients with heart failure (HF) may inform prognosis, clinical decisions regarding treatment selection, and new trial planning. The VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Frac ... Full text Link to item Cite

2020 American Heart Association and American College of Cardiology Consensus Conference on Professionalism and Ethics: A Consensus Conference Report.

Journal Article Circulation · June 22, 2021 Full text Link to item Cite

2020 American Heart Association and American College of Cardiology Consensus Conference on Professionalism and Ethics: A Consensus Conference Report.

Conference J Am Coll Cardiol · June 22, 2021 Full text Link to item Cite

Enabling patient-reported outcome measures in clinical trials, exemplified by cardiovascular trials.

Journal Article Health Qual Life Outcomes · June 13, 2021 OBJECTIVES: There has been limited success in achieving integration of patient-reported outcomes (PROs) in clinical trials. We describe how stakeholders envision a solution to this challenge. METHODS: Stakeholders from academia, industry, non-profits, insu ... Full text Link to item Cite

Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event: Insights From the VICTORIA Trial.

Journal Article JAMA Cardiol · June 1, 2021 IMPORTANCE: The period following heart failure hospitalization (HFH) is a vulnerable time with high rates of death or recurrent HFH. OBJECTIVE: To evaluate clinical characteristics, outcomes, and treatment response to vericiguat according to prespecified i ... Full text Link to item Cite

Interleukin-6 and Outcomes in Acute Heart Failure: An ASCEND-HF Substudy.

Journal Article J Card Fail · June 2021 BACKGROUND: The inflammatory cytokine IL-6 has been previously implicated in the pathophysiology of acute decompensated heart failure (HF). Prior observations in acute HF patients have suggested that IL-6 may be associated with outcomes and modulated by ne ... Full text Link to item Cite

Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease.

Journal Article N Engl J Med · May 27, 2021 BACKGROUND: The appropriate dose of aspirin to lower the risk of death, myocardial infarction, and stroke and to minimize major bleeding in patients with established atherosclerotic cardiovascular disease is a subject of controversy. METHODS: Using an open ... Full text Link to item Cite

Impact of Percutaneous Coronary Intervention on Outcomes in Patients With Heart Failure: JACC State-of-the-Art Review.

Journal Article J Am Coll Cardiol · May 18, 2021 Coronary artery disease (CAD) is highly prevalent in patients with heart failure (HF) and accounts for nearly two-thirds of cases. The use of percutaneous coronary intervention (PCI) in HF patients with CAD has markedly increased and has been suggested to ... Full text Link to item Cite

Cardiovascular and renal safety of metformin in patients with diabetes and moderate or severe chronic kidney disease: Observations from the EXSCEL and SAVOR-TIMI 53 cardiovascular outcomes trials.

Journal Article Diabetes Obes Metab · May 2021 AIM: To provide evidence on the cardiovascular and renal safety of metformin in chronic kidney disease (CKD) stages 3 to 4. MATERIALS AND METHODS: This post hoc analysis compared participants with an estimated glomerular filtration rate (eGFR) of 15 to 59 ... Full text Link to item Cite

Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities.

Journal Article Am Heart J · May 2021 BACKGROUND: In patients with heart failure and reduced ejection fraction (HFrEF), angiotensin converting enzyme inhibitors (ACEi), angiotensin II receptor blockers (ARB), or angiotensin receptor neprilysin inhibitor (ARNI), mineralocorticoid receptor antag ... Full text Link to item Cite

Impact of the Early Phase of the COVID-19 Pandemic on US Healthcare Workers: Results from the HERO Registry.

Journal Article J Gen Intern Med · May 2021 BACKGROUND: The HERO registry was established to support research on the impact of the COVID-19 pandemic on US healthcare workers. OBJECTIVE: Describe the COVID-19 pandemic experiences of and effects on individuals participating in the HERO registry. DESIG ... Full text Link to item Cite

Comparison of New York Heart Association Class and Patient-Reported Outcomes for Heart Failure With Reduced Ejection Fraction.

Journal Article JAMA Cardiol · May 1, 2021 IMPORTANCE: It is unclear how New York Heart Association (NYHA) functional class compares with patient-reported outcomes among patients with heart failure (HF) in contemporary US clinical practice. OBJECTIVE: To characterize longitudinal changes and concor ... Full text Link to item Cite

Sex Differences in Clinical Course and Patient-Reported Outcomes Among Patients Hospitalized for Heart Failure.

Journal Article JACC Heart Fail · May 2021 OBJECTIVES: The goal of this study was to evaluate differences in clinical and patient-reported outcomes between women and men hospitalized for acute HF. BACKGROUND: Among patients hospitalized for heart failure (HF), it is unclear if symptom burden, respo ... Full text Link to item Cite

Randomized Placebo-Controlled Trial of Ferric Carboxymaltose in Heart Failure With Iron Deficiency: Rationale and Design.

Journal Article Circ Heart Fail · May 2021 BACKGROUND: Iron deficiency (ID) has a prevalence of ≈40% to 50% among patients in heart failure (HF) with reduced ejection fraction and is associated with worse prognosis. Several trials demonstrated that intravenous ferric carboxymaltose leads to early a ... Full text Link to item Cite

Echocardiogram Utilization Patterns and Association With Mortality Following Severe Traumatic Brain Injury.

Journal Article Anesth Analg · April 1, 2021 BACKGROUND: Severe traumatic brain injury (TBI) can result in left ventricular dysfunction, which can lead to hypotension and secondary brain injuries. Although echocardiography is often used to examine cardiovascular function in multiple clinical settings ... Full text Open Access Link to item Cite

Corrigendum to "Impact of baseline covariate imbalance on bias in treatment effect estimation in cluster randomized trials: Race as an example" [Contemporary Clinical Trials volume 88 (2020) 105775].

Journal Article Contemp Clin Trials · April 2021 Full text Link to item Cite

Splanchnic Nerve Block Mediated Changes in Stressed Blood Volume in Heart Failure.

Journal Article JACC Heart Fail · April 2021 OBJECTIVES: The authors estimated changes of stressed blood volume (SBV) induced by splanchnic nerve block (SNB) in patients with either decompensated or ambulatory heart failure with reduced ejection fraction (HFrEF). BACKGROUND: The splanchnic vascular c ... Full text Link to item Cite

Prognostic Role of Prior Heart Failure Hospitalization Among Patients Hospitalized for Worsening Chronic Heart Failure.

Journal Article Circ Heart Fail · April 2021 BACKGROUND: Hospitalization for heart failure (HF) is associated with increased risk of death among patients with chronic HF. The degree to which hospitalization for HF is a distinct biologic entity with independent prognostic value versus a marker of high ... Full text Link to item Cite

Data Sharing Goals for Nonprofit Funders of Clinical Trials.

Journal Article J Particip Med · March 29, 2021 Sharing clinical trial data can provide value to research participants and communities by accelerating the development of new knowledge and therapies as investigators merge data sets to conduct new analyses, reproduce published findings to raise standards ... Full text Link to item Cite

Plasma Volume Status and Its Association With In-Hospital and Postdischarge Outcomes in Decompensated Heart Failure.

Journal Article J Card Fail · March 2021 BACKGROUND: Prior analyses suggest an association between formula-based plasma volume (PV) estimates and outcomes in heart failure (HF). We assessed the association between estimated PV status by the Duarte-ePV and Kaplan Hakim (KH-ePVS) formulas, and in-h ... Full text Link to item Cite

2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Journal Article Circulation · February 2, 2021 AIM: This executive summary of the valvular heart disease guideline provides recommendations for clinicians to diagnose and manage valvular heart disease as well as supporting documentation to encourage their use. METHODS: A comprehensive literature search ... Full text Link to item Cite

Implications of peripheral oedema in heart failure with preserved ejection fraction: a heart failure network analysis.

Journal Article ESC Heart Fail · February 2021 AIMS: Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous condition, and tissue congestion manifested by oedema is not present in all patients. We compared clinical characteristics, exercise capacity, and outcomes in patients with HFp ... Full text Link to item Cite

Streamlining the institutional review board process in pragmatic randomized clinical trials: challenges and lessons learned from the Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-Term Effectiveness (ADAPTABLE) trial.

Journal Article Trials · January 25, 2021 BACKGROUND: New considerations during the ethical review processes may emerge from innovative, yet unfamiliar operational methods enabled in pragmatic randomized controlled trials (RCT), potentially making institutional review board (IRB) evaluation more c ... Full text Link to item Cite

Generating evidence for therapeutic effects: the need for well-conducted randomized trials.

Journal Article J Clin Invest · January 19, 2021 Full text Open Access Link to item Cite

Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease: A Randomized Clinical Trial.

Journal Article JAMA · January 5, 2021 IMPORTANCE: Influenza is temporally associated with cardiopulmonary morbidity and mortality among those with cardiovascular disease who may mount a less vigorous immune response to vaccination. Higher influenza vaccine dose has been associated with reduced ... Full text Link to item Cite

PCORnet® 2020: current state, accomplishments, and future directions.

Journal Article J Clin Epidemiol · January 2021 OBJECTIVE: To describe PCORnet, a clinical research network developed for patient-centered outcomes research on a national scale. STUDY DESIGN AND SETTING: Descriptive study of the current state and future directions for PCORnet. We conducted cross-section ... Full text Link to item Cite

Heart Failure Hospitalization and Guideline-Directed Prescribing Patterns Among Heart Failure With Reduced Ejection Fraction Patients.

Journal Article JACC Heart Fail · January 2021 OBJECTIVES: The authors sought to evaluate the association of heart failure hospitalization (HFH) with guideline-directed medical therapy (GDMT) prescribing patterns among patients with heart failure with reduced ejection fraction (HFrEF). BACKGROUND: HFH ... Full text Link to item Cite

Return of individual research results: What do participants prefer and expect?

Journal Article PLoS One · 2021 Newer data platforms offer increased opportunity to share multidimensional health data with research participants, but the preferences of participants for which data to receive and how is evolving. Our objective is to describe the preferences and expectati ... Full text Link to item Cite

2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Journal Article Circulation · December 22, 2020 Full text Link to item Cite

Ultrafiltration in Acute Heart Failure: Implications of Ejection Fraction and Early Response to Treatment From CARRESS-HF.

Journal Article J Am Heart Assoc · December 15, 2020 Background Ultrafiltration is not commonly used because of higher incidence of worsening renal function without improved decongestion. We examined differential outcomes of high versus low fluid removal and preserved versus reduced ejection fraction (EF) in ... Full text Open Access Link to item Cite

Cardiopulmonary Impact of Particulate Air Pollution in High-Risk Populations: JACC State-of-the-Art Review.

Journal Article J Am Coll Cardiol · December 15, 2020 Fine particulate air pollution <2.5 μm in diameter (PM2.5) is a major environmental threat to global public health. Multiple national and international medical and governmental organizations have recognized PM2.5 as a risk factor for cardiopulmonary diseas ... Full text Link to item Cite

Sample size requirements for detecting treatment effect heterogeneity in cluster randomized trials.

Journal Article Stat Med · December 10, 2020 Cluster randomized trials (CRTs) refer to experiments with randomization carried out at the cluster or the group level. While numerous statistical methods have been developed for the design and analysis of CRTs, most of the existing methods focused on test ... Full text Link to item Cite

PROVIDE-HF primary results: Patient-Reported Outcomes inVestigation following Initiation of Drug therapy with Entresto (sacubitril/valsartan) in heart failure.

Journal Article Am Heart J · December 2020 BACKGROUND: In PARADIGM-HF, sacubitril/valsartan improved quality of life (QOL) versus enalapril in heart failure with reduced ejection fraction (HFrEF), yet limited data are available regarding QOL changes after sacubitril/valsartan initiation in routine ... Full text Link to item Cite

Disseminating trial results: We can have both faster and better.

Journal Article Healthc (Amst) · December 2020 Full text Link to item Cite

Designing, Conducting, Monitoring, and Analyzing Data from Pragmatic Randomized Clinical Trials: Proceedings from a Multi-stakeholder Think Tank Meeting.

Journal Article Ther Innov Regul Sci · November 2020 In late 2018, the Food and Drug Administration (FDA) outlined a framework for evaluating the possible use of real-world evidence (RWE) to support regulatory decision-making. This framework was created to facilitate studies that would generate high-quality ... Full text Link to item Cite

The Use of Sacubitril/Valsartan for Hospitalized Heart Failure-Why Do We Care About Cost and Value?

Journal Article JAMA Cardiol · November 1, 2020 Full text Link to item Cite

N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study.

Journal Article JACC Heart Fail · November 2020 OBJECTIVES: The purpose of this study was to examine the treatment effect of vericiguat in relation to N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels at randomization. BACKGROUND: Vericiguat compared with placebo reduced the primary outcome o ... Full text Link to item Cite

Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial.

Journal Article JAMA · October 20, 2020 IMPORTANCE: Patients with heart failure and preserved ejection fraction (HFpEF) are at high risk of mortality, hospitalizations, and reduced functional capacity and quality of life. OBJECTIVE: To assess the efficacy of the oral soluble guanylate cyclase st ... Full text Link to item Cite

Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial.

Journal Article JACC Heart Fail · October 2020 The PARADIGM-HF (Prospective Comparison of Angiotensin II Receptor Blocker Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial reported that sacubitril/valsartan (S ... Full text Link to item Cite

Improving Care for Patients after Hospitalization with AKI.

Journal Article J Am Soc Nephrol · October 2020 Full text Link to item Cite

Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization.

Journal Article Circulation · September 22, 2020 With worsening epidemiological trends for both the incidence and prevalence of type 2 diabetes mellitus (T2DM) and heart failure (HF) worldwide, it is critical to implement optimal prevention and treatment strategies for patients with these comorbidities, ... Full text Link to item Cite

Splanchnic Nerve Block for Chronic Heart Failure.

Journal Article JACC Heart Fail · September 2020 OBJECTIVES: We hypothesized that splanchnic nerve blockade (SNB) would attenuate increased exercise-induced cardiac filling pressures in patients with chronic HF. BACKGROUND: Chronic heart failure (HF) is characterized by limited exercise capacity driven i ... Full text Link to item Cite

Heart Failure Clinical Trial Operations During the COVID-19 Pandemic: Results From a Multicenter Survey.

Journal Article Circ Heart Fail · September 2020 Full text Link to item Cite

National Hospital Quality Rankings: Improving the Value of Information in Hospital Rating Systems.

Journal Article JAMA · September 1, 2020 Full text Link to item Cite

Weighing the Benefits and Risks of Proliferating Observational Treatment Assessments: Observational Cacophony, Randomized Harmony.

Journal Article JAMA · August 18, 2020 Full text Link to item Cite

Randomized Trials Versus Common Sense and Clinical Observation: JACC Review Topic of the Week.

Journal Article J Am Coll Cardiol · August 4, 2020 Concerns about the external validity of traditional randomized clinical trials (RCTs), together with the widespread availability of real-world data and advanced data analytic tools, have led to claims that common sense and clinical observation, rather than ... Full text Open Access Link to item Cite

Association between potassium level and outcomes in heart failure with reduced ejection fraction: a cohort study from the Swedish Heart Failure Registry.

Conference Eur J Heart Fail · August 2020 AIMS: Hyperkalaemia and hypokalaemia are common in heart failure and associated with worse outcomes. However, the optimal potassium range is unknown. We sought to determine the optimal range of potassium in patients with heart failure and reduced ejection ... Full text Link to item Cite

A Novel In-hospital Congestion Score to Risk Stratify Patients Admitted for Worsening Heart Failure (from ASCEND-HF).

Journal Article J Cardiovasc Transl Res · August 2020 Patients hospitalized for heart failure (HF) remain at high risk for early readmission. A post hoc analysis was performed of the biomarker substudy of the ASCEND-HF trial. An in-hospital congestion score was derived using orthopnea, pedal edema, and NT-pro ... Full text Link to item Cite

Outcomes and cost among Medicare beneficiaries hospitalized for heart failure assigned to accountable care organizations.

Journal Article Am Heart J · August 2020 UNLABELLED: Little is known about the impact of accountable care organizations (ACO) on hospitalized heart failure (HF) patients, a high-cost and high-risk population. OBJECTIVE: We linked Medicare fee-for-service claims from 2013 to 2015 with data from Am ... Full text Link to item Cite

Lipoprotein (a): An Update on a Marker of Residual Risk and Associated Clinical Manifestations.

Journal Article Am J Cardiol · July 1, 2020 Lipoprotein (a) [Lp(a)] is a low-density, cholesterol-containing lipoprotein that differs from other low-density lipoproteins due to the presence of apolipoprotein(a) bound to its surface apolipoprotein B100. Multiple epidemiologic studies, including Mende ... Full text Link to item Cite

Improvement in Left Ventricular Ejection Fraction in Outpatients With Heart Failure With Reduced Ejection Fraction: Data From CHAMP-HF.

Journal Article Circ Heart Fail · July 2020 BACKGROUND: Among patients with heart failure (HF) with reduced ejection fraction (EF), improvements in left ventricular EF (LVEF) are associated with better outcomes and remain an important treatment goal. Patient factors associated with LVEF improvement ... Full text Link to item Cite

Improving Cardiovascular Drug and Device Development and Evidence Through Patient-Centered Research and Clinical Trials: A Call to Action From the Value in Healthcare Initiative's Partnering With Regulators Learning Collaborative.

Journal Article Circ Cardiovasc Qual Outcomes · July 2020 The pipeline of new cardiovascular drugs is relatively limited compared with many other clinical areas. Challenges causing lagging drug innovation include the duration and expense of cardiovascular clinical trials needed for regulatory evaluation and appro ... Full text Link to item Cite

Association Between Switching to a High-Deductible Health Plan and Major Cardiovascular Outcomes.

Journal Article JAMA Netw Open · July 1, 2020 IMPORTANCE: Most people with commercial health insurance in the US have high-deductible plans, but the association of such plans with major health outcomes is unknown. OBJECTIVE: To describe the association between enrollment in high-deductible health plan ... Full text Link to item Cite

Comparative Effectiveness of Primary Prevention Implantable Cardioverter-Defibrillators in Older Heart Failure Patients With Diabetes Mellitus.

Journal Article J Am Heart Assoc · June 16, 2020 Background There are conflicting data regarding the benefit of primary prevention implantable cardioverter-defibrillators (ICDs) in patients with diabetes mellitus and heart failure (HF) with reduced ejection fraction. We aimed to assess the comparative ef ... Full text Link to item Cite

Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).

Journal Article Eur Heart J · June 7, 2020 The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has important implications for the safety of participants in clinical trials and the research staff caring for them and, consequen ... Full text Link to item Cite

Trends in Treatment for Patients Hospitalized with Heart Failure with Preserved Ejection Fraction Before and After Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT).

Journal Article Am J Cardiol · June 1, 2020 The TOPCAT trial investigated spironolactone vs placebo in patients with heart failure with preserved ejection fraction (HFpEF). Although the primary endpoint was not statistically significant, treatment with spironolactone did reduce heart failure hospita ... Full text Link to item Cite

Periprocedural Risk and Survival Associated With Implantable Cardioverter-Defibrillator Placement in Older Patients With Advanced Heart Failure.

Journal Article JAMA Cardiol · June 1, 2020 IMPORTANCE: Little is known about the utilization rates and outcomes of implantable cardioverter-defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) placement among patients with advanced heart failure (HF). OBJECTIVE: To examin ... Full text Link to item Cite

The burden of non-cardiac comorbidities and association with clinical outcomes in an acute heart failure trial - insights from ASCEND-HF.

Journal Article Eur J Heart Fail · June 2020 AIMS: Non-cardiac comorbidities are highly prevalent in patients with heart failure (HF). Our objective was to define the association between non-cardiac comorbidity burden and clinical outcomes, costs of care, and length of stay within a large randomized ... Full text Link to item Cite

Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF: The CHAMP-HF Registry.

Journal Article JACC Heart Fail · June 2020 OBJECTIVES: The purpose of this study was to characterize the clinical profile, treatment patterns, and clinical outcomes of patients with comorbid diabetes mellitus (DM) and heart failure with reduced ejection fraction (HFrEF) in a contemporary, real-worl ... Full text Link to item Cite

Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.

Journal Article N Engl J Med · May 14, 2020 BACKGROUND: The effect of vericiguat, a novel oral soluble guanylate cyclase stimulator, in patients with heart failure and reduced ejection fraction who had recently been hospitalized or had received intravenous diuretic therapy is unclear. METHODS: In th ... Full text Link to item Cite

Diastolic Dysfunction in Patients With Human Immunodeficiency Virus Receiving Antiretroviral Therapy: Results From the CHART Study.

Journal Article J Card Fail · May 2020 BACKGROUND: Diastolic dysfunction (DD) is common and occurs at an earlier age among human immunodeficiency virus-infected (HIV+) individuals, but the mechanisms and consequences of DD among HIV+ individuals are unclear. METHODS AND RESULTS: The Characteriz ... Full text Link to item Cite

Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL.

Journal Article Diabetes Obes Metab · May 2020 AIM: To assess whether the previously developed multivariable risk prediction framework (PRE score) could predict the renal effects observed in the EXSCEL cardiovascular outcomes trial using short-term changes in cardio-renal risk markers. MATERIALS AND ME ... Full text Link to item Cite

Rationale and Design of the Aspirin Dosing-A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial.

Journal Article JAMA Cardiol · May 1, 2020 IMPORTANCE: Determining the right dosage of aspirin for the secondary prevention treatment of atherosclerotic cardiovascular disease (ASCVD) remains an unanswered and critical question. OBJECTIVE: To report the rationale and design for a randomized clinica ... Full text Link to item Cite

PredischaRge initiation of Ivabradine in the ManagEment of Heart Failure: Results of the PRIME-HF Trial.

Journal Article Am Heart J · May 2020 BACKGROUND: Ivabradine is guideline-recommended to reduce heart failure (HF) hospitalization in patients with stable chronic HF with reduced ejection fraction (EF). Ivabradine initiation following acute HF has had limited evaluation, and there are few rand ... Full text Link to item Cite

Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction: Insights From the FIGHT Trial.

Journal Article Circ Heart Fail · May 2020 BACKGROUND: The FIGHT (Functional Impact of GLP-1 [glucagon-like peptide-1] for Heart Failure Treatment) trial randomized 300 patients with heart failure with reduced ejection fraction (HFrEF) and a recent hospitalization for heart failure to liraglutide v ... Full text Link to item Cite

Hydroxychloroquine, Coronavirus Disease 2019, and QT Prolongation.

Journal Article JAMA Cardiol · May 1, 2020 Full text Link to item Cite

The Status of Specialized Ambulatory Heart Failure Care in Canada: A Joint Canadian Heart Failure Society and Canadian Cardiovascular Society Heart Failure Guidelines Survey.

Journal Article CJC Open · May 2020 This joint Canadian Heart Failure Society and the CCS Heart Failure guidelines report has been developed to provide a pan-Canadian snapshot of the current state of clinic-based ambulatory heart failure (HF) care in Canada with specific reference to element ... Full text Link to item Cite

Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL Outcomes.

Journal Article Circulation · April 28, 2020 BACKGROUND: EXSCEL (Exenatide Study of Cardiovascular Event Lowering) assessed the impact of once-weekly exenatide 2 mg versus placebo in patients with type 2 diabetes mellitus, while aiming for glycemic equipoise. Consequently, greater drop-in of open-lab ... Full text Link to item Cite

Evidence from Pragmatic Trials during Routine Care - Slouching toward a Learning Health System.

Journal Article N Engl J Med · April 16, 2020 Full text Link to item Cite

Speckle Tracking Analysis of Left Ventricular Systolic Function Following Traumatic Brain Injury: A Pilot Prospective Observational Cohort Study.

Journal Article J Neurosurg Anesthesiol · April 2020 BACKGROUND: Systolic dysfunction and reduction in left ventricular ejection fraction (LVEF) has been documented after traumatic brain injury (TBI). Speckle tracking is an emerging technology for myocardial strain assessment which has been utilized to ident ... Full text Link to item Cite

Association of Implantable Device Measured Physical Activity With Hospitalization for Heart Failure.

Journal Article JACC. Heart failure · April 2020 ObjectivesThe purpose of this study was to evaluate the association of physical activity (PA) level and longitudinal PA trajectory with a composite heart failure hospitalization and mortality endpoint over a 5-year follow-up period following impla ... Full text Cite

Testing for Coronary Artery Disease in Older Patients With New-Onset Heart Failure: Findings From Get With The Guidelines-Heart Failure.

Journal Article Circ Heart Fail · April 2020 BACKGROUND: Current guidelines recommend evaluation for underlying heart disease and reversible conditions for patients with new-onset heart failure (HF). There are limited data on contemporary testing for coronary artery disease (CAD) in patients with new ... Full text Link to item Cite

Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized With Heart Failure and Reduced Ejection Fraction.

Journal Article Circ Heart Fail · April 2020 BACKGROUND: In PIONEER-HF (Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-pro BNP in Patients Stabilized From an Acute Heart Failure Episode), the in-hospital initiation of sacubitril/valsartan in patients hospitalized for acute decomp ... Full text Link to item Cite

Generating comparative evidence on new drugs and devices after approval.

Journal Article Lancet · March 21, 2020 Certain limitations of evidence available on drugs and devices at the time of market approval often persist in the post-marketing period. Often, post-marketing research landscape is fragmented. When regulatory agencies require pharmaceutical and device man ... Full text Link to item Cite

Time for NIH to lead on data sharing.

Journal Article Science · March 20, 2020 Full text Link to item Cite

Strict Versus Lenient Versus Poor Rate Control Among Patients With Atrial Fibrillation and Heart Failure (from the Get With The Guidelines - Heart Failure Program).

Journal Article Am J Cardiol · March 15, 2020 Randomized data suggest lenient rate control (resting heart rate <110 beats/min) is noninferior to strict rate control (resting heart rate <80 beats/min) in patients with atrial fibrillation (AF). However, the optimal rate control strategy in patients with ... Full text Link to item Cite

Thrombolytic therapy in older acute ischemic stroke patients with gastrointestinal malignancy or recent bleeding.

Journal Article Eur Stroke J · March 2020 BACKGROUND: There are limited data on the safety of intravenous recombinant tissue plasminogen activator (rtPA) for treating acute ischemic stroke in patients with gastrointestinal malignancy or recent gastrointestinal bleeding within 21 days of their inde ... Full text Link to item Cite

Biomarker Profile of Left Atrial Myopathy in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial.

Journal Article J Card Fail · March 2020 BACKGROUND: Although left atrial (LA) mechanical dysfunction in heart failure with preserved ejection fraction (HFpEF) is associated with poor clinical outcomes, the influence of LA myopathy on temporal changes in cardiovascular biomarkers is unclear. METH ... Full text Link to item Cite

Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL.

Journal Article Diabetes Care · March 2020 OBJECTIVE: We sought to confirm a bidirectional association between severe hypoglycemic events (SHEs) and cardiovascular (CV) event risk and to characterize individuals at dual risk. RESEARCH DESIGN AND METHODS: In a post hoc analysis of 14,752 Exenatide S ... Full text Link to item Cite

Considerations for using distributed research networks to conduct aspects of randomized trials.

Journal Article Contemp Clin Trials Commun · March 2020 Stakeholders in the clinical research enterprise are aligned around the need to make clinical research in general, and randomized controlled trials in particular, more meaningful and efficient. To that end, we have built distributed research networks (DRNs ... Full text Link to item Cite

Renal Dysfunction in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial.

Journal Article J Card Fail · March 2020 BACKGROUND: Patients with heart failure with preserved ejection fraction (HFpEF) and chronic kidney disease (CKD) represent a high-risk phenotype. The Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Heart Failure with Pre ... Full text Link to item Cite

Prospective and External Evaluation of a Machine Learning Model to Predict In-Hospital Mortality of Adults at Time of Admission.

Journal Article JAMA Netw Open · February 5, 2020 IMPORTANCE: The ability to accurately predict in-hospital mortality for patients at the time of admission could improve clinical and operational decision-making and outcomes. Few of the machine learning models that have been developed to predict in-hospita ... Full text Link to item Cite

Extended prophylaxis of venous thromboembolism with betrixaban in acutely ill medical patients with and without cancer: insights from the APEX trial.

Journal Article J Thromb Thrombolysis · February 2020 Acutely ill medical patients with cancer are at increased risk of venous thromboembolism (VTE). Thromboprophylaxis is recommended in the presence of cancer, but its safety is not known. The aim of this study was to assess the efficacy and safety of extende ... Full text Link to item Cite

Eligibility of sodium-glucose co-transporter-2 inhibitors among patients with diabetes mellitus admitted for heart failure.

Journal Article ESC Heart Fail · February 2020 AIMS: Sodium-glucose co-transporter (SGLT)-2 inhibitors have been shown to reduce the risk of cardiovascular death and heart failure (HF) hospitalization in patients with type 2 diabetes mellitus (DM) and high cardiovascular risk in two large clinical outc ... Full text Link to item Cite

Does Guideline-Directed Medical Therapy for Heart Failure Offer Benefits After LVAD Placement?-A Call for a Randomized Clinical Trial.

Journal Article JAMA Cardiol · February 1, 2020 Full text Link to item Cite

Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure: Rationale and design of CONNECT-HF.

Journal Article Am Heart J · February 2020 Many therapies have been shown to improve outcomes for patients with heart failure (HF) in controlled settings, but there are limited data available to inform best practices for hospital and post-discharge quality improvement initiatives. The CONNECT-HF st ... Full text Link to item Cite

Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial.

Journal Article Diabetes Care · February 2020 OBJECTIVE: To evaluate the impact of once-weekly exenatide (EQW) on microvascular and cardiovascular (CV) outcomes by baseline renal function in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). RESEARCH DESIGN AND METHODS: Least squares mean ... Full text Link to item Cite

Are existing and emerging biomarkers associated with cardiorespiratory fitness in patients with chronic heart failure?

Journal Article Am Heart J · February 2020 BACKGROUND: Cardiorespiratory fitness (CRF) is closely linked to health status and clinical outcomes in heart failure (HF) patients. We aimed to test whether biomarkers can reflect CRF and its change over time. METHODS: This post hoc analysis used data fro ... Full text Link to item Cite

Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).

Journal Article Diabetes Care · February 2020 OBJECTIVE: To compare medical resource use, costs, and health utilities for 14,752 patients with type 2 diabetes who were randomized to once-weekly exenatide (EQW) or placebo in addition to usual diabetes care in the Exenatide Study of Cardiovascular Event ... Full text Link to item Cite

CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis.

Journal Article Can J Cardiol · February 2020 In this update, we focus on selected topics of high clinical relevance for health care providers who treat patients with heart failure (HF), on the basis of clinical trials published after 2017. Our objective was to review the evidence, and provide recomme ... Full text Link to item Cite

Machine learning to predict venous thrombosis in acutely ill medical patients.

Journal Article Res Pract Thromb Haemost · February 2020 BACKGROUND: The identification of acutely ill patients at high risk for venous thromboembolism (VTE) may be determined clinically or by use of integer-based scoring systems. These scores demonstrated modest performance in external data sets. OBJECTIVES: To ... Full text Link to item Cite

Hospital Factors Associated With Interhospital Transfer Destination for Stroke in the Northeast United States.

Journal Article J Am Heart Assoc · January 7, 2020 Background We aimed to determine if there is an association between hospital quality and the likelihood of a given hospital being a preferred transfer destination for stroke patients. Methods and Results Data from Medicare claims identified acute ischemic ... Full text Open Access Link to item Cite

Impact of baseline covariate imbalance on bias in treatment effect estimation in cluster randomized trials: Race as an example.

Journal Article Contemp Clin Trials · January 2020 Individual-level baseline covariate imbalance could happen more frequently in cluster randomized trials, and may influence the observed treatment effect. Using computer and real-data simulations, this paper quantifies the extent and impact of covariate imb ... Full text Link to item Cite

Circulating Neprilysin in Patients With Heart Failure and Preserved Ejection Fraction.

Journal Article JACC Heart Fail · January 2020 BACKGROUND: In heart failure with reduced ejection fraction (HFrEF), elevated soluble neprilysin (sNEP) levels are associated with an increased risk of cardiovascular death, and its inhibition with sacubitril/valsartan has improved survival. OBJECTIVES: Th ... Full text Link to item Cite

The Hospital Readmissions Reduction Program: Nationwide Perspectives and Recommendations: A JACC: Heart Failure Position Paper.

Journal Article JACC Heart Fail · January 2020 The mandatory federal pay-for-performance Hospital Readmissions Reduction Program (HRRP) was created to decrease 30-day hospital readmissions by instituting accountability and stimulating quality care and coordination, particularly during care transitions. ... Full text Link to item Cite

From Theory to Practice: The Use of Real-World Data to Evaluate New Heart Failure Therapies.

Journal Article JACC Heart Fail · January 2020 Full text Link to item Cite

Safety and Outcomes of Intravenous tPA in Acute Ischemic Stroke Patients With Prior Stroke Within 3 Months: Findings From Get With The Guidelines-Stroke.

Journal Article Circ Cardiovasc Qual Outcomes · January 2020 Background Guidelines recommend against the use of intravenous tPA (tissue-type plasminogen activator; IV tPA) in acute ischemic stroke patients with prior ischemic stroke within 3 months. However, there are limited data on the safety of IV tPA in this pop ... Full text Link to item Cite

The Project Baseline Health Study: a step towards a broader mission to map human health.

Journal Article NPJ Digit Med · 2020 The Project Baseline Health Study (PBHS) was launched to map human health through a comprehensive understanding of both the health of an individual and how it relates to the broader population. The study will contribute to the creation of a biomedical info ... Full text Open Access Link to item Cite

Rhythm Control Versus Rate Control in Patients With Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction: Insights From Get With The Guidelines-Heart Failure.

Journal Article J Am Heart Assoc · December 17, 2019 Background Limited data exist to guide treatment for patients with heart failure with preserved ejection fraction and atrial fibrillation, including the important decision regarding rate versus rhythm control. Methods and Results We analyzed the Get With T ... Full text Link to item Cite

Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues.

Journal Article Circulation · December 17, 2019 Following regulatory guidance set forth in 2008 by the US Food and Drug Administration for new drugs for type 2 diabetes mellitus, many large randomized, controlled trials have been conducted with the primary goal of assessing the safety of antihyperglycem ... Full text Link to item Cite

Comparison of Hydralazine/Nitrate and Angiotensin Receptor Neprilysin Inhibitor Use Among Black Versus Nonblack Americans With Heart Failure and Reduced Ejection Fraction (from CHAMP-HF).

Journal Article Am J Cardiol · December 15, 2019 Underuse of hydralazine/nitrate (HYD/NIT) in black patients with heart failure and reduced ejection fraction (HFrEF) has been previously described, but whether this important treatment gap persists in contemporary practice is unknown. Sacubitril/valsartan ... Full text Link to item Cite

Net-clinical benefit of extended prophylaxis of venous thromboembolism with betrixaban in medically ill patients aged 80 or more.

Journal Article J Thromb Haemost · December 2019 BACKGROUND: Extended-duration thromboprophylaxis with betrixaban reduces the risk of venous thromboembolism (VTE) without increasing major bleeding rates in acutely ill medical patients as compared to standard duration enoxaparin. We aimed to assess the ri ... Full text Link to item Cite

PARAGON-HF Clinical Trial Eligibility in a Population of Patients Hospitalized With Heart Failure.

Journal Article J Card Fail · December 2019 Full text Link to item Cite

Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: Results From the EXSCEL Trial.

Journal Article Circ Cardiovasc Interv · December 2019 BACKGROUND: Recent trials have identified anti-diabetes mellitus agents that lower major adverse cardiovascular event (MACE) rates, although some increase rates of lower-extremity amputation (LEA). Patients with peripheral artery disease (PAD) have greater ... Full text Link to item Cite

Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial.

Journal Article Eur J Heart Fail · December 2019 AIM: Describe the distinguishing features of heart failure (HF) patients with reduced ejection fraction (HFrEF) in the VICTORIA (Vericiguat Global Study in Patients with Heart Failure with Reduced Ejection Fraction) trial. METHODS AND RESULTS: Key backgrou ... Full text Link to item Cite

Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial.

Journal Article Circulation · November 12, 2019 BACKGROUND: Once-weekly exenatide (EQW) had a neutral effect on hospitalization for heart failure (HHF) in the EXSCEL study (Exenatide Study of Cardiovascular Event Lowering), with no differential treatment effect on major adverse cardiac events by baselin ... Full text Link to item Cite

Haemoconcentration during treatment of acute heart failure with cardiorenal syndrome: from the CARRESS-HF trial.

Journal Article Eur J Heart Fail · November 2019 Full text Link to item Cite

Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, double-blind, placebo-controlled trial.

Journal Article Eur J Heart Fail · November 2019 AIMS: Neladenoson bialanate is a partial adenosine A1 receptor agonist with demonstrated beneficial effects on cardiac function in animal models. We aimed to assess the dose-response effect of neladenoson bialanate on cardiac structure and function, clinic ... Full text Link to item Cite

Representativeness of a Heart Failure Trial by Race and Sex: Results From ASCEND-HF and GWTG-HF.

Journal Article JACC Heart Fail · November 2019 OBJECTIVES: This study sought to determine the degree to which U.S. patients enrolled in a heart failure (HF) trial represent patients in routine U.S. clinical practice according to race and sex. BACKGROUND: Black patients and women are frequently under-re ... Full text Link to item Cite

The Future of Wearables in Heart Failure Patients.

Journal Article JACC Heart Fail · November 2019 The adoption of mobile health (mHealth) devices is creating a unique opportunity to improve heart failure (HF) care. The rise of mHealth is driven by multiple factors including consumerism, policy changes in health care, and innovations in technology. Wear ... Full text Link to item Cite

Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial.

Journal Article Cardiovasc Diabetol · October 22, 2019 BACKGROUND: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) improve cardiovascular and renal outcomes in patients with type 2 diabetes through distinct mechanisms. However, evidence on clinical ou ... Full text Link to item Cite

Clinical Effectiveness of Direct Oral Anticoagulants vs Warfarin in Older Patients With Atrial Fibrillation and Ischemic Stroke: Findings From the Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) Study.

Journal Article JAMA Neurol · October 1, 2019 IMPORTANCE: Current guidelines recommend direct oral anticoagulants (DOACs) over warfarin for stroke prevention in patients with atrial fibrillation (AF) who are at high risk. Despite demonstrated efficacy in clinical trials, real-world data of DOACs vs wa ... Full text Open Access Link to item Cite

Revisiting the Role of Aspirin for the Primary Prevention of Cardiovascular Disease.

Journal Article Circulation · September 24, 2019 Aspirin is the cornerstone of the antithrombotic management of patients with established atherosclerotic cardiovascular disease, but major guidelines provide conflicting recommendations for its use in primary prevention. Findings from recent randomized tri ... Full text Link to item Cite

Prognostic Implications of Changes in Amino-Terminal Pro-B-Type Natriuretic Peptide in Acute Decompensated Heart Failure: Insights From ASCEND-HF.

Journal Article J Card Fail · September 2019 BACKGROUND: Amino-terminal pro-B-type natriuretic peptide (NTproBNP) is closely associated with prognosis in acute decompensated heart failure (ADHF). As a result, there has been great interest measuring it during the course of treatment. The prognostic im ... Full text Link to item Cite

Spironolactone in Acute Heart Failure Patients With Renal Dysfunction and Risk Factors for Diuretic Resistance: From the ATHENA-HF Trial.

Journal Article Can J Cardiol · September 2019 BACKGROUND: Acute heart failure (HF) patients with renal insufficiency and risk factors for diuretic resistance may be most likely to derive incremental improvement in congestion with the addition of spironolactone. METHODS: The Aldosterone Targeted Neuroh ... Full text Link to item Cite

The Burden of Congestion in Patients Hospitalized With Acute Decompensated Heart Failure.

Journal Article Am J Cardiol · August 15, 2019 Congestion is associated with adverse outcomes in heart failure (HF) patients. We characterized congestion in patients hospitalized for HF and examined the association between congestion severity at admission and postdischarge outcomes. Using the OPTIMIZE- ... Full text Link to item Cite

Recent Myocardial Infarction is Associated With Increased Risk in Older Adults With Acute Ischemic Stroke Receiving Thrombolytic Therapy.

Journal Article J Am Heart Assoc · August 6, 2019 Background Intravenous recombinant tissue-type plasminogen activator (rtPA) remains the only medical therapy to improve outcomes for acute ischemic stroke (AIS), but the safety of rtPA in AIS patients with a history of recent myocardial infarction (MI) rem ... Full text Open Access Link to item Cite

Addressing guideline and policy changes during pragmatic clinical trials.

Journal Article Clin Trials · August 2019 While conducting a set of large-scale multi-site pragmatic clinical trials involving high-impact public health issues such as end-stage renal disease, opioid use, and colorectal cancer, there were substantial changes to both policies and guidelines relevan ... Full text Link to item Cite

Intravenous Tissue Plasminogen Activator in Stroke Mimics.

Journal Article Circ Cardiovasc Qual Outcomes · August 2019 BACKGROUND: The necessity for rapid evaluation and treatment of acute ischemic stroke with intravenous tPA (tissue-type plasminogen activator) may increase the risk of administrating tPA to patients presenting with noncerebrovascular conditions that closel ... Full text Link to item Cite

Evolving the Hospital Readmissions Reduction Program: A Call for Peace, Happiness, and Improved Patient-Centered Outcomes.

Journal Article J Am Coll Cardiol · July 16, 2019 Full text Link to item Cite

Association of Changes in Heart Failure Treatment With Patients' Health Status: Real-World Evidence From CHAMP-HF.

Journal Article JACC Heart Fail · July 2019 OBJECTIVES: The aim of this study was to use a multicenter, observational outpatient registry of patients with heart failure with reduced ejection fraction (HFrEF) to describe the association between changes in patients' medications with changes in health ... Full text Link to item Cite

Transitioning to the National Institutes of Health single institutional review board model: Piloting the use of the Streamlined, Multi-site, Accelerated Resources for Trials IRB Reliance.

Journal Article Clin Trials · June 2019 BACKGROUND/AIMS: Obtaining ethical approval from multiple institutional review boards is a long-standing challenge to multi-site clinical trials and often leads to significant delays in study activation and enrollment. As of 25 January 2018, the National I ... Full text Link to item Cite

Association of post-discharge specialty outpatient visits with readmissions and mortality in high-risk heart failure patients.

Journal Article Am Heart J · June 2019 UNLABELLED: Heart failure (HF) outcomes are especially poor in high-risk patients with certain comorbidities including diabetes mellitus (DM), chronic kidney disease (CKD), and chronic obstructive pulmonary disease (COPD). Whether early specialty or primar ... Full text Link to item Cite

Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL).

Journal Article Diabetes Care · June 2019 OBJECTIVE: Increases in serum calcitonin, a tumor marker for medullary thyroid carcinoma (MTC), have been associated with glucagon-like peptide 1 receptor agonist use in some preclinical studies. We report calcitonin changes in exenatide-treated and placeb ... Full text Link to item Cite

Intravenous Tissue-Type Plasminogen Activator in Acute Ischemic Stroke Patients With History of Stroke Plus Diabetes Mellitus.

Journal Article Stroke · June 2019 Background and Purpose- Acute ischemic stroke patients with history of prior ischemic stroke plus concomitant diabetes mellitus (DM) were excluded from the ECASS III trial (European Cooperative Acute Stroke Study) because of safety concerns. However, there ... Full text Link to item Cite

Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction.

Journal Article J Am Coll Cardiol · May 21, 2019 BACKGROUND: Guidelines recommend that patients with heart failure with reduced ejection fraction (HFrEF) have medical therapy titrated to target doses derived from clinical trials, as tolerated. The degree to which titration occurs in contemporary U.S. pra ... Full text Link to item Cite

The Association of Black Cardiologists (ABC) Cardiovascular Implementation Study (CVIS): A Research Registry Integrating Social Determinants to Support Care for Underserved Patients.

Journal Article Int J Environ Res Public Health · May 10, 2019 African Americans, other minorities and underserved populations are consistently under- represented in clinical trials. Such underrepresentation results in a gap in the evidence base, and health disparities. The ABC Cardiovascular Implementation Study (CVI ... Full text Link to item Cite

PCSK9 Inhibitor Use in the Real World: Data From the National Patient-Centered Research Network.

Journal Article J Am Heart Assoc · May 7, 2019 Background PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors effectively lower LDL (low-density lipoprotein) cholesterol and have been shown to reduce cardiovascular outcomes in high-risk patients. We used real-world electronic health record ... Full text Link to item Cite

Long-term outcomes for heart failure patients with and without diabetes: From the Get With The Guidelines-Heart Failure Registry.

Journal Article Am Heart J · May 2019 BACKGROUND: Diabetes mellitus is an increasingly prevalent condition among heart failure (HF) patients. The long-term morbidity and mortality among patients with and without diabetes with HF with reduced (HFrEF), borderline (HFbEF), and preserved ejection ... Full text Link to item Cite

Trends in Readmissions and Length of Stay for Patients Hospitalized With Heart Failure in Canada and the United States.

Journal Article JAMA Cardiol · May 1, 2019 IMPORTANCE: Over the past decade, reducing 30-day readmission rates has been emphasized in the United States (including via the implementation of the Hospital Readmissions Reduction Program) but not Canada. OBJECTIVE: To examine changes that occurred from ... Full text Link to item Cite

Rationale and Design of the VITALITY-HFpEF Trial.

Journal Article Circ Heart Fail · May 2019 Background The VITALITY-HFpEF trial (Evaluate the Efficacy and Safety of the Oral sGC Stimulator Vericiguat to Improve Physical Functioning in Daily Living Activities of Patients With Heart Failure and Preserved Ejection Fraction) is designed to determine ... Full text Link to item Cite

Splanchnic nerve blockade in chronic heart failure (Splanchnic HF-2)

Conference EUROPEAN JOURNAL OF HEART FAILURE · May 1, 2019 Link to item Cite

Identifying responders to oral iron supplementation in heart failure with a reduced ejection fraction: a post-hoc analysis of the IRONOUT-HF trial.

Journal Article J Cardiovasc Med (Hagerstown) · April 2019 BACKGROUND: The IRONOUT-HF trial previously demonstrated that oral iron supplementation minimally increased iron stores and did not improve exercise capacity in patients with heart failure with a reduced ejection fraction (HFrEF) and iron deficiency. METHO ... Full text Link to item Cite

Target Doses of Heart Failure Medical Therapy and Blood Pressure: Insights From the CHAMP-HF Registry.

Journal Article JACC Heart Fail · April 2019 OBJECTIVES: This study sought to determine the rate of use of target doses of foundational guideline-directed medical therapy (GDMT) in a contemporary cohort of patients with heart failure with reduced ejection fraction (HFrEF) across systolic blood pressu ... Full text Link to item Cite

Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy.

Journal Article Intensive Care Med · April 2019 PURPOSE: To assess the efficacy and safety of betrixaban for venous thromboembolism (VTE) prophylaxis among critically ill patients. METHODS: The APEX trial randomized 7513 acutely ill hospitalized patients to betrixaban for 35-42 days or enoxaparin for 10 ... Full text Link to item Cite

Heart failure drug treatment.

Journal Article Lancet · March 9, 2019 Heart failure is the most common cardiovascular reason for hospital admission for people older than 60 years of age. Few areas in medicine have progressed as remarkably as heart failure treatment over the past three decades. However, progress has been cons ... Full text Link to item Cite

Hospital-based quality improvement interventions for patients with heart failure: a systematic review.

Journal Article Heart · March 2019 OBJECTIVE: To estimate the direction and magnitude of effect and quality of evidence for hospital-based heart failure (HF) quality improvement interventions on process of care measures and clinical outcomes among patients with acute HF. REVIEW METHODS: We ... Full text Link to item Cite

What Is Needed Now to Improve Cardiovascular Clinical Registries in the Future.

Journal Article JAMA Cardiol · March 1, 2019 Full text Link to item Cite

Phenotypic features of patients with Type 2 diabetes at increased risk of severe hypoglycemic events occurring before or after cardiovascular events

Conference DIABETIC MEDICINE · March 1, 2019 Link to item Cite

LONGITUDINAL CHANGES IN MEDICATION DOSING AMONG PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION: FROM THE CHAMP-HF REGISTRY

Conference Journal of the American College of Cardiology · March 2019 Full text Cite

PATIENTS WITH DIABETES AND PERIPHERAL ARTERIAL DISEASE: RESULTS FROM THE EXSCEL TRIAL

Conference Journal of the American College of Cardiology · March 2019 Full text Cite

ASSOCIATION BETWEEN ASSIGNMENT TO AN ACCOUNTABLE CARE ORGANIZATION AND QUALITY OF CARE AND OUTCOMES AMONG MEDICARE BENEFICIARIES HOSPITALIZED FOR HEART FAILURE

Conference Journal of the American College of Cardiology · March 2019 Full text Cite

USE OF HYDRALAZINE/NITRATE, ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITOR AND OTHER GUIDELINE-DIRECTED MEDICAL THERAPIES AMONGST AFRICAN AMERICANS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION: INSIGHTS FROM CHAMP-HF

Conference Journal of the American College of Cardiology · March 2019 Full text Cite

SOLUBLE NEPRILYSIN IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION

Conference Journal of the American College of Cardiology · March 2019 Full text Cite

INCREASED RISK OF SEVERE HYPOGLYCEMIC EVENTS BEFORE AND AFTER CARDIOVASCULAR EVENTS IN TYPE 2 DIABETES: VALIDATION OF A NOVEL CONCEPT

Conference Journal of the American College of Cardiology · March 2019 Full text Cite

OUTCOMES OF NON-SURGICAL PATIENTS WITH SEVERE TRICUSPID REGURGITATION AND CONGESTIVE HEART FAILURE

Conference Journal of the American College of Cardiology · March 2019 Full text Cite

IMPACT OF TRICUSPID DISEASE IN PATIENTS WITH CONGESTIVE HEART FAILURE AND MITRAL VALVE DISEASE: A NATIONWIDE COHORT STUDY

Conference Journal of the American College of Cardiology · March 2019 Full text Cite

PARADOXICAL PROTECTIVE EFFECT OF OBESITY ON THE RISK OF VENOUS THROMBOEMBOLISM: OBSERVATIONS FROM APEX TRIAL

Conference Journal of the American College of Cardiology · March 2019 Full text Cite

Reduction of Cardiovascular Mortality and Ischemic Events in Acute Medically Ill Patients.

Journal Article Circulation · February 26, 2019 Full text Link to item Cite

Glycated Hemoglobin and Outcomes of Heart Failure (from Get With the Guidelines-Heart Failure).

Journal Article Am J Cardiol · February 15, 2019 Glycated hemoglobin (HbA1C) is a risk factor for new onset heart failure (HF). There is however a paucity of data evaluating its association with outcomes in patients with established HF. We assessed the relation of HbA1C with outcomes among hospitalized H ... Full text Link to item Cite

Heart Failure With Preserved Ejection Fraction and Diabetes: JACC State-of-the-Art Review.

Journal Article J Am Coll Cardiol · February 12, 2019 Heart failure with preserved ejection fraction (HFpEF) is now the most common form of HF, affecting over 3 million adults in the United States alone. HFpEF is a heterogenous syndrome. One important phenotype may be related to comorbid conditions, including ... Full text Link to item Cite

Relationship Between Hospital Characteristics and Early Adoption of Angiotensin-Receptor/Neprilysin Inhibitor Among Eligible Patients Hospitalized for Heart Failure.

Journal Article J Am Heart Assoc · February 5, 2019 Background The angiotensin-receptor/neprilysin inhibitor ( ARNI ) sacubitril/valsartan reduces hospitalization and mortality for patients with heart failure with reduced ejection fraction. However, adoption of ARNI into clinical practice has been slow. Fac ... Full text Link to item Cite

Ischemic Stroke Transfer Patterns in the Northeast United States.

Journal Article J Stroke Cerebrovasc Dis · February 2019 BACKGROUND: Little is known about how hospitals are connected in the transfer of ischemic stroke (IS) patients. We aimed to describe differences in characteristics of transferred versus nontransferred patients and between transferring and receiving hospita ... Full text Link to item Cite

Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL.

Journal Article Diabetes Care · February 2019 OBJECTIVE: The sodium-glucose cotransporter 2 inhibitors (SGLT2i) empagliflozin and canagliflozin reduce the incidence of major adverse cardiovascular events (MACE), all-cause mortality (ACM), and renal events in cardiovascular outcomes trials, with observ ... Full text Link to item Cite

Timing of cardiac resynchronization therapy device implantation in heart failure patients and its association with outcomes.

Journal Article Clin Cardiol · February 2019 BACKGROUND: When used in appropriately selected heart failure (HF) patients, cardiac resynchronization therapy (CRT) reduces mortality and hospitalization. It is not understood whether CRT implantation during hospitalization for HF is associated with simil ... Full text Link to item Cite

High-Density Lipoprotein Particle Subfractions in Heart Failure With Preserved or Reduced Ejection Fraction.

Journal Article J Am Coll Cardiol · January 22, 2019 BACKGROUND: Circulating high-density lipoprotein particle (HDL-P) subfractions impact atherogenesis, inflammation, and endothelial function, all of which are implicated in the pathobiology of heart failure (HF). OBJECTIVES: The authors sought to identify k ... Full text Link to item Cite

Inverse relationship of serum albumin to the risk of venous thromboembolism among acutely ill hospitalized patients: Analysis from the APEX trial.

Journal Article Am J Hematol · January 2019 Hypoalbuminemia is a common finding and independent predictor for unfavorable prognosis. The prognostic value of albumin measurement for short-term VTE prediction in hospitalized patients remains unclear. In the APEX trial (ClinicalTrials.gov identifier: N ... Full text Link to item Cite

History of Atrial Fibrillation and Trajectory of Decongestion in Acute Heart Failure.

Journal Article JACC Heart Fail · January 2019 OBJECTIVES: This study sought to characterize the course of decongestion among patients hospitalized for acute heart failure (AHF) by history of atrial fibrillation (AF) and/or atrial flutter (AFL). BACKGROUND: AF/AFL and chronic heart failure (HF) commonl ... Full text Link to item Cite

Reply: Vaccination in Patients With Heart Failure: An Established Recommendation in Patients With Chronic Heart Disease.

Journal Article JACC Heart Fail · January 2019 Full text Link to item Cite

Statistical Code for Clinical Research Papers.

Journal Article Ann Intern Med · January 1, 2019 Full text Link to item Cite

Characteristics of Acute Heart Failure Hospitalizations Based on Presenting Severity.

Journal Article Circ Heart Fail · January 2019 BACKGROUND: Hospitalizations for acute heart failure (HF) are significant events with downstream implications for patients, as well as healthcare systems and payers. However, from anecdotal experience, both hospitalization and postdischarge courses vary si ... Full text Link to item Cite

Assessing heterogeneity of treatment effect analyses in health-related cluster randomized trials: A systematic review.

Journal Article PLoS One · 2019 BACKGROUND: Cluster-randomized trials (CRTs) are being increasingly used to test a range of interventions, including medical interventions commonly used in clinical practice. Policies created by the NIH and the Food and Drug Administration (FDA) require th ... Full text Link to item Cite

Estimation of Acutely Ill Medical Patients at Venous Thromboembolism Risk Eligible for Extended Thromboprophylaxis Using APEX Criteria in US Hospitals.

Journal Article Clin Appl Thromb Hemost · 2019 Major medical illnesses place patients at risk of venous thromboembolism (VTE). Some risk factors including age ≥75 years or history of cancer place them at increased risk of VTE that extends for at least 5 to 6 weeks following hospital admission. Betrixab ... Full text Link to item Cite

Incidence of statin use in older adults with and without cardiovascular disease and diabetes mellitus, January 2008- March 2018.

Journal Article PLoS One · 2019 BACKGROUND: Data from randomized controlled trials and observational studies on older adults who take statins for primary prevention of atherosclerotic cardiovascular disease are limited. To determine the incidence of statin use in older adults with and wi ... Full text Link to item Cite

Splanchnic nerve block for decompensated chronic heart failure: splanchnic-HF.

Journal Article Eur Heart J · December 21, 2018 Full text Link to item Cite

High-Sensitivity Troponin I in Hospitalized and Ambulatory Patients With Heart Failure With Preserved Ejection Fraction: Insights From the Heart Failure Clinical Research Network.

Conference J Am Heart Assoc · December 18, 2018 Background We sought to study the prevalence of high-sensitivity troponin and its association with cardiac structure and outcomes in ambulatory and hospitalized patients with heart failure with a preserved ejection fraction ( HF p EF ). Methods and Results ... Full text Link to item Cite

PCSK9 Inhibitor Use in the Real World: Data From the National Patient Centered Outcomes Research Network (PCORNet)

Conference CIRCULATION · December 18, 2018 Link to item Cite

Is Time From Last Hospitalization for Heart Failure to Placement of a Primary Prevention Implantable Cardioverter-Defibrillator Associated With Patient Outcomes?

Journal Article Circulation · December 11, 2018 BACKGROUND: Landmark studies have demonstrated the safety and efficacy of implantable cardioverter-defibrillators (ICDs) in selected stable ambulatory patients with heart failure (HF) with a reduced ejection fraction receiving optimal medical therapy. It i ... Full text Link to item Cite

Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial.

Conference ESC Heart Fail · December 2018 AIMS: Obesity is present in up to 45% of patients with heart failure (HF). Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor antagonist, facilitates weight loss in obese patients. The efficacy of liraglutide as a weight loss agent among patients with ... Full text Link to item Cite

Asymptomatic Deep Vein Thrombosis is Associated with an Increased Risk of Death: Insights from the APEX Trial.

Journal Article Thromb Haemost · December 2018 AIM: Asymptomatic deep vein thrombosis (DVT) diagnosed with compression ultrasound (CUS) is a common endpoint in trials assessing the efficacy of anticoagulants to prevent venous thromboembolism (VTE), but the relationship of asymptomatic thrombus to mort ... Full text Link to item Cite

Association of Kidney Function With 30-Day and 1-Year Poststroke Mortality and Hospital Readmission.

Journal Article Stroke · December 2018 Background and Purpose- Kidney dysfunction is common among patients hospitalized for ischemic stroke. Understanding the association of kidney disease with poststroke outcomes is important to properly adjust for case mix in outcome studies, payment models a ... Full text Link to item Cite

Providing Individual Research Results to Participants-Reply.

Journal Article JAMA · December 2018 Full text Cite

Engaging patients throughout the health system: A landscape analysis of cold-call policies and recommendations for future policy change.

Journal Article J Clin Transl Sci · December 2018 Healthcare institutions may often prohibit "cold-calling" or direct contact with a potential research participant when the person initiating contact is unknown to the patient. This policy aims to maintain patient privacy, but may have unintended consequenc ... Full text Open Access Link to item Cite

Effects of Once-Weekly Exenatide on Clinical Outcomes in Patients With Preexisting Cardiovascular Disease.

Journal Article Circulation · November 27, 2018 Full text Link to item Cite

Response by Kumbhani et al to Letters Regarding Article, "Association Between Hospital Volume, Processes of Care, and Outcomes in Patients Admitted With Heart Failure: Insights From Get With The Guidelines-Heart Failure".

Journal Article Circulation · November 13, 2018 Full text Link to item Cite

Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: The INDIE-HFpEF Randomized Clinical Trial.

Journal Article JAMA · November 6, 2018 IMPORTANCE: There are few effective treatments for heart failure with preserved ejection fraction (HFpEF). Short-term administration of inorganic nitrite or nitrate preparations has been shown to enhance nitric oxide signaling, which may improve aerobic ca ... Full text Link to item Cite

Relation of Volume Overload to Clinical Outcomes in Acute Heart Failure (From ASCEND-HF).

Journal Article Am J Cardiol · November 1, 2018 We aimed to study whether jugular venous distension (JVD) and peripheral edema were associated with worse outcomes in patients with acute heart failure in the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure trial. Of 7,14 ... Full text Link to item Cite

Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1-receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction.

Journal Article Eur J Heart Fail · November 2018 Despite major advances in the treatment of chronic heart failure (HF) with reduced ejection fraction (HFrEF), morbidity and mortality associated with the condition remain high, suggesting the need for additional treatment options, particularly haemodynamic ... Full text Link to item Cite

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.

Journal Article Lancet · October 27, 2018 BACKGROUND: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine t ... Full text Link to item Cite

International Comparison of Patient Characteristics and Quality of Care for Ischemic Stroke: Analysis of the China National Stroke Registry and the American Heart Association Get With The Guidelines--Stroke Program.

Journal Article J Am Heart Assoc · October 16, 2018 Background Adherence to evidence-based guidelines is an important quality indicator; yet, there is lack of assessment of adherence to performance measures in acute ischemic stroke for most world regions. Methods and Results We analyzed 19 604 patients with ... Full text Open Access Link to item Cite

Effect of Once-Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial.

Journal Article J Am Heart Assoc · October 2, 2018 Background In the EXSCEL (Exenatide Study of Cardiovascular Event Lowering), exenatide once-weekly resulted in a nonsignificant reduction in major adverse cardiovascular events ( MACEs ) and a nominal 14% reduction in all-cause mortality in 14 752 patients ... Full text Open Access Link to item Cite

Vaccination Trends in Patients With Heart Failure: Insights From Get With The Guidelines-Heart Failure.

Journal Article JACC Heart Fail · October 2018 OBJECTIVES: This study sought to evaluate and contribute to the limited data on U.S. hospital practice patterns with respect to respiratory vaccination in patients hospitalized with heart failure (HF). BACKGROUND: Respiratory infection is a major driver of ... Full text Link to item Cite

Trends in Hospice Discharge and Relative Outcomes Among Medicare Patients in the Get With The Guidelines-Heart Failure Registry.

Journal Article JAMA Cardiol · October 1, 2018 IMPORTANCE: While 1 in 10 older patients hospitalized with heart failure (HF) die within 30 days, end-of-life care for this population is not well described. OBJECTIVE: To assess rates of discharge to hospice, readmission after hospice, and survival in hos ... Full text Link to item Cite

Impact of exenatide on medical costs and health utilities in type 2 diabetes: experience from EXSCEL

Conference DIABETOLOGIA · October 1, 2018 Link to item Cite

Lifetime cost-effectiveness simulation of exenatide once-weekly in type 2 diabetes: evidence from the EXSCEL trial

Conference DIABETOLOGIA · October 1, 2018 Link to item Cite

Potential impact of differential drop-in of open-label diabetes medications in EXSCEL

Conference DIABETOLOGIA · October 1, 2018 Link to item Cite

Changes in serum calcitonin concentrations and incidence of adjudicated medullary thyroid carcinoma in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)

Conference DIABETOLOGIA · October 1, 2018 Link to item Cite

Cardiovascular safety and efficacy of exenatide once-weekly in patients with moderate renal dysfunction in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)

Conference DIABETOLOGIA · October 1, 2018 Link to item Cite

Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points.

Journal Article Circ Cardiovasc Qual Outcomes · October 2018 BACKGROUND: Globalization of clinical trials fosters inclusion of higher and lower income countries, but the influence of enrolling country income level on heart failure trial performance is unclear. This study sought to evaluate associations between enrol ... Full text Link to item Cite

Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus-Rationale, design, and baseline characteristics.

Journal Article Am Heart J · September 2018 BACKGROUND: Albiglutide is a long-acting glucagon-like peptide-1 receptor agonist that improves glycemic control in patients with type 2 diabetes mellitus (T2DM). Harmony Outcomes is a randomized, double-blind, placebo-controlled trial of the effect of alb ... Full text Link to item Cite

The emerging role of novel antihyperglycemic agents in the treatment of heart failure and diabetes: A focus on cardiorenal outcomes.

Journal Article Clin Cardiol · September 2018 Heart failure (HF) and type 2 diabetes mellitus (T2DM) are two global pandemics, affecting over 25 and 420 million people, respectively. The prevalence of comorbid HF and T2DM is rising, and the prognosis remains poor. One central area of overlap of these ... Full text Link to item Cite

Intravenous tPA (Tissue-Type Plasminogen Activator) in Patients With Acute Ischemic Stroke Taking Non-Vitamin K Antagonist Oral Anticoagulants Preceding Stroke.

Journal Article Stroke · September 2018 Background and Purpose- Although there are no trials or large cohorts to inform clinical care, current guidelines caution against giving intravenous tPA (tissue-type plasminogen activator) to patients with acute ischemic stroke who are taking non-vitamin K ... Full text Link to item Cite

Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States.

Journal Article Circ Heart Fail · September 2018 Background Current guidelines recommend sacubitril/valsartan for patients with heart failure with reduced ejection fraction, but the rate of adoption in the United States has been slow. Methods and Results Using data from CHAMP-HF (Change the Management of ... Full text Link to item Cite

Splanchnic Nerve Block for Acute Heart Failure.

Journal Article Circulation · August 28, 2018 Full text Link to item Cite

Return of Research Results to Study Participants: Uncharted and Untested.

Journal Article JAMA · August 7, 2018 Full text Link to item Cite

Association of Anemia with Venous Thromboembolism in Acutely Ill Hospitalized Patients: An APEX Trial Substudy.

Journal Article Am J Med · August 2018 BACKGROUND: Anemia is a common finding and independent predictor for adverse outcomes in hospitalized patients with medical illness. It remains unclear whether anemia is a risk factor for venous thromboembolism and whether the presence of anemia can refine ... Full text Link to item Cite

Leveraging electronic health records for clinical research.

Journal Article Am Heart J · August 2018 Electronic health records (EHRs) can be a major tool in the quest to decrease costs and timelines of clinical trial research, generate better evidence for clinical decision making, and advance health care. Over the past decade, EHRs have increasingly offer ... Full text Link to item Cite

Maximizing benefits and mitigating risks with mineralocorticoid receptor antagonist therapy.

Journal Article Eur J Heart Fail · August 2018 Full text Link to item Cite

High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trial.

Journal Article Am Heart J · August 2018 BACKGROUND: Influenza leads to significant cardiopulmonary morbidity and mortality-particularly in patients with cardiovascular disease-that may be prevented with a standard influenza vaccine. However, patients with cardiovascular conditions have a reduced ... Full text Link to item Cite

Circulating Cardiac Troponin I Levels Measured by a Novel Highly Sensitive Assay in Acute Decompensated Heart Failure: Insights From the ASCEND-HF Trial.

Journal Article J Card Fail · August 2018 BACKGROUND: Circulating cardiac troponin levels (cTn), representative of myocardial injury, are commonly elevated in heart failure (HF) and related to adverse clinical events. However, whether cTn represents a spectrum of risk in HF is unclear. METHODS: Ba ... Full text Link to item Cite

2018 ACC/HRS/NASCI/SCAI/SCCT Expert Consensus Document on Optimal Use of Ionizing Radiation in Cardiovascular Imaging-Best Practices for Safety and Effectiveness, Part 1: Radiation Physics and Radiation Biology: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways Developed in Collaboration With Mended Hearts.

Journal Article Catheter Cardiovasc Interv · August 1, 2018 The stimulus to create this document was the recognition that ionizing radiation-guided cardiovascular procedures are being performed with increasing frequency, leading to greater patient radiation exposure and, potentially, to greater exposure for clinica ... Full text Link to item Cite

2018 ACC/HRS/NASCI/SCAI/SCCT Expert Consensus Document on Optimal Use of Ionizing Radiation in Cardiovascular Imaging: Best Practices for Safety and Effectiveness.

Journal Article Catheter Cardiovasc Interv · August 1, 2018 Full text Link to item Cite

2018 ACC/HRS/NASCI/SCAI/SCCT Expert Consensus Document on Optimal Use of Ionizing Radiation in Cardiovascular Imaging-Best Practices for Safety and Effectiveness, Part 2: Radiological Equipment Operation, Dose-Sparing Methodologies, Patient and Medical Personnel Protection.

Periprocedural Risk and Survival after ICD Placement in Patients with Advanced Heart Failure

Conference Journal of Cardiac Failure · August 2018 Full text Cite

Diabetes is Associated with Worse In-Hospital and 30-Day Post-Discharge Morbidity in Patients with Heart Failure with Preserved Ejection Fraction: Findings from the Get With The Guidelines Heart Failure Registry

Conference Journal of Cardiac Failure · August 2018 Full text Cite

Association between Sacubitril/Valsartan Initiation and Health Status Outcomes inHeart Failure with Reduced Ejection Fraction:Findings from the CHAMP-HF Registry

Conference Journal of Cardiac Failure · August 2018 Full text Cite

Use of Target Doses of Guideline Directed Medical Therapy in Heart Failure by Systolic Blood Pressure: Insights from the CHAMP-HF Registry

Conference Journal of Cardiac Failure · August 2018 Full text Cite

Improvements in Health Status Associated with Medication Adjustments in Outpatients with HFrEF: Insights from the CHAMP-HF Registry

Conference Journal of Cardiac Failure · August 2018 Full text Cite

Patient and Practice Characteristics Associated with Sacubitril/Valsartan Use in the United States

Conference Journal of Cardiac Failure · August 2018 Full text Cite

Can biomarkers be used to predict cardiopulmonary exercise test performance in patients with chronic heart failure?

Conference EUROPEAN HEART JOURNAL · August 1, 2018 Link to item Cite

Asymptomatic deep vein thrombosis in acutely ill medical patients: insights from the APEX trial

Conference EUROPEAN HEART JOURNAL · August 1, 2018 Link to item Cite

Betrixaban compared to enoxaparin among obese acute medically ill subjects: an APEX trial subgroup analysis

Conference EUROPEAN HEART JOURNAL · August 1, 2018 Link to item Cite

Association of low hemoglobin with venous thromboembolism in acutely ill hospitalized medical patients: findings from the APEX trial

Conference EUROPEAN HEART JOURNAL · August 1, 2018 Link to item Cite

Effects of once-weekly exenatide on clinical outcomes in the subgroup of patients with pre-existing cardiovascular disease: insights from EXSCEL

Conference EUROPEAN HEART JOURNAL · August 1, 2018 Link to item Cite

Betrixaban versus enoxaparin for venous thromboembolism prophylaxis in critically ill patients: findings from the APEX trial

Conference EUROPEAN HEART JOURNAL · August 1, 2018 Link to item Cite

Performance of a machine learning model vs. IMPROVE score for VTE prediction in acute medically ill patients: insights from the APEX trial

Conference EUROPEAN HEART JOURNAL · August 1, 2018 Link to item Cite

Characterization of major and clinically relevant non-major bleeding in the APEX trial

Conference EUROPEAN HEART JOURNAL · August 1, 2018 Link to item Cite

Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry.

Journal Article J Am Coll Cardiol · July 24, 2018 BACKGROUND: Guidelines strongly recommend patients with heart failure with reduced ejection fraction (HFrEF) be treated with multiple medications proven to improve clinical outcomes, as tolerated. The degree to which gaps in medication use and dosing persi ... Full text Link to item Cite

Diabetes and long-term outcomes of ischaemic stroke: findings from Get With The Guidelines-Stroke.

Journal Article Eur Heart J · July 1, 2018 AIMS: There is a paucity of data on the influence of diabetes on long-term outcomes after ischaemic stroke (IS). We assessed whether outcomes after IS differ between patients with and without diabetes. METHODS AND RESULTS: Patients aged ≥65 years (n = 409 ... Full text Link to item Cite

Determinants of Diuretic Responsiveness and Associated Outcomes During Acute Heart Failure Hospitalization: An Analysis From the NHLBI Heart Failure Network Clinical Trials.

Journal Article J Card Fail · July 2018 BACKGROUND: Poor response to loop diuretic therapy is a marker of risk during heart failure hospitalization. We sought to describe baseline determinants of diuretic response and to further explore the relationship between this response and clinical outcome ... Full text Link to item Cite

Rate pressure product and the components of heart rate and systolic blood pressure in hospitalized heart failure patients with preserved ejection fraction: Insights from ASCEND-HF.

Journal Article Clin Cardiol · July 2018 BACKGROUND: Heart rate and systolic blood pressure (SBP) are prognostic markers in heart failure (HF) with reduced ejection fraction (HFrEF). Their combination in rate pressure product (RPP) as well as their role in heart failure with preserved ejection fr ... Full text Link to item Cite

Association of the Affordable Care Act's Medicaid Expansion With Care Quality and Outcomes for Low-Income Patients Hospitalized With Heart Failure.

Journal Article Circ Cardiovasc Qual Outcomes · July 2018 BACKGROUND: Heart failure (HF) is the leading cause of morbidity and mortality in the United States. Despite advancement in the management of HF, outcomes remain suboptimal, particularly among the uninsured. In 2014, the Affordable Care Act expanded Medica ... Full text Link to item Cite

Review: In noncardiac surgery, amiodarone, β-blocker, or statin prophylaxis reduces postoperative AF.

Journal Article Annals of internal medicine · July 2018 Full text Cite

Impact of SGLT2 Inhibitors (SGLT2i) on Cardiovascular (CV) Risk and Estimated Glomerular Filtration Rate (eGFR) in the EXSCEL Placebo Group

Conference Diabetes · July 1, 2018 SGLT2i, empagliflozin and canagliflozin, have been shown to reduce the incidence of major adverse CV events (MACE), all-cause mortality (ACM) and renal events in CV outcomes trials (CVOTs), with robust real-world evidence (RWE) suggesting class eff ... Full text Cite

Renal Outcomes in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)

Conference Diabetes · July 1, 2018 Background: EXSCEL was a multinational, randomized, blinded, placebo-controlled, pragmatic CV outcome trial of once-weekly exenatide on the background of usual care. We report exenatide’s impact on estimated glomerular filtration rate (eGFR), new m ... Full text Cite

EXSCEL—Once-Weekly Exenatide Reduces Medical Resource Utilization in Patients with Type 2 Diabetes Mellitus

Conference Diabetes · July 1, 2018 Objectives: To evaluate the effect of exenatide 2mg once-weekly vs. placebo in addition to usual care on medical resource use among 14,572 patients with type 2 diabetes enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL), whic ... Full text Cite

Home-Time After Discharge Among Patients Hospitalized With Heart Failure.

Journal Article J Am Coll Cardiol · June 12, 2018 BACKGROUND: Surveys of patients with cardiovascular disease have suggested that "home-time"-being alive and out of any health care institution-is a prioritized outcome. This novel measure has not been studied among patients with heart failure (HF). OBJECTI ... Full text Link to item Cite

Characteristics and Treatments of Patients Enrolled in the CHAMP-HF Registry Compared With Patients Enrolled in the PARADIGM-HF Trial.

Journal Article J Am Heart Assoc · June 12, 2018 BACKGROUND: The US Food and Drug Administration approved sacubitril/valsartan for patients with chronic heart failure (HF) with reduced ejection fraction in 2015 on the basis of the results of the PARADIGM-HF (Prospective Comparison of ARNI [Angiotensin Re ... Full text Link to item Cite

Primary graft dysfunction after heart transplantation: Incidence, trends, and associated risk factors.

Journal Article Am J Transplant · June 2018 Changes in heart transplantation (HT) donor and recipient demographics may influence the incidence of primary graft dysfunction (PGD). We conducted a retrospective study to evaluate PGD incidence, trends, and associated risk factors by analyzing consecutiv ... Full text Link to item Cite

A Hospital Level Analysis of 30-Day Readmission Performance for Heart Failure Patients and Long-Term Survival: Findings from Get With The Guidelines-Heart Failure.

Journal Article Am Heart J · June 2018 BACKGROUND: Medicare utilizes 30-day risk-standardized readmission rates (RSRR) as a measure of hospital quality and applies penalties based on this measure. The objective of this study was to identify the relationship between hospital performance on 30-da ... Full text Link to item Cite

Sustained sex-based treatment differences in acute coronary syndrome care: Insights from the American Heart Association Get With The Guidelines Coronary Artery Disease Registry.

Journal Article Clin Cardiol · June 2018 BACKGROUND: Sex-based differences in acute coronary syndrome (ACS) mortality may attenuate with age due to better symptom recognition and prompt care. HYPOTHESIS: Age is a modifier of temporal trends in sex-based differences in ACS care. METHODS: Among 104 ... Full text Link to item Cite

Association of Hospital Performance Based on 30-Day Risk-Standardized Mortality Rate With Long-term Survival After Heart Failure Hospitalization: An Analysis of the Get With The Guidelines-Heart Failure Registry.

Journal Article JAMA Cardiol · June 1, 2018 IMPORTANCE: Among patients hospitalized with heart failure (HF), the long-term clinical implications of hospitalization at hospitals based on 30-day risk-standardized mortality rates (RSMRs) is not known. OBJECTIVE: To evaluate the association of hospital- ... Full text Link to item Cite

Early impact of guideline publication on angiotensin-receptor neprilysin inhibitor use among patients hospitalized for heart failure.

Journal Article Am Heart J · June 2018 BACKGROUND: On May 20, 2016, US professional organizations in cardiology published joint treatment guidelines recommending the use of angiotensin-receptor neprilysin inhibitor (ARNI) for eligible patients with heart failure with reduced ejection fraction ( ... Full text Link to item Cite

Trends in Noncardiovascular Comorbidities Among Patients Hospitalized for Heart Failure: Insights From the Get With The Guidelines-Heart Failure Registry.

Journal Article Circ Heart Fail · June 2018 BACKGROUND: The increase in medical complexity among patients hospitalized with heart failure (HF) may be reflected by an increase in concomitant noncardiovascular comorbidities. Among patients hospitalized with HF, the temporal trends in the prevalence of ... Full text Link to item Cite

The Call for Precision Health Trials in Older Adults: One Size Does Not Fit All.

Journal Article Journal of the American College of Cardiology · June 2018 Full text Cite

Health Status Disparities by Sex, Race/Ethnicity, and Socioeconomic Status in Outpatients With Heart Failure.

Journal Article JACC Heart Fail · June 2018 OBJECTIVES: This study sought to describe the health status of outpatients with heart failure and reduced ejection fraction (HFrEF) by sex, race/ethnicity, and socioeconomic status (SES). BACKGROUND: Although a primary goal in treating patients with HFrEF ... Full text Link to item Cite

Worsening Renal Function in Patients With Acute Heart Failure Undergoing Aggressive Diuresis Is Not Associated With Tubular Injury.

Journal Article Circulation · May 8, 2018 BACKGROUND: Worsening renal function (WRF) in the setting of aggressive diuresis for acute heart failure treatment may reflect renal tubular injury or simply indicate a hemodynamic or functional change in glomerular filtration. Well-validated tubular injur ... Full text Link to item Cite

Trends and outcomes of cardiac transplantation from donors dying of drug intoxication.

Journal Article Am Heart J · May 2018 BACKGROUND: Deaths from drug intoxication have increased in the United States but outcomes of recipients of orthotopic heart transplantation (OHT) from these donors are not well characterized. METHODS: We performed a retrospective analysis of the United Ne ... Full text Link to item Cite

Medicare Expenditures by Race/Ethnicity After Hospitalization for Heart Failure With Preserved Ejection Fraction.

Journal Article JACC Heart Fail · May 2018 OBJECTIVES: The purpose of this study was to analyze cumulative Medicare expenditures at index admission and after discharge by race or ethnicity. BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is a growing proportion of heart failure ( ... Full text Link to item Cite

Association Between Hospital Volume, Processes of Care, and Outcomes in Patients Admitted With Heart Failure: Insights From Get With The Guidelines-Heart Failure.

Journal Article Circulation · April 17, 2018 BACKGROUND: Hospital volume is frequently used as a structural metric for assessing quality of care, but its utility in patients admitted with acute heart failure (HF) is not well characterized. Accordingly, we sought to determine the relationship between ... Full text Link to item Cite

Permanent pacemaker use among patients with heart failure and preserved ejection fraction: Findings from the Acute Decompensated Heart Failure National Registry (ADHERE) National Registry.

Journal Article Am Heart J · April 2018 BACKGROUND: Heart failure with preserved ejection fraction may be associated with chronotropic incompetence, but little is known about the incidence and prevalence of permanent pacemaker use in this population or factors associated with its use. METHODS: W ... Full text Link to item Cite

Symptomatic event reduction with extended-duration betrixaban in acute medically ill hospitalized patients.

Journal Article Am Heart J · April 2018 BACKGROUND: Approximately 15%-30% of patients in trials of medical thromboprophylaxis will have missing compression ultrasound (CUS) data. The goal of the present analysis was to perform analyses to minimize missing data. METHODS: The APEX trial randomized ... Full text Link to item Cite

Diastolic Dysfunction in Individuals With Human Immunodeficiency Virus Infection: Literature Review, Rationale and Design of the Characterizing Heart Function on Antiretroviral Therapy (CHART) Study.

Journal Article J Card Fail · April 2018 Antiretroviral therapy (ART) has been associated with a shift in the epidemiology of human immunodeficiency virus (HIV)-associated cardiomyopathy from a phenotype of primarily left ventricular (LV) systolic dysfunction to LV diastolic dysfunction (DD). Pat ... Full text Link to item Cite

Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial.

Journal Article Am Heart J · April 2018 OBJECTIVE: The objective is to assess the safety, tolerability, and efficacy of sacubitril/valsartan compared with enalapril in patients with heart failure (HF) with a reduced ejection fraction (EF) stabilized during hospitalization for acute decompensated ... Full text Link to item Cite

Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure: Insights From ASCEND-HF Trial.

Journal Article JACC Heart Fail · April 2018 OBJECTIVES: As the largest acute heart failure (AHF) trial conducted to date, the global ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) trial database presented an opportunity to systematically describe the r ... Full text Link to item Cite

Health Status Variation Across Practices in Outpatients With Heart Failure: Insights From the CHAMP-HF (Change the Management of Patients With Heart Failure) Registry.

Journal Article Circ Cardiovasc Qual Outcomes · April 2018 BACKGROUND: Although a key treatment goal for patients with heart failure with reduced ejection fraction is to optimize their health status (their symptoms, function, and quality of life), the variability across outpatient practices in achieving this goal ... Full text Link to item Cite

Timing of Postdischarge Follow-Up and Medication Adherence Among Patients With Heart Failure.

Journal Article J Am Heart Assoc · April 1, 2018 BACKGROUND: Medication adherence improves outcomes for patients with heart failure, but adherence rates remain low. We examined the association between earlier postdischarge follow-up and medication adherence. METHODS AND RESULTS: We performed a retrospect ... Full text Link to item Cite

Early Ambulation Among Hospitalized Heart Failure Patients Is Associated With Reduced Length of Stay and 30-Day Readmissions.

Journal Article Circ Heart Fail · April 2018 BACKGROUND: Early ambulation (EA) is associated with improved outcomes for mechanically ventilated and stroke patients. Whether the same association exists for patients hospitalized with acute heart failure is unknown. We sought to determine whether EA amo ... Full text Link to item Cite

EFFECT OF HIGH-DEDUCTIBLE INSURANCE ON MYOCARDIAL INFARCTION, STROKE, AND AMPUTATION

Conference JOURNAL OF GENERAL INTERNAL MEDICINE · April 1, 2018 Link to item Cite

Association of Electronic Health Record Use With Quality of Care and Outcomes in Heart Failure: An Analysis of Get With The Guidelines-Heart Failure.

Journal Article J Am Heart Assoc · March 30, 2018 BACKGROUND: Adoption of electronic health record (EHR) systems has increased significantly across the nation. Whether EHR use has translated into improved quality of care and outcomes in heart failure (HF) is not well studied. METHODS AND RESULTS: We exami ... Full text Link to item Cite

Paving a Better Path for Patients Dying of Heart Disease.

Journal Article Circulation · March 20, 2018 Full text Link to item Cite

Sudden cardiac death after acute heart failure hospital admission: insights from ASCEND-HF.

Conference Eur J Heart Fail · March 2018 AIMS: The incidence of and factors associated with sudden cardiac death (SCD) early after an acute heart failure (HF) hospital admission have not been well defined. METHODS AND RESULTS: We assessed SCD and ventricular arrhythmias in the Acute Study of Clin ... Full text Link to item Cite

Relationship between Hospital 30-Day Mortality Rates for Heart Failure and Patterns of Early Inpatient Comfort Care.

Journal Article J Hosp Med · March 2018 BACKGROUND: The Centers for Medicare & Medicaid Services rewards hospitals that have low 30-day riskstandardized mortality rates (RSMR) for heart failure (HF). OBJECTIVE: To describe the use of early comfort care for patients with HF, and whether hospitals ... Full text Link to item Cite

PRIOR HEART FAILURE HOSPITALIZATION AMONG PATIENTS HOSPITALIZED FOR WORSENING CHRONIC HEART FAILURE: FROM THE ASCEND-HF TRIAL

Conference Journal of the American College of Cardiology · March 2018 Full text Cite

EARLY IMPACT OF GUIDELINE PUBLICATION ON ANGIOTENSIN-RECEPTOR NEPRILYSIN INHIBITOR USE AMONG PATIENTS HOSPITALIZED FOR HEART FAILURE

Conference Journal of the American College of Cardiology · March 2018 Full text Cite

PREDICTORS OF 30-DAY READMISSION IN PATIENTS WITH SYNCOPE

Conference Journal of the American College of Cardiology · March 2018 Full text Cite

POPULATION-SPECIFIC GENETIC VARIATIONS INCREASE HAZARD OF MORTALITY OR REHOSPITALIZATION IN HEART FAILURE PATIENTS

Conference Journal of the American College of Cardiology · March 2018 Full text Cite

Association of Intracerebral Hemorrhage Among Patients Taking Non-Vitamin K Antagonist vs Vitamin K Antagonist Oral Anticoagulants With In-Hospital Mortality.

Journal Article JAMA · February 6, 2018 IMPORTANCE: Although non-vitamin K antagonist oral anticoagulants (NOACs) are increasingly used to prevent thromboembolic disease, there are limited data on NOAC-related intracerebral hemorrhage (ICH). OBJECTIVE: To assess the association between preceding ... Full text Open Access Link to item Cite

Interaction of Body Mass Index on the Association Between N-Terminal-Pro-b-Type Natriuretic Peptide and Morbidity and Mortality in Patients With Acute Heart Failure: Findings From ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure).

Journal Article J Am Heart Assoc · February 3, 2018 BACKGROUND: Higher body mass index (BMI) is associated with lower circulating levels of N-terminal-pro-b-type natriuretic peptide (NT-proBNP). The Interaction between BMI and NT-proBNP with respect to clinical outcomes is not well characterized in patients ... Full text Link to item Cite

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial.

Journal Article JACC Heart Fail · February 2018 This trial sought to evaluate whether vericiguat, a novel oral soluble guanylate cyclase (sGC) stimulator, was superior to placebo, on a background of standard of care, in increasing the time to the first occurrence of the composite endpoints of cardiovasc ... Full text Link to item Cite

Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: insights from ASCEND-HF.

Journal Article Eur J Heart Fail · February 2018 AIMS: Patients hospitalized for heart failure (HF) are at high risk for 30-day readmission. This study sought to examine the timings and causes of readmission within 30 days of an HF hospitalization. METHODS AND RESULTS: Timing and cause of readmission in ... Full text Link to item Cite

Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.

Journal Article Lancet Diabetes Endocrinol · February 2018 BACKGROUND: Glucagon-like peptide-1 (GLP-1) receptor agonists are effective glucose-lowering drugs. Findings from cardiovascular outcome trials showed cardiovascular safety of GLP-1 receptor agonists, but results for cardiovascular efficacy were varied. We ... Full text Link to item Cite

Absence of July Phenomenon in Acute Ischemic Stroke Care Quality and Outcomes.

Journal Article J Am Heart Assoc · January 31, 2018 BACKGROUND: Lower care quality and an increase in adverse outcomes as a result of new medical trainees is a concept well rooted in popular belief, termed the "July phenomenon." Whether this phenomenon occurs in acute ischemic stroke has not been well studi ... Full text Open Access Link to item Cite

2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.

Journal Article J Am Coll Cardiol · January 16, 2018 Full text Link to item Cite

Assessing Frailty in Patients Undergoing Destination Therapy Left Ventricular Assist Device: Observations from Interagency Registry for Mechanically Assisted Circulatory Support.

Journal Article ASAIO J · 2018 Frailty and heart failure share common pathways with symptoms that often coexist. Assessment of frailty may inform patient selection for left ventricular assist device (LVAD) therapy. Using Interagency Registry for Mechanically Assisted Circulatory Support ... Full text Link to item Cite

Association of the Hospital Readmissions Reduction Program Implementation With Readmission and Mortality Outcomes in Heart Failure.

Journal Article JAMA Cardiol · January 1, 2018 IMPORTANCE: Public reporting of hospitals' 30-day risk-standardized readmission rates following heart failure hospitalization and the financial penalization of hospitals with higher rates have been associated with a reduction in 30-day readmissions but hav ... Full text Link to item Cite

Increased benefit of betrixaban among patients with a history of venous thromboembolism: a post-hoc analysis of the APEX trial.

Journal Article J Thromb Thrombolysis · January 2018 UNLABELLED: Hospitalized acute medically ill patients with a history of venous thromboembolism (VTE) are at increased risk for recurrent VTE. We characterized the efficacy and safety of betrixaban for prevention of recurrent VTE in these high risk patients ... Full text Link to item Cite

Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients: Findings From the APEX Trial (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban Trial).

Journal Article Circulation · January 2018 Full text Cite

Intra-Aortic Balloon Pump Use Before Left Ventricular Assist Device Implantation: Insights From the INTERMACS Registry.

Journal Article ASAIO J · 2018 Use of durable, continuous-flow left ventricular assist devices (LVADs) has expanded rapidly, although data are limited regarding optimization strategies before LVAD implantation. We examined current use of intra-aortic balloon pumps (IABPs) before LVAD im ... Full text Link to item Cite

Increasing Interfacility Transfers Among Northeastern Hospitals in the Care of Stroke Patients

Conference STROKE · January 1, 2018 Link to item Cite

Impact of Concomitant Use of Antiplatelet and Anticoagulation Therapies on Outcomes in Patients With Intracerebral Hemorrhage

Conference STROKE · January 1, 2018 Link to item Cite

Patterns of Discharge Antidepressant Therapy Use After Acute Ischemic Stroke: Insights From the Prosper Study

Conference STROKE · January 1, 2018 Link to item Cite

Use of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Comorbid Diabetes Mellitus or Chronic Kidney Disease.

Journal Article J Am Heart Assoc · December 23, 2017 BACKGROUND: Perceived risks of hyperkalemia and acute renal insufficiency may limit use of mineralocorticoid receptor antagonist (MRA) therapy in patients with heart failure, especially those with diabetes mellitus or chronic kidney disease. METHODS AND RE ... Full text Link to item Cite

Once-Weekly Exenatide and Cardiovascular Outcomes in Type 2 Diabetes.

Journal Article N Engl J Med · December 21, 2017 Full text Link to item Cite

Effect of Exenatide Once-Weekly on Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease: Insights From the EXSCEL Trial

Conference CIRCULATION · December 12, 2017 Link to item Cite

Thrombus Burden of Deep Vein Thrombosis and Its Association with Thromboprophylaxis and D-Dimer Measurement: Insights from the APEX Trial.

Journal Article Thrombosis and haemostasis · December 2017 Background The aim of this study was to evaluate the effect of betrixaban on the occurrence of deep vein thrombosis (DVT) and also the extent of thrombus and to assess the association of baseline D-dimer with subsequent thrombus burden. Methods In the APE ... Full text Cite

Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes.

Journal Article J Am Coll Cardiol · November 14, 2017 BACKGROUND: Patients with heart failure (HF) have a poor prognosis and are categorized by ejection fraction (EF). OBJECTIVES: This study sought to characterize differences in outcomes in patients hospitalized with heart failure with preserved ejection frac ... Full text Link to item Cite

Implementation of the Hospital Readmissions Reduction Program, Readmissions, and Mortality in Heart Failure

Conference CIRCULATION · November 14, 2017 Link to item Cite

Home-Time as a Novel Post-Discharge Outcome for Patients Hospitalized With Heart Failure

Conference CIRCULATION · November 14, 2017 Link to item Cite

Intracranial Hemorrhage in Patients Receiving Non-Vitamin K Oral Anticoagulants

Conference CIRCULATION · November 14, 2017 Link to item Cite

Timing of Postdischarge Follow-Up and Medication Adherence Among Heart Failure Patients

Conference CIRCULATION · November 14, 2017 Link to item Cite

Extended-Duration Betrixaban Reduces the Risk of Venous Thromboembolism-Related Rehospitalization Among Acutely Ill Hospitalized Medical Patients: An APEX Trial Substudy

Conference CIRCULATION · November 14, 2017 Link to item Cite

Gender and Socioeconomic Disparities With Health Status in Outpatients With Heart Failure: Insights From the CHAMP-HF Registry

Conference CIRCULATION · November 14, 2017 Link to item Cite

Comparative Effectiveness of Sulfonylurea versus Metformin in Patients With Heart Failure and Diabetes Mellitus

Conference CIRCULATION · November 14, 2017 Link to item Cite

Eliminate Thromboembolism: Improving Anticoagulation in Non-Valvular Atrial Fibrillation Patients' (ELITE) Registry - Insights From the Baseline Results

Conference CIRCULATION · November 14, 2017 Link to item Cite

Betrixaban Reduces Not Only the Presence of Thrombus but Also Extent of Thrombus: An APEX Trial Substudy

Conference CIRCULATION · November 14, 2017 Link to item Cite

Full-Dose Betrixaban Reduces Venous Thromboembolism-Related Mortality: An APEX Trial Substudy

Conference CIRCULATION · November 14, 2017 Link to item Cite

Data Sharing and Embedded Research.

Journal Article Ann Intern Med · November 7, 2017 Full text Link to item Cite

2017 ACC Expert Consensus Decision Pathway on the Management of Mitral Regurgitation: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.

Journal Article J Am Coll Cardiol · November 7, 2017 Mitral regurgitation (MR) is a complex valve lesion that can pose significant management challenges for the cardiovascular clinician. This Expert Consensus Document emphasizes that recognition of MR should prompt an assessment of its etiology, mechanism, a ... Full text Link to item Cite

Competing risk analysis in a large cardiovascular clinical trial: An APEX substudy.

Journal Article Pharm Stat · November 2017 Competing risk methods are time-to-event analyses that account for fatal and/or nonfatal events that may potentially alter or prevent a subject from experiencing the primary endpoint. Competing risk methods may provide a more accurate and less biased estim ... Full text Link to item Cite

N-terminal pro-B-type natriuretic peptide and the risk of stroke among patients hospitalized with acute heart failure: an APEX trial substudy.

Journal Article J Thromb Thrombolysis · November 2017 BACKGROUND: Among patients hospitalized with acute heart failure (HF), the prognostic value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in short-term stroke prediction remains unclear. METHODS: In the APEX trial, 7513 patients hospitalized for ... Full text Link to item Cite

When Should Patients Be Involved in Cardiovascular Clinical Trial Design?: Always, Early, and Often.

Journal Article JAMA Cardiol · November 1, 2017 Full text Link to item Cite

2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure.

Journal Article Can J Cardiol · November 2017 Since the inception of the Canadian Cardiovascular Society heart failure (HF) guidelines in 2006, much has changed in the care for patients with HF. Over the past decade, the HF Guidelines Committee has published regular updates. However, because of the ma ... Full text Link to item Cite

Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.

Journal Article J Thromb Haemost · October 2017 UNLABELLED: Essentials Anticoagulants prevent venous thromboembolism but may be associated with greater bleeding risks. Bivariate analysis assumes a non-linear relationship between efficacy and safety outcomes. Extended full-dose betrixaban is favorable ov ... Full text Link to item Cite

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.

Journal Article N Engl J Med · September 28, 2017 BACKGROUND: The cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes are unknown. METHODS: We randomly assigned patients with type 2 diabetes, with or without previous cardiovascular disease, ... Full text Open Access Link to item Cite

Pragmatic clinical trials embedded in healthcare systems: generalizable lessons from the NIH Collaboratory.

Journal Article BMC Med Res Methodol · September 18, 2017 BACKGROUND: The clinical research enterprise is not producing the evidence decision makers arguably need in a timely and cost effective manner; research currently involves the use of labor-intensive parallel systems that are separate from clinical care. Th ... Full text Link to item Cite

How Medicine Has Changed the End of Life for Patients With Cardiovascular Disease.

Journal Article J Am Coll Cardiol · September 5, 2017 Advances in medicine have changed how patients experience the end of life. With longer life spans, there has also been an increase in years lived with disability. The clustering of illnesses in the last years of life is particularly pronounced in patients ... Full text Link to item Cite

Improving heart failure health: is there a secret Swedish sauce?

Journal Article Eur J Heart Fail · September 2017 Full text Link to item Cite

Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial.

Journal Article JAMA Cardiol · September 1, 2017 IMPORTANCE: Persistent congestion is associated with worse outcomes in acute heart failure (AHF). Mineralocorticoid receptor antagonists administered at high doses may relieve congestion, overcome diuretic resistance, and mitigate the effects of adverse ne ... Full text Link to item Cite

Representativeness of Medicare Participants in the Jackson Heart Study for African American Medicare Beneficiaries.

Journal Article Epidemiology · September 2017 BACKGROUND: The Jackson Heart Study (JHS) assesses cardiovascular disease risk factors among African Americans in Jackson, Mississippi. Whether characteristics of JHS participants differ from those of a broader African American population are unknown. METH ... Full text Link to item Cite

Leveraging Behavioral Economics to Improve Heart Failure Care and Outcomes.

Journal Article Circulation · August 22, 2017 Behavioral challenges are often present in human illness, so behavioral economics is increasingly being applied in healthcare settings to better understand why patients choose healthy or unhealthy behaviors. The application of behavioral economics to healt ... Full text Link to item Cite

Role of Volume Redistribution in the Congestion of Heart Failure.

Journal Article J Am Heart Assoc · August 17, 2017 Full text Link to item Cite

Sildenafil Treatment in Heart Failure With Preserved Ejection Fraction: Targeted Metabolomic Profiling in the RELAX Trial.

Journal Article JAMA Cardiol · August 1, 2017 IMPORTANCE: Phosphodiesterase-5 inhibition with sildenafil compared with a placebo had no effect on the exercise capacity or clinical status of patients with heart failure with preserved ejection fraction (HFpEF) in the PhosphodiesteRasE-5 Inhibition to Im ... Full text Link to item Cite

The Burden of Non-Cardiac Comorbidities in Acute Heart Failure: Insights From ASCEND-HF

Conference Journal of Cardiac Failure · August 2017 Full text Cite

Extended duration betrixaban in acutely ill medical patients is associated with reduction in fatal or irreversible ischemic or bleeding events compared with standard dose enoxaparin: an APEX substudy

Conference EUROPEAN HEART JOURNAL · August 1, 2017 Link to item Cite

Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy.

Journal Article J Am Heart Assoc · July 11, 2017 BACKGROUND: Extended-duration betrixaban showed a significant reduction in venous thromboembolism in the APEX trial (Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study). Given the variable clinical impact of different efficacy and s ... Full text Link to item Cite

Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the RELAX trial.

Conference Eur J Heart Fail · July 2017 BACKGROUND: While abnormal left ventricular (LV) global longitudinal strain (GLS) has been described in patients with heart failure with preserved ejection fraction (HFpEF), its prevalence and clinical significance are poorly understood. METHODS AND RESULT ... Full text Link to item Cite

Utilization of cardiac resynchronization therapy in eligible patients hospitalized for heart failure and its association with patient outcomes.

Conference Am Heart J · July 2017 OBJECTIVES: We examined trends in CRT utilization overall and by sex and race and to assess whether CRT use is associated with a reduction in HF hospitalization and mortality. BACKGROUND: It is unknown whether underutilization and race/sex-based difference ... Full text Link to item Cite

When academic research organizations and clinical research organizations disagree: Processes to minimize discrepancies prior to unblinding of randomized trials.

Journal Article Am Heart J · July 2017 Full text Link to item Cite

Race/Ethnic Differences in Outcomes Among Hospitalized Medicare Patients With Heart Failure and Preserved Ejection Fraction.

Journal Article JACC Heart Fail · July 2017 OBJECTIVES: This study analyzed HFpEF patient characteristics and clinical outcomes according to race/ethnicity and adjusted for patient and hospital characteristics along with socioeconomic status (SES). BACKGROUND: The proportion of hospitalizations for ... Full text Link to item Cite

Trajectory of Congestion Metrics by Ejection Fraction in Patients With Acute Heart Failure (from the Heart Failure Network).

Journal Article Am J Cardiol · July 1, 2017 Differences in the clinical course of congestion by underlying ejection fraction (EF) have not been well-characterized in acute heart failure (AHF). A post hoc analysis was performed using pooled data from the Diuretic Optimization Strategies Evaluation in ... Full text Link to item Cite

Seasonal and circadian variations of acute myocardial infarction: Findings from the Get With The Guidelines-Coronary Artery Disease (GWTG-CAD) program.

Journal Article Am Heart J · July 2017 BACKGROUND: Seasonal variation with winter preponderance of myocardial infarction incidence has been described decades ago, but only a few small studies have classified myocardial infarction based on ST-segment elevation. It is unclear whether seasonal and ... Full text Link to item Cite

Cardiovascular events and hospital resource utilization pre- and post-transcatheter mitral valve repair in high-surgical risk patients.

Journal Article Am Heart J · July 2017 UNLABELLED: MitraClip is an approved therapy for mitral regurgitation (MR); however, health care resource utilization pre- and post-MitraClip remains understudied. METHODS: Patients with functional and degenerative MR at high surgical risk in the EVEREST I ... Full text Link to item Cite

Change the management of patients with heart failure: Rationale and design of the CHAMP-HF registry.

Journal Article Am Heart J · July 2017 Heart failure (HF) with reduced ejection fraction (HFrEF) is a common and costly condition that diminishes patients' health status and confers a poor prognosis. Despite the availability of multiple guideline-recommended pharmacologic and cardiac device the ... Full text Link to item Cite

Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure: From the ASCEND-HF Trial.

Journal Article J Am Coll Cardiol · June 27, 2017 BACKGROUND: It is unclear how patients hospitalized for acute heart failure (HF) who are long-term chronic HF survivors differ from those with more recent HF diagnoses. OBJECTIVES: The goal of this study was to evaluate the influence of HF chronicity on ac ... Full text Link to item Cite

Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI-Cardiovascular Medical Research and Education Fund Workshop Report.

Journal Article Am J Respir Crit Care Med · June 15, 2017 The Division of Lung Diseases of the NHLBI and the Cardiovascular Medical Education and Research Fund held a workshop to discuss how to leverage the anticipated scientific output from the recently launched "Redefining Pulmonary Hypertension through Pulmona ... Full text Link to item Cite

Accelerometer-Measured Daily Activity in Heart Failure With Preserved Ejection Fraction: Clinical Correlates and Association With Standard Heart Failure Severity Indices.

Conference Circ Heart Fail · June 2017 BACKGROUND: Daily physical activity assessed by accelerometers represents a novel method to assess the impact of interventions on heart failure (HF) patients' functional status. We hypothesized that daily activity varies by patient characteristics and corr ... Full text Link to item Cite

Characterization of hemodynamically stable acute heart failure patients requiring a critical care unit admission: Derivation, validation, and refinement of a risk score.

Journal Article Am Heart J · June 2017 BACKGROUND: Most patients with acute heart failure (AHF) admitted to critical care units (CCUs) are low acuity and do not require CCU-specific therapies, suggesting that they could be managed in a lower-cost ward environment. This study identified the pred ... Full text Link to item Cite

Integrating Research With Clinical Practice: Keeping It Simple.

Journal Article JAMA Cardiol · June 1, 2017 Full text Link to item Cite

Scope of Sacubitril/Valsartan Eligibility After Heart Failure Hospitalization: Findings From the GWTG-HF Registry (Get With The Guidelines-Heart Failure).

Journal Article Circulation · May 23, 2017 Full text Link to item Cite

Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial.

Journal Article JAMA · May 16, 2017 IMPORTANCE: Iron deficiency is present in approximately 50% of patients with heart failure with reduced left ventricular ejection fraction (HFrEF) and is an independent predictor of reduced functional capacity and mortality. However, the efficacy of inexpe ... Full text Link to item Cite

An Initial Evaluation of the Impact of Pokémon GO on Physical Activity.

Journal Article J Am Heart Assoc · May 16, 2017 BACKGROUND: Pokémon GO is a location-based augmented reality game. Using GPS and the camera on a smartphone, the game requires players to travel in real world to capture animated creatures, called Pokémon. We examined the impact of Pokémon GO on physical a ... Full text Open Access Link to item Cite

Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).

Journal Article Am Heart J · May 2017 BACKGROUND: EXSCEL is a randomized, double-blind, placebo-controlled trial examining the effect of exenatide once-weekly (EQW) versus placebo on time to the primary composite outcome (cardiovascular death, nonfatal myocardial infarction or nonfatal stroke) ... Full text Link to item Cite

Acute Heart Failure: Alternatives to Hospitalization.

Journal Article JACC Heart Fail · May 2017 Acute heart failure (HF) is a major public health problem with substantial associated economic costs. Because most patients who present to hospitals are admitted irrespective of their level of risk, novel approaches to manage acute HF are needed, such as t ... Full text Link to item Cite

Impact of Current Versus Previous Cardiac Resynchronization Therapy Guidelines on the Proportion of Patients With Heart Failure Eligible for Therapy.

Journal Article JACC Heart Fail · May 2017 OBJECTIVES: This study sought to ascertain the impact of heart failure (HF) guideline change on the number of patients eligible to undergo cardiac resynchronization therapy (CRT). BACKGROUND: The 2013 HF guideline of the American College of Cardiology Foun ... Full text Link to item Cite

INDIE-HFpEF (Inorganic Nitrite Delivery to Improve Exercise Capacity in Heart Failure With Preserved Ejection Fraction): Rationale and Design.

Journal Article Circulation. Heart failure · May 2017 Approximately half of patients with heart failure have preserved ejection fraction. There is no proven treatment that improves outcome. The pathophysiology of heart failure with preserved ejection fraction is complex and includes left ventricular systolic ... Full text Cite

The changing non-cardiovascular comorbidity profile of patients hospitalized with heart failure: Insights from the Get With The Guidelines-Heart Failure registry

Conference EUROPEAN JOURNAL OF HEART FAILURE · May 1, 2017 Link to item Cite

Engagement, Research, and Evidence: Leveraging the National Patient-Centered Clinical Research Network for Better Cardiovascular Health.

Journal Article Circulation · April 18, 2017 Full text Link to item Cite

Sex and Age Interactions and Differences in Outcomes After Intracerebral Hemorrhage.

Journal Article J Womens Health (Larchmt) · April 2017 BACKGROUND: Compared to ischemic stroke, sex differences in response to intracerebral hemorrhage (ICH) are largely unexplored, and their potential interactions with patient age have not been examined. This study hypothesized that risk for poor outcome is g ... Full text Link to item Cite

Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction: Insights From Get With the Guidelines-Heart Failure (GWTG-HF).

Journal Article JACC Heart Fail · April 2017 OBJECTIVES: The aim of this study was to assess the prevalence and variation in angiotensin receptor/neprilysin inhibitor (ARNI) prescription among a real-world population with heart failure with reduced ejection fraction (HFrEF). BACKGROUND: The U.S. Food ... Full text Link to item Cite

Prescription of Guideline-Recommended Implantable Cardioverter Defibrillator and Cardiac Resynchronization Therapy Among Patients Hospitalized With Heart Failure and Varying Degrees of Renal Function.

Journal Article Am J Cardiol · March 15, 2017 Implantable cardioverter defibrillators (ICD) and cardiac resynchronization therapy (CRT) reduce mortality in many patients with heart failure (HF), but the current use and effectiveness of ICD/CRT in patients with chronic kidney disease (CKD) are uncertai ... Full text Link to item Cite

Use of Intravenous Recombinant Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke Who Take Non-Vitamin K Antagonist Oral Anticoagulants Before Stroke.

Journal Article Circulation · March 14, 2017 BACKGROUND: Intravenous rt-PA (recombinant tissue-type plasminogen activator) is effective in improving outcomes in ischemic stroke; however, there are few data on the use of rt-PA in patients who are receiving a non-vitamin K antagonist oral anticoagulant ... Full text Link to item Cite

2017 ACC Expert Consensus Decision Pathway for Transcatheter Aortic Valve Replacement in the Management of Adults With Aortic Stenosis: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents.

Journal Article J Am Coll Cardiol · March 14, 2017 Full text Link to item Cite

Association of Preceding Antithrombotic Treatment With Acute Ischemic Stroke Severity and In-Hospital Outcomes Among Patients With Atrial Fibrillation.

Journal Article JAMA · March 14, 2017 IMPORTANCE: Antithrombotic therapies are known to prevent stroke for patients with atrial fibrillation (AF) but are often underused in community practice. OBJECTIVES: To examine the prevalence of patients with acute ischemic stroke with known history of AF ... Full text Open Access Link to item Cite

Does Pokemon Go Help Players be More Active? An Evaluation of Pokemon Go and Physical Activity

Conference CIRCULATION · March 7, 2017 Link to item Cite

The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial.

Journal Article Am Heart J · March 2017 BACKGROUND: The APEX trial assessed the safety and efficacy of extended-duration thromboprophylaxis using betrixaban versus standard dosing of enoxaparin among hospitalized, acutely ill medical patients. The 80-mg betrixaban dose was halved to 40 mg among ... Full text Link to item Cite

Can Vaccinations Improve Heart Failure Outcomes?: Contemporary Data and Future Directions.

Journal Article JACC Heart Fail · March 2017 Heart failure (HF) is a chronic syndrome characterized by acute exacerbations. There is significant overlap between respiratory infections and exacerbation of underlying HF. Vaccination against respiratory infections in patients with HF could serve as a po ... Full text Link to item Cite

TIMING AND CLINICAL PREDICTORS OF EARLY VERSUS LATE READMISSION AMONG PATIENTS HOSPITALIZED FOR ACUTE HEART FAILURE: INSIGHTS FROM ASCEND-HF

Conference Journal of the American College of Cardiology · March 2017 Full text Cite

HEMOCONCENTRATION DURING MANAGEMENT OF PATIENTS WITH ACUTE HEART FAILURE AND CARDIORENAL SYNDROME: INSIGHTS FROM CARRESS-HF

Conference Journal of the American College of Cardiology · March 2017 Full text Cite

Can Vaccinations Improve Heart Failure Outcomes? Contemporary Data and Future Directions

Journal Article JACC-HEART FAILURE · March 1, 2017 Link to item Cite

TIME OF PRESENTATION AMONG PATIENTS HOSPITALIZED FOR ACUTE HEART FAILURE (CLINICAL CHARACTERISTICS, INITIAL THERAPIES AND OUTCOMES): INSIGHTS FROM ASCEND-HF

Conference Journal of the American College of Cardiology · March 2017 Full text Cite

HEART FAILURE WITH REDUCED EJECTION FRACTION CARE PATTERNS IN THE OUTPATIENT PRACTICE SETTING: INITIAL FINDINGS FROM CHAMP-HF

Conference Journal of the American College of Cardiology · March 2017 Full text Cite

A HOSPITAL LEVEL ANALYSIS OF 30-DAY READMISSION RATES FOR HEART FAILURE PATIENTS AND LONG-TERM SURVIVAL AMONG HIGHEST AND LOWEST PERFORMING HOSPITALS, FINDINGS FROM GET WITH THE GUIDELINES-HEART FAILURE

Conference Journal of the American College of Cardiology · March 2017 Full text Cite

THE IMPACT OF THE CURRENT VERSUS PRIOR CARDIAC RESYNCHRONIZATION GUIDELINES ON THE PROPORTION OF HOSPITALIZED HEART FAILURE PATIENTS ELIGIBLE FOR THERAPY

Conference Journal of the American College of Cardiology · March 2017 Full text Cite

Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban).

Journal Article Circulation · February 14, 2017 BACKGROUND: Stroke is a morbid and potentially mortal complication among patients hospitalized with acute medical illness. The potential of extended-duration thromboprophylaxis with the factor Xa inhibitor betrixaban to reduce the risk of stroke compared w ... Full text Link to item Cite

Initiation, Continuation, or Withdrawal of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction.

Journal Article J Am Heart Assoc · February 11, 2017 BACKGROUND: Guidelines recommend continuation or initiation of guideline-directed medical therapy, including angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (ACEi/ARB), in hospitalized patients with heart failure with reduced ejec ... Full text Open Access Link to item Cite

Healthcare Resource Availability, Quality of Care, and Acute Ischemic Stroke Outcomes.

Journal Article J Am Heart Assoc · February 3, 2017 BACKGROUND: Healthcare resources vary geographically, but associations between hospital-based resources and acute stroke quality and outcomes remain unclear. METHODS AND RESULTS: Using Get With The Guidelines-Stroke and Dartmouth Atlas of Health Care data, ... Full text Link to item Cite

Amiodarone use in patients listed for heart transplant is associated with increased 1-year post-transplant mortality.

Journal Article J Heart Lung Transplant · February 2017 BACKGROUND: Pre-transplant amiodarone use has been postulated as a risk factor for morbidity and mortality after orthotopic heart transplantation (OHT). We assessed pre-OHT amiodarone use and tested the hypothesis that it is associated with impaired post-O ... Full text Link to item Cite

Insufficient reduction in heart rate during hospitalization despite beta-blocker treatment in acute decompensated heart failure: insights from the ASCEND-HF trial.

Journal Article Eur J Heart Fail · February 2017 AIMS: Heart failure (HF) can be associated with a higher resting heart rate (HR), and an elevated HR is associated with adverse long-term events. However, the mechanistic and causal role of HR in HF is unclear. This study aimed to investigate changes in HR ... Full text Link to item Cite

Resting Heart Rate and Long-term Outcomes Among the African American Population: Insights From the Jackson Heart Study.

Journal Article JAMA Cardiol · February 1, 2017 IMPORTANCE: Increased resting heart rate is associated with worse outcomes in studies of mostly white populations, but its significance is not well established in African Americans persons whose cardiac comorbidities and structural abnormalities differ. OB ... Full text Link to item Cite

Prediction of 30-Day All-Cause Readmissions in Patients Hospitalized for Heart Failure: Comparison of Machine Learning and Other Statistical Approaches.

Journal Article JAMA Cardiol · February 1, 2017 IMPORTANCE: Several attempts have been made at developing models to predict 30-day readmissions in patients with heart failure, but none have sufficient discriminatory capacity for clinical use. Machine-learning (ML) algorithms represent a novel approach a ... Full text Link to item Cite

Factors Associated With and Prognostic Implications of Cardiac Troponin Elevation in Decompensated Heart Failure With Preserved Ejection Fraction: Findings From the American Heart Association Get With The Guidelines-Heart Failure Program.

Journal Article JAMA Cardiol · February 1, 2017 IMPORTANCE: Elevated levels of cardiac troponins are associated with adverse clinical outcomes among patients with heart failure (HF) and reduced ejection fraction. However, the clinical significance of troponin elevation in the setting of decompensated HF ... Full text Link to item Cite

Renal Dysfunction Is Associated With Poststroke Discharge Disposition and In-Hospital Mortality: Findings From Get With The Guidelines-Stroke.

Journal Article Stroke · February 2017 BACKGROUND AND PURPOSE: Kidney disease is a frequent comorbidity in patients presenting with acute ischemic stroke. We evaluated whether the estimated glomerular filtration rate (eGFR) on admission is associated with poststroke in-hospital mortality or dis ... Full text Link to item Cite

Impact of an Expanded Hospital Recognition Program for Stroke Quality of Care.

Journal Article J Am Heart Assoc · January 21, 2017 BACKGROUND: In 2009, the Get With The Guidelines-Stroke (GWTG-Stroke) program offered additional recognition if hospitals performed well on certain stroke quality measures. We sought to determine whether quality of care for all hospitals participating in G ... Full text Link to item Cite

Response by Hess et al to Letter Regarding Article, "Sex and Race/Ethnicity Differences in Implantable Cardioverter-Defibrillator Counseling and Use Among Patients Hospitalized With Heart Failure: Findings From the Get With The Guidelines-Heart Failure Program".

Journal Article Circulation · January 17, 2017 Full text Link to item Cite

Treatment With Tissue Plasminogen Activator in the Golden Hour and the Shape of the 4.5-Hour Time-Benefit Curve in the National United States Get With The Guidelines-Stroke Population.

Journal Article Circulation · January 10, 2017 BACKGROUND: Earlier tissue plasminogen activator treatment improves ischemic stroke outcome, but aspects of the time-benefit relationship still not well delineated are: (1) the degree of additional benefit accrued with treatment in the first 60 minutes aft ... Full text Link to item Cite

Management of newly treated diabetes in Medicare beneficiaries with and without heart failure.

Journal Article Clin Cardiol · January 2017 BACKGROUND: Several diabetes mellitus (DM) therapies are associated with worse heart failure (HF) outcomes, yet limited data exist characterizing routine DM management based on HF status. HYPOTHESIS: DM medications prescribed for patients with HF will diff ... Full text Link to item Cite

Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes: Findings From the ASCEND-HF Trial.

Journal Article JACC Heart Fail · January 2017 OBJECTIVES: This study sought to examine the relationships between in-hospital and post-discharge body weight changes and outcomes among patients hospitalized for acute heart failure (AHF). BACKGROUND: Body weight changes during and after hospitalization f ... Full text Link to item Cite

Characterization of Mineralocorticoid Receptor Antagonist Therapy Initiation in High-Risk Patients With Heart Failure.

Journal Article Circ Cardiovasc Qual Outcomes · January 2017 BACKGROUND: Heart failure guidelines recommend routine monitoring of serum potassium, and renal function in patients treated with a mineralocorticoid receptor antagonist (MRA). How these recommendations are implemented in high-risk patients or according to ... Full text Link to item Cite

Use of Strategies to Improve Door-to-Needle Times With Tissue-Type Plasminogen Activator in Acute Ischemic Stroke in Clinical Practice: Findings from Target: Stroke.

Journal Article Circ Cardiovasc Qual Outcomes · January 2017 BACKGROUND: The implementation of Target: Stroke Phase I, the first stage of the American Heart Association's national quality improvement initiative to accelerate door-to-needle (DTN) times, was associated with an average 15-minute reduction in DTN times. ... Full text Link to item Cite

Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes Findings From the ASCEND-HF Trial

Journal Article JACC-HEART FAILURE · January 1, 2017 Link to item Cite

Country Income Level, Protocol Completion, and Trial Endpoints Among Patients With Acute Heart Failure: Insights From the ASCEND-HF Trial

Conference · 2017 Introduction: Globalization of clinical trials fosters inclusion of patients from higher and lower income countries. The influence of enrolling country income level on heart failure (HF) trial performance is unclear.Methods: Associations between country in ... Cite

Making Every Mobile Heart Count!

Journal Article JAMA Cardiol · January 1, 2017 Full text Link to item Cite

Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure (ATHENA-HF) Trial

Conference CIRCULATION · December 20, 2016 Link to item Cite

Oral Iron Repletion effects on Oxygen Uptake in Heart Failure (IRONOUT HF)

Conference CIRCULATION · December 20, 2016 Link to item Cite

Associations Between Blood Pressure and Outcomes Among Blacks in the Jackson Heart Study.

Journal Article J Am Heart Assoc · December 7, 2016 BACKGROUND: In 2014, new hypertension guidelines liberalized blood pressure goals for persons 60 years and older. Little is known about the implications for blacks. METHODS AND RESULTS: Using data from 2000 through 2011 for 5280 participants in the Jackson ... Full text Link to item Cite

The Safety and Efficacy of Full Versus Reduced Dose Betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention with Extended Duration Betrixaban (APEX) Trial

Conference Blood · December 2, 2016 AbstractBackground: The exposure of all the currently licenced DOACs is increased in renal impairment and by certain drug interactions. The Acute Medically Ill VTE (Venous Thromboembolism) Prevention with Ex ... Full text Cite

Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: Findings from Get With The Guidelines-Heart Failure registry.

Journal Article Am Heart J · December 2016 BACKGROUND: The contribution of diabetes to the burden of heart failure (HF) remains largely undescribed. Assessing diabetes temporal trends among US patients hospitalized with HF and their relation with quality measures in real-world practice can help to ... Full text Link to item Cite

Acute management of stroke patients taking non-vitamin K antagonist oral anticoagulants Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry: Design and rationale.

Journal Article Am Heart J · December 2016 BACKGROUND: Non-vitamin K antagonist oral anticoagulants (NOACs, dabigatran, rivaroxaban, apixaban, and edoxaban) have been increasingly used as alternatives to warfarin for stroke prophylaxis in patients with atrial fibrillation. Yet there is substantial ... Full text Link to item Cite

Association of 30-Day Readmission Metric for Heart Failure Under the Hospital Readmissions Reduction Program With Quality of Care and Outcomes.

Journal Article JACC Heart Fail · December 2016 OBJECTIVES: This study sought to determine whether processes of care and long-term clinical outcomes for heart failure (HF) admissions across Get With The Guidelines-Heart Failure (GWTG-HF) program participating centers differ according to HF-specific risk ... Full text Link to item Cite

Trajectory of Congestion Metrics by Ejection Fraction in Acute Heart Failure - Findings From the Heart Failure Network

Conference CIRCULATION · November 11, 2016 Link to item Cite

Trajectory of Congestion Metrics by Ejection Fraction in Acute Heart Failure - Findings From the Heart Failure Network

Conference CIRCULATION · November 11, 2016 Link to item Cite

Hospitalization for De Novo versus Worsening Chronic Heart Failure: Insights From the ASCEND-HF Trial

Conference CIRCULATION · November 11, 2016 Link to item Cite

Hospitalization for De Novo versus Worsening Chronic Heart Failure: Insights From the ASCEND-HF Trial

Conference CIRCULATION · November 11, 2016 Link to item Cite

Association of Risk Adjusted 30 Day Heart Failure Readmission Rates Under the Hospital Readmissions Reduction Program With Quality of Care and Outcomes: Findings From the American Heart Association Get With the Guidelines-Heart Failure Program

Conference CIRCULATION · November 11, 2016 Link to item Cite

Mineralocorticoid Receptor Antagonist Use in Patients With Heart Failure and Co-Morbid Diabetes or Chronic Kidney Disease

Conference CIRCULATION · November 11, 2016 Link to item Cite

Initiation, Continuation, or Withdrawal of Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction

Conference CIRCULATION · November 11, 2016 Link to item Cite

Mineralocorticoid Receptor Antagonist Use in Patients With Heart Failure and Co-Morbid Diabetes or Chronic Kidney Disease

Conference CIRCULATION · November 11, 2016 Link to item Cite

Initiation, Continuation, or Withdrawal of Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction

Conference CIRCULATION · November 11, 2016 Link to item Cite

The Scope of Sacubitril/Valsartan Eligibility Post-Heart Failure Hospitalization: Findings From the Get With the Guidelines-Heart Failure Registry

Conference CIRCULATION · November 11, 2016 Link to item Cite

Evaluation of Novel Metrics of Symptom Relief in Acute Heart Failure: The Worst Symptom Score.

Journal Article J Card Fail · November 2016 OBJECTIVE: To characterize a novel "worst"-symptom visual analogue scale (WS-VAS) versus the traditional dyspnea visual analogue scale (DVAS) in an acute heart failure (AHF) trial. BACKGROUND: AHF trials assess symptom relief as a pivotal endpoint with the ... Full text Link to item Cite

Guideline-Appropriate Care and In-Hospital Outcomes in Patients With Heart Failure in Teaching and Nonteaching Hospitals: Findings From Get With The Guidelines-Heart Failure.

Journal Article Circ Cardiovasc Qual Outcomes · November 2016 BACKGROUND: Despite increasing awareness regarding evidence-based guidelines, considerable gaps exist for heart failure (HF) quality of care at teaching hospitals (TH) and nonteaching hospitals (NTH). We analyzed data from Get With The Guidelines (GWTG)-HF ... Full text Link to item Cite

TCT-645 Cardiovascular Events and Hospital Resource Utilization Pre and Post Transcatheter Mitral Valve Repair in High Surgical Risk Patients.

Journal Article J Am Coll Cardiol · November 1, 2016 Full text Link to item Cite

The Changing Landscape of Randomized Clinical Trials in Cardiovascular Disease.

Journal Article J Am Coll Cardiol · October 25, 2016 Large randomized clinical trials in cardiovascular disease have proliferated over the past 3 decades, with results that have influenced every aspect of cardiology practice. Despite these advances, there remains a substantial need for more high-quality evid ... Full text Link to item Cite

Temporal Trends in Care and Outcomes of Patients Receiving Fibrinolytic Therapy Compared to Primary Percutaneous Coronary Intervention: Insights From the Get With The Guidelines Coronary Artery Disease (GWTG-CAD) Registry.

Journal Article J Am Heart Assoc · October 6, 2016 BACKGROUND: Timely reperfusion after ST-elevation myocardial infarction (STEMI) improves survival. Guidelines recommend primary percutaneous coronary intervention (PPCI) within 90 minutes of arrival at a PCI-capable hospital. The alternative is fibrinolysi ... Full text Open Access Link to item Cite

Sex Differences in the Management and Outcomes of Heart Failure With Preserved Ejection Fraction in Patients Presenting to the Emergency Department With Acute Heart Failure.

Conference J Card Fail · October 2016 BACKGROUND: Heart failure (HF) with preserved ejection fraction (HFpEF) is more common in women than in men; data characterizing sex differences in the management and outcomes of HFpEF patients presenting to the emergency department (ED) are limited. METHO ... Full text Link to item Cite

Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis.

Journal Article Eur J Heart Fail · October 2016 AIMS: The combined neprilysin/renin-angiotensin system (RAS) inhibitor sacubitril/valsartan reduced cardiovascular death or heart failure hospitalization, cardiovascular death, and all-cause mortality in a large outcomes trial. While sacubitril/valsartan i ... Full text Link to item Cite

Hospital Variation in Home-Time After Acute Ischemic Stroke: Insights From the PROSPER Study (Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research).

Journal Article Stroke · October 2016 BACKGROUND AND PURPOSE: Stroke survivors identify home-time as a high-priority outcome; there are limited data on factors influencing home-time and home-time variability among discharging hospitals. METHODS: We ascertained home-time (ie, time alive out of ... Full text Link to item Cite

Serum Bicarbonate in Acute Heart Failure: Relationship to Treatment Strategies and Clinical Outcomes.

Journal Article J Card Fail · September 2016 BACKGROUND: Though commonly noted in clinical practice, it is unknown if decongestion in acute heart failure (AHF) results in increased serum bicarbonate. METHODS AND RESULTS: For 678 AHF patients in the DOSE-AHF, CARRESS-HF, and ROSE-AHF trials, we assess ... Full text Link to item Cite

Use of Heart Failure Medical Therapies Among Patients With Left Ventricular Assist Devices: Insights From INTERMACS.

Journal Article J Card Fail · September 2016 BACKGROUND: Use of left ventricular assist devices (LVADs) for treatment of advanced heart failure has expanded significantly over the past decade. However, concomitant use of heart failure medical therapies after implant is poorly characterized. METHODS A ... Full text Link to item Cite

Potential Mortality Reduction With Optimal Implementation of Angiotensin Receptor Neprilysin Inhibitor Therapy in Heart Failure.

Journal Article JAMA Cardiol · September 1, 2016 IMPORTANCE: Angiotensin receptor neprilysin inhibition (ARNI) therapy provided incremental survival benefit to patients with heart failure and reduced ejection fraction (HFrEF) in clinical trials. To date, estimation of the potential benefits that could be ... Full text Link to item Cite

Heart failure medications prescribed at discharge for patients with left ventricular assist devices.

Journal Article Am Heart J · September 2016 BACKGROUND: Real-world use of traditional heart failure (HF) medications for patients with left ventricular assist devices (LVADs) is not well known. METHODS: We conducted a retrospective, observational analysis of 1,887 advanced HF patients with and witho ... Full text Link to item Cite

Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure.

Journal Article JACC Heart Fail · September 2016 Although therapy with mineralocorticoid receptor antagonists (MRAs) is recommended for patients with chronic heart failure (HF) with reduced ejection fraction and in post-infarction HF, it has not been studied well in acute HF (AHF) despite being commonly ... Full text Link to item Cite

Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure).

Journal Article Circ Heart Fail · September 2016 BACKGROUND: Most international acute heart failure trials have failed to show benefit with respect to key end points. The impact of site enrollment and protocol execution on trial performance is unclear. METHODS AND RESULTS: We assessed the impact of varyi ... Full text Link to item Cite

The Potential Impact of Expanding Cardiac Rehabilitation in Heart Failure.

Journal Article J Am Coll Cardiol · August 30, 2016 Full text Link to item Cite

Sex and Race/Ethnicity Differences in Implantable Cardioverter-Defibrillator Counseling and Use Among Patients Hospitalized With Heart Failure: Findings from the Get With The Guidelines-Heart Failure Program.

Journal Article Circulation · August 16, 2016 BACKGROUND: Previous studies have found that women and black patients eligible for a primary prevention implantable cardioverter-defibrillator (ICD) are less likely than men or white patients to receive one. METHODS: We performed an observational analysis ... Full text Link to item Cite

Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients.

Journal Article N Engl J Med · August 11, 2016 BACKGROUND: Patients with acute medical illnesses are at prolonged risk for venous thrombosis. However, the appropriate duration of thromboprophylaxis remains unknown. METHODS: Patients who were hospitalized for acute medical illnesses were randomly assign ... Full text Link to item Cite

Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.

Journal Article JAMA · August 2, 2016 IMPORTANCE: Abnormal cardiac metabolism contributes to the pathophysiology of advanced heart failure with reduced left ventricular ejection fraction (LVEF). Glucagon-like peptide 1 (GLP-1) agonists have shown cardioprotective effects in early clinical stud ... Full text Link to item Cite

The Obesity and Heart Failure Epidemics Among African Americans: Insights From the Jackson Heart Study.

Journal Article J Card Fail · August 2016 BACKGROUND: Higher rates of obesity and heart failure have been observed in African Americans, but associations with mortality are not well-described. We examined intermediate and long-term clinical implications of obesity in African Americans and associat ... Full text Link to item Cite

TRENDS IN THE CARE AND OUTCOMES OF MEDICARE BENEFICIARIES WITH TYPE 2 DIABETES, 2002-2011.

Journal Article Endocr Pract · August 2016 OBJECTIVE: To summarize characteristics of Medicare beneficiaries with type 2 diabetes and to describe changing trends in care and outcomes. METHODS: We conducted a retrospective cohort study of a nationally representative 5% sample of fee-for-service Medi ... Full text Link to item Cite

Trends in the Use of Guideline-Directed Therapies Among Dialysis Patients Hospitalized With Systolic Heart Failure: Findings From the American Heart Association Get With The Guidelines-Heart Failure Program.

Journal Article JACC Heart Fail · August 2016 OBJECTIVES: The purpose of this study was to determine the temporal trends in the adherence to heart failure (HF)-related process of care measures and clinical outcomes among patients with acute decompensated HF with reduced ejection fraction (HFrEF) and e ... Full text Link to item Cite

The ADAPTABLE Trial and Aspirin Dosing in Secondary Prevention for Patients with Coronary Artery Disease.

Journal Article Curr Cardiol Rep · August 2016 Coronary artery disease (CAD) is the underlying cause of death in one out of seven deaths in the USA. Aspirin therapy has been proven to decrease mortality and major adverse cardiovascular events in patients with CAD. Despite a plethora of studies showing ... Full text Link to item Cite

Development and validation of a risk model for in-hospital worsening heart failure from the Acute Decompensated Heart Failure National Registry (ADHERE).

Journal Article Am Heart J · August 2016 BACKGROUND: A subset of patients hospitalized with acute heart failure experiences in-hospital worsening heart failure, defined as persistent or worsening signs or symptoms requiring an escalation of therapy. METHODS: We analyzed data from the Acute Decomp ... Full text Link to item Cite

Laboratory Monitoring after Inpatient and Outpatient Initiation of Mineralocorticoid Receptor Antagonist Therapy in Patients with Heart Failure

Conference Journal of Cardiac Failure · August 2016 Full text Cite

Regional Differences during Acute Heart Failure Hospitalizations of Patients with Heart Failure with Preserved Ejection Fraction: Insights From ASCEND-HF

Conference Journal of Cardiac Failure · August 2016 Full text Cite

Plasma amino acid concentrations are independently associated with adverse outcomes in heart failure and preserved ejection fraction: prognostic utility of amino acid profiles in HFpEF

Conference European Heart Journal · August 1, 2016 Link to item Cite

Metabolomic Profiling Identifies Novel Circulating Biomarkers of Mitochondrial Dysfunction Differentially Elevated in Heart Failure With Preserved Versus Reduced Ejection Fraction: Evidence for Shared Metabolic Impairments in Clinical Heart Failure.

Journal Article J Am Heart Assoc · July 29, 2016 BACKGROUND: Metabolic impairment is an important contributor to heart failure (HF) pathogenesis and progression. Dysregulated metabolic pathways remain poorly characterized in patients with HF and preserved ejection fraction (HFpEF). We sought to determine ... Full text Open Access Link to item Cite

Finerenone in heart failure: walking a fine line.

Journal Article Eur Heart J · July 14, 2016 Full text Link to item Cite

Antihyperglycemic Medication Use Among Medicare Beneficiaries With Heart Failure, Diabetes Mellitus, and Chronic Kidney Disease.

Journal Article Circ Heart Fail · July 2016 BACKGROUND: Diabetes mellitus, heart failure (HF), and chronic kidney disease are common comorbidities, but overall use and safety of antihyperglycemic medications (AHMs) among patients with these comorbidities are poorly understood. METHODS AND RESULTS: U ... Full text Link to item Cite

Nesiritide in patients hospitalized for acute heart failure: does timing matter? Implication for future acute heart failure trials.

Journal Article Eur J Heart Fail · June 2016 AIMS: It remains unclear if early administration of i.v. nesiritide in patients hospitalized with acute heart failure (AHF) is associated with improved clinical outcomes. METHODS AND RESULTS: We analysed data from 7007 patients enrolled in ASCEND-HF to exa ... Full text Link to item Cite

Dichotomous Relationship Between Age and 30-Day Death or Rehospitalization in Heart Failure Patients Admitted With Acute Decompensated Heart Failure: Results From the ASCEND-HF Trial.

Journal Article J Card Fail · June 2016 BACKGROUND: Younger age as an independent predictor of death or all-cause rehospitalization at 30 days post-randomization for hospitalized heart failure (HF) patients has not been well described. METHODS AND RESULTS: ASCEND-HF enrolled 7141 hospitalized ac ... Full text Link to item Cite

Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF Trial).

Journal Article Am J Cardiol · June 1, 2016 A growing number of countries and geographical regions are involved in major clinical trials. Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure is the largest trial in acutely decompensated heart failure (HF) with patients ... Full text Link to item Cite

Precipitating Clinical Factors, Heart Failure Characterization, and Outcomes in Patients Hospitalized With Heart Failure With Reduced, Borderline, and Preserved Ejection Fraction.

Journal Article JACC Heart Fail · June 2016 OBJECTIVES: This study assessed the comparative frequency of precipitating clinical factors leading to hospitalization among heart failure (HF) patients with reduced, borderline, and preserved ejection fraction (EF) BACKGROUND: There are few data assessing ... Full text Link to item Cite

Response to Letter Regarding Article, "Temporal Trends and Variation in Early Scheduled Follow-up After a Hospitalization for Heart Failure: Findings from Get With The Guidelines-Heart Failure.

Journal Article Circ Heart Fail · June 2016 Full text Link to item Cite

Comparative Effectiveness of Cardiac Resynchronization Therapy Among Patients With Heart Failure and Atrial Fibrillation: Findings From the National Cardiovascular Data Registry's Implantable Cardioverter-Defibrillator Registry.

Journal Article Circ Heart Fail · June 2016 BACKGROUND: Atrial fibrillation is common in patients with heart failure, but outcomes of patients with both conditions who receive cardiac resynchronization therapy with defibrillator (CRT-D) compared with an implantable cardioverter-defibrillator (ICD) a ... Full text Link to item Cite

Trends in 30-Day Readmission Rates for Patients Hospitalized With Heart Failure: Findings From the Get With The Guidelines-Heart Failure Registry.

Journal Article Circ Heart Fail · June 2016 BACKGROUND: Reducing hospital readmissions for patients with heart failure is a national priority, and quality improvement campaigns are targeting reductions of ≥20%. However, there are limited data on whether such targets have been met. METHODS AND RESULT ... Full text Link to item Cite

Baseline Characteristics of Patients Enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)

Conference DIABETES · June 1, 2016 Link to item Cite

The effect of frequent hemodialysis on self-reported sleep quality: Frequent Hemodialysis Network Trials.

Journal Article Nephrol Dial Transplant · June 2016 BACKGROUND: Many patients who receive maintenance hemodialysis experience poor sleep. Uncontrolled studies suggest frequent hemodialysis improves sleep quality, which is a strong motivation for some patients to undertake the treatment. We studied the effec ... Full text Link to item Cite

Extended-Duration Thromboprophylaxis Among Acute Medically Ill Patients: An Unmet Need.

Journal Article J Cardiovasc Pharmacol Ther · May 2016 Acute medical illnesses are associated with a prolonged elevation in inflammatory markers that predisposes patients to thrombosis beyond the duration of their hospital stay. In parallel, both observational and randomized data have demonstrated a rate of po ... Full text Link to item Cite

Trends and outcomes of patients with adult congenital heart disease and pulmonary hypertension listed for orthotopic heart transplantation in the United States.

Journal Article J Heart Lung Transplant · May 2016 BACKGROUND: Heart transplantation is increasing in patients with adult congenital heart disease (ACHD). In this population, the association of pulmonary hypertension (PH) with post-transplant outcomes is not well-defined. METHODS: Using data from the Unite ... Full text Link to item Cite

Temporal Trends of Digoxin Use in Patients Hospitalized With Heart Failure: Analysis From the American Heart Association Get With The Guidelines-Heart Failure Registry.

Conference JACC Heart Fail · May 2016 OBJECTIVES: The aim of this study was to assess temporal trends and factors associated with digoxin use at discharge among patients admitted with heart failure (HF). BACKGROUND: Digoxin has class IIa recommendations for treating HF with reduced ejection fr ... Full text Link to item Cite

Association of Get With The Guidelines-Stroke Program Participation and Clinical Outcomes for Medicare Beneficiaries With Ischemic Stroke.

Journal Article Stroke · May 2016 BACKGROUND AND PURPOSE: Get With The Guidelines (GWTG)-Stroke is a national, hospital-based quality improvement program developed by the American Heart Association. Although studies have suggested improved processes of care in GWTG-Stroke-participating hos ... Full text Link to item Cite

Oral Iron Therapy for Heart Failure With Reduced Ejection Fraction: Design and Rationale for Oral Iron Repletion Effects on Oxygen Uptake in Heart Failure.

Journal Article Circ Heart Fail · May 2016 UNLABELLED: : Iron deficiency is present in ≈50% of patients with heart failure and is an independent predictor of mortality. Despite growing recognition of the functional and prognostic significance of iron deficiency, randomized multicenter trials explor ... Full text Link to item Cite

Response to Letter Regarding Article, "Comparative Effectiveness of Implantable Cardioverter Defibrillators for Primary Prevention in Women".

Journal Article Circ Heart Fail · May 2016 Full text Link to item Cite

VTE Prevention in Acutely Ill Medical Patients with Extended Duration Betrixaban - A Multicenter, Randomized, Active-Controlled Efficacy and Safety Study Comparing Extended Duration Betrixaban with Standard of Care Enoxaparin

Journal Article JOURNAL OF THROMBOSIS AND HAEMOSTASIS · May 1, 2016 Link to item Cite

Liver function tests in patients with acute heart failure and associated outcomes: insights from ASCEND-HF.

Journal Article Eur J Heart Fail · April 2016 AIMS: We aimed to characterize abnormal liver function tests in patients with heart failure (HF), as they are commonly encountered yet poorly defined. METHODS AND RESULTS: We used data from ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in ... Full text Link to item Cite

Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial.

Journal Article Am Heart J · April 2016 Exenatide once-weekly is an extended release formulation of exenatide, a glucagon-like peptide-1 receptor agonist, which can improve glycemic control, body weight, blood pressure, and lipid levels in patients with type 2 diabetes mellitus (T2DM). The EXena ... Full text Link to item Cite

Post-discharge Follow-up Characteristics Associated With 30-Day Readmission After Heart Failure Hospitalization.

Journal Article Med Care · April 2016 BACKGROUND: Readmission within 30 days after hospitalization for heart failure (HF) is a major public health problem. OBJECTIVE: To examine whether timing and type of post-discharge follow-up impacts risk of 30-day readmission in adults hospitalized for HF ... Full text Link to item Cite

THE ROLE OF IMPLANTABLE CARDIOVERTER DEFIBRILLATORS (ICDS) IN PATIENTS WITH A LEFT VENTRICULAR ASSIST DEVICE (LVAD): A SYSTEMATIC REVIEW AND META-ANALYSIS

Conference Journal of the American College of Cardiology · April 2016 Full text Cite

Implications of Amiodarone Use Before Heart Transplantation

Conference The Journal of Heart and Lung Transplantation · April 2016 Full text Cite

INFLUENCE OF CLINICAL TRIAL SITE ENROLLMENT ON PATIENT CHARACTERISTICS, PROTOCOL COMPLETION, AND ENDPOINTS: INSIGHTS FROM THE ASCEND-HF TRIAL

Conference Journal of the American College of Cardiology · April 2016 Full text Cite

THE RELATIONSHIP BETWEEN BODY WEIGHT CHANGE DURING HOSPITALIZATION FOR ACUTE HEART FAILURE AND PATIENT CHARACTERISTICS, MARKERS OF CONGESTION, AND OUTCOMES: FINDINGS FROM ASCEND-HF

Conference Journal of the American College of Cardiology · April 2016 Full text Cite

PROGNOSTIC VALUE OF RIGHT-SIDED VOLUME OVERLOAD IN PATIENTS PRESENTING WITH ACUTE HEART FAILURE: INSIGHTS FROM ASCEND-HF

Conference Journal of the American College of Cardiology · April 2016 Full text Cite

Arrival by ambulance in acute heart failure: insights into the mode of presentation from Acute Studies of Nesiritide in Decompensated Heart Failure (ASCEND-HF).

Journal Article BMJ Open · March 17, 2016 OBJECTIVES: Limited data exist assessing the relationship between ambulance versus self-presentation and outcomes in patients with acute heart failure (AHF). SETTING: Clinical trial sites in North America. PARTICIPANTS: 1068 patients enrolled in the Acute ... Full text Link to item Cite

Relation of Elevated Heart Rate in Patients With Heart Failure With Reduced Ejection Fraction to One-Year Outcomes and Costs.

Journal Article Am J Cardiol · March 15, 2016 There are limited data describing outcomes associated with an elevated heart rate in patients with heart failure with reduced ejection fraction (HFrEF) in routine clinical practice. We identified patients with HFrEF at Duke University Hospital undergoing e ... Full text Link to item Cite

Cardiac transplantation for older patients: Characteristics and outcomes in the septuagenarian population.

Journal Article J Heart Lung Transplant · March 2016 BACKGROUND: With increasing age of patients with heart failure, it is important to understand the potential role for orthotopic heart transplant (OHT) in elderly patients. We examined recipient and donor characteristics and long-term outcomes of older reci ... Full text Link to item Cite

The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCEND-HF.

Journal Article Eur J Heart Fail · March 2016 AIMS: A longitudinal and comprehensive analysis of health-related quality of life (HRQOL) was performed during hospitalization for heart failure (HF) or soon after discharge. METHODS AND RESULTS: A post-hoc analysis was performed of the ASCEND-HF trial. Th ... Full text Link to item Cite

Increased mortality with elevated plasma endothelin-1 in acute heart failure: an ASCEND-HF biomarker substudy.

Journal Article Eur J Heart Fail · March 2016 AIMS: Endothelin-1 (ET-1) is an endogenous vasoconstrictor implicated in pulmonary and systemic hypertension, as well as ventricular dysfunction, through effects on vascular smooth muscle, the kidneys, and cardiomyocytes. We aimed to determine the associat ... Full text Link to item Cite

Discharge heart rate and β-blocker dose in patients hospitalized with heart failure: Findings from the OPTIMIZE-HF registry.

Journal Article Am Heart J · March 2016 BACKGROUND: Elevated heart rate of ≥70 beats/min despite β-blocker use may represent a new treatment target in patients in sinus rhythm with heart failure with reduced ejection fraction. However, little is known about the proportion of patients with elevat ... Full text Link to item Cite

Assessment of Home-Time After Acute Ischemic Stroke in Medicare Beneficiaries.

Journal Article Stroke · March 2016 BACKGROUND AND PURPOSE: Stroke survivors have identified home-time as a meaningful outcome. We evaluated home-time as a patient-centered outcome in Medicare beneficiaries with ischemic stroke in comparison with modified Rankin Scale (mRS) score at 90 days ... Full text Link to item Cite

Statin use, intensity, and 3-year clinical outcomes among older patients with coronary artery disease.

Journal Article Am Heart J · March 2016 BACKGROUND: Clinical trial evidence suggests that statin therapy reduces adverse clinical events and provides even greater benefit at high-intensity doses in coronary artery disease (CAD) patients, yet few studies have examined this in clinical practice. M ... Full text Link to item Cite

Has Public Reporting of Hospital Readmission Rates Affected Patient Outcomes?: Analysis of Medicare Claims Data.

Journal Article J Am Coll Cardiol · March 1, 2016 BACKGROUND: In 2009, the Centers for Medicare & Medicaid Services (CMS) began publicly reporting 30-day hospital readmission rates for patients discharged with acute myocardial infarction (MI), heart failure (HF), or pneumonia. OBJECTIVES: This study asses ... Full text Link to item Cite

Good Clinical Practice Guidance and Pragmatic Clinical Trials: Balancing the Best of Both Worlds.

Journal Article Circulation · March 1, 2016 Randomized, clinical trials are commonly regarded as the highest level of evidence to support clinical decisions. Good Clinical Practice guidelines have been constructed to provide an ethical and scientific quality standard for trials that involve human su ... Full text Link to item Cite

Utility of Patient-Reported Outcome Instruments in Heart Failure.

Journal Article JACC Heart Fail · March 2016 Patient-reported outcomes (PRO) are defined as reports coming directly from patients about how they feel or function in relation to a health condition and its therapy. Although there are numerous compelling reasons why PRO could be an important help in cli ... Full text Link to item Cite

Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial).

Journal Article Am J Cardiol · February 1, 2016 Furosemide is the most commonly used loop diuretic in patients with heart failure (HF) despite data suggesting potential pharmacologic and antifibrotic benefits with torsemide. We investigated patients with HF in Acute Study of Clinical Effectiveness of Ne ... Full text Link to item Cite

Evaluation of a provocative dyspnea severity score in acute heart failure.

Journal Article Am Heart J · February 2016 BACKGROUND: The acute heart failure (AHF) Syndromes International Working Group proposed that dyspnea be assessed under standardized, incrementally provocative maneuvers and called for studies to assess the feasibility of this approach. We sought to assess ... Full text Link to item Cite

Clinical Effectiveness of Hydralazine-Isosorbide Dinitrate Therapy in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Get With The Guidelines-Heart Failure Registry.

Journal Article Circ Heart Fail · February 2016 BACKGROUND: In clinical trials, hydralazine-isosorbide dinitrate (H-ISDN) for heart failure with reduced ejection fraction reduced morbidity and mortality among black patients and patients with intolerance to angiotensin-converting enzyme inhibitors or ang ... Full text Link to item Cite

Sex and Race/Ethnicity-Related Disparities in Care and Outcomes After Hospitalization for Coronary Artery Disease Among Older Adults.

Journal Article Circ Cardiovasc Qual Outcomes · February 2016 BACKGROUND: It is unclear to what extent cardiovascular health disparities exist and can be modified among sexes, racial/ethnic groups, and geographic regions in US hospitals. METHODS AND RESULTS: We conducted a cohort study of 49 358 patients aged 65 year ... Full text Link to item Cite

Assessment of Home Time Following Acute Ischemic Stroke in Medicare Beneficiaries

Conference STROKE · February 1, 2016 Link to item Cite

The Association of Chronic Kidney Disease (CKD) With 30-day and 1-year Post Ischemic Stroke Mortality and Rehospitalization: Get With the Guidelines (GWTG) Stroke

Conference STROKE · February 1, 2016 Link to item Cite

Quality of Ischemic Stroke-related Care in Patients With Chronic Kidney Disease (CKD) on Dialysis: Findings From Get With the Guidelines-stroke

Conference STROKE · February 1, 2016 Link to item Cite

International Comparison of Patient Characteristics and Performance Measures in Acute Ischemic Stroke: Analysis of the American Heart Association Get With the Guidelines-Stroke Registry and China National Stroke Registry

Conference STROKE · February 1, 2016 Link to item Cite

Improving Door-to-Needle Times in Acute Ischemic Stroke: Interim Fundings From Target: Stroke Phase II

Conference STROKE · February 1, 2016 Link to item Cite

Equitable Improvements in Sex and Race/Ethnic Specific Door-to-Needle Times in Acute Ischemic Stroke: Findings From Target: Stroke Phase 1

Conference STROKE · February 1, 2016 Link to item Cite

Systematic Review of Radiographic and Symptomatic Brain Infarcts in Carotid Artery Interventions.

Conference STROKE · February 1, 2016 Link to item Cite

Intensification of Medication Therapy for Cardiorenal Syndrome in Acute Decompensated Heart Failure.

Journal Article J Card Fail · January 2016 BACKGROUND: Worsening renal function in heart failure may be related to increased venous congestion, decreased cardiac output, or both. Diuretics are universally used in acute decompensated heart failure, but they may be ineffective and may lead to azotemi ... Full text Link to item Cite

Risks and Benefits Associated With Prestroke Antiplatelet Therapy Among Patients With Acute Ischemic Stroke Treated With Intravenous Tissue Plasminogen Activator.

Journal Article JAMA Neurol · January 2016 IMPORTANCE: Intravenous tissue plasminogen activator (tPA) is known to improve outcomes in ischemic stroke; however, many patients may have been receiving antiplatelet therapy before acute ischemic stroke and could face an increased risk for bleeding when ... Full text Open Access Link to item Cite

Prognostic Value of Baseline and Changes in Circulating Soluble ST2 Levels and the Effects of Nesiritide in Acute Decompensated Heart Failure.

Journal Article JACC Heart Fail · January 2016 OBJECTIVES: The study sought to investigate the association between soluble growth stimulation expressed gene 2 (sST2) level and adverse outcomes in acute heart failure (HF). BACKGROUND: Several studies have demonstrated the prognostic utility of sST2 leve ... Full text Link to item Cite

Association of Arterial Pulse Pressure With Long-Term Clinical Outcomes in Patients With Heart Failure.

Journal Article JACC Heart Fail · January 2016 OBJECTIVES: This study assessed the association between pulse pressure (PP) and adverse outcomes at 1 year in patients hospitalized for heart failure (HF). BACKGROUND: PP has been shown to be predictive of the development of HF. The value and utility of PP ... Full text Link to item Cite

Comparative Effectiveness of Implantable Cardioverter Defibrillators for Primary Prevention in Women.

Journal Article Circ Heart Fail · January 2016 BACKGROUND: Clinical trials of implantable cardioverter defibrillators (ICDs) for primary prevention enrolled a limited number of women. We sought to examine clinical practice data to compare survival rates among women with heart failure with or without a ... Full text Link to item Cite

Temporal Trends and Variation in Early Scheduled Follow-Up After a Hospitalization for Heart Failure: Findings from Get With The Guidelines-Heart Failure.

Journal Article Circ Heart Fail · January 2016 BACKGROUND: Previous data demonstrate early follow-up (ie, within 7 days of discharge) after a hospitalization for heart failure is associated with a lower risk of readmission, yet is uncommon and varies widely across hospitals. Limited data exist on wheth ... Full text Link to item Cite

Pulmonary Hypertension in the Era of Mechanical Circulatory Support.

Journal Article ASAIO J · 2016 Left heart disease (LHD) represents the most common cause of pulmonary hypertension (PH), and is associated with worse prognosis compared with LHD without PH. In addition, PH due to LHD may prevent patients from receiving heart transplantation, because of ... Full text Link to item Cite

Left Atrial Structure and Function in Heart Failure with Preserved Ejection Fraction: A RELAX Substudy.

Journal Article PLoS One · 2016 Given the emerging recognition of left atrial structure and function as an important marker of disease in heart failure with preserved ejection fraction (HF-pEF), we investigated the association between left atrial volume and function with markers of disea ... Full text Link to item Cite

Global Metabolomic Profiling in Heart Failure With Preserved Ejection Fraction Identifies Markers of Myocardial Dysfunction

Conference Circulation Journal · 2016 Cite

Design and Architecture of a Distributed Network Pragmatic Clinical Trial: The PCORnet ADAPTABLE Study.

Conference CRI · 2016 Cite

Comparative Effectiveness of CRT-D Versus Defibrillator Alone in HF Patients With Moderate-to-Severe Chronic Kidney Disease.

Journal Article J Am Coll Cardiol · December 15, 2015 BACKGROUND: Patients with moderate-to-severe chronic kidney disease (CKD) are poorly represented in clinical trials of cardiac resynchronization therapy (CRT). OBJECTIVES: This study sought to assess the real-world comparative effectiveness of CRT with def ... Full text Link to item Cite

Late-Breaking Clinical Trial Abstracts

Conference Circulation · December 8, 2015 Full text Cite

Differences in health care use and outcomes by the timing of in-hospital worsening heart failure.

Journal Article Am Heart J · December 2015 BACKGROUND: Patients hospitalized with acute heart failure may experience worsening symptoms requiring escalation of therapy. In-hospital worsening heart failure is associated with worse in-hospital and postdischarge outcomes, but associations between the ... Full text Link to item Cite

Consistency of Laboratory Monitoring During Initiation of Mineralocorticoid Receptor Antagonist Therapy in Patients With Heart Failure.

Journal Article JAMA · November 10, 2015 Full text Link to item Cite

Regulatory Implications of Different Definitions and Outcomes in Worsening Heart Failure

Conference CIRCULATION · November 10, 2015 Link to item Cite

The Potential Impact of Expanding Cardiac Rehabilitation Coverage in Heart Failure: Insights From Get With the Guidelines Heart Failure

Conference CIRCULATION · November 10, 2015 Link to item Cite

Identifying Patients With Acute Heart Failure who Require a Critical Care Admission: ASCEND-HF Insights

Conference CIRCULATION · November 10, 2015 Link to item Cite

Sex and Race Related Disparities in Care and Outcomes After Hospitalization for Coronary Artery Disease Among Older Adults

Conference CIRCULATION · November 10, 2015 Link to item Cite

Years of Life Lost Due to Heart Failure in the United States (US)

Conference CIRCULATION · November 10, 2015 Link to item Cite

The Association Between Blood Pressure Control and Outcomes Among Black Participants in the Jackson Heart Study

Conference CIRCULATION · November 10, 2015 Link to item Cite

Measuring heart failure quality: does perfection matter?

Journal Article Heart · November 2015 Full text Link to item Cite

Characteristics, Treatments, and Outcomes of Hospitalized Heart Failure Patients Stratified by Etiologies of Cardiomyopathy.

Journal Article JACC Heart Fail · November 2015 OBJECTIVES: The authors sought to describe characteristics, treatments, and in-hospital outcomes of hospitalized heart failure (HF) patients stratified by etiology. BACKGROUND: Whether characteristics and outcomes of HF patients differ by cardiomyopathy et ... Full text Link to item Cite

Depressive Symptoms and Risk of Cardiovascular Events in Blacks: Findings From the Jackson Heart Study.

Journal Article Circ Cardiovasc Qual Outcomes · November 2015 BACKGROUND: Most studies of depression and cardiovascular risk have been conducted in white populations. We investigated this association in a community-based cohort of blacks. METHODS AND RESULTS: We used data from the Jackson Heart Study to investigate a ... Full text Link to item Cite

The ADAPTABLE Trial and PCORnet: Shining Light on a New Research Paradigm.

Journal Article Ann Intern Med · October 20, 2015 Full text Link to item Cite

Clinical Effectiveness of Statin Therapy After Ischemic Stroke: Primary Results From the Statin Therapeutic Area of the Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) Study.

Journal Article Circulation · October 13, 2015 BACKGROUND: In patients with ischemic stroke, data on the real-world effectiveness of statin therapy for clinical and patient-centered outcomes are needed to better inform shared decision making. METHODS AND RESULTS: Patient-Centered Research Into Outcomes ... Full text Link to item Cite

Medication Initiation Burden Required to Comply With Heart Failure Guideline Recommendations and Hospital Quality Measures.

Journal Article Circulation · October 6, 2015 BACKGROUND: Guidelines for heart failure (HF) recommend prescription of guideline-directed medical therapy before hospital discharge; some of these therapies are included in publicly reported performance measures. The burden of new medications for individu ... Full text Link to item Cite

What's Harder: Seeing a Doctor or Reducing Readmissions?

Journal Article JACC Heart Fail · October 2015 Full text Open Access Link to item Cite

Circulating Kidney Injury Molecule-1 Levels in Acute Heart Failure: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure).

Journal Article JACC Heart Fail · October 2015 OBJECTIVES: This study sought to determine the relationship of KIM-1 levels with adverse clinical outcomes in acute decompensated heart failure (ADHF). BACKGROUND: Kidney injury molecule (KIM)-1 is a biomarker expressed by the nephron in acute tubular inju ... Full text Link to item Cite

Smoking Paradox in Patients Hospitalized With Coronary Artery Disease or Acute Ischemic Stroke: Findings From Get With The Guidelines.

Journal Article Circ Cardiovasc Qual Outcomes · October 2015 BACKGROUND: Smoking is a potent risk factor for coronary artery disease (CAD) and acute ischemic stroke (AIS), but there are numerous reports of lower in-hospital mortality among smokers versus nonsmokers hospitalized for these events. METHODS AND RESULTS: ... Full text Link to item Cite

Quality of Care and Ischemic Stroke Risk After Hospitalization for Transient Ischemic Attack: Findings From Get With The Guidelines-Stroke.

Journal Article Circ Cardiovasc Qual Outcomes · October 2015 BACKGROUND: Patients with transient ischemic attack (TIA) are at increased risk for ischemic stroke. We derived a prediction rule for 1-year ischemic stroke risk post-TIA, examining estimated risk, receipt of inpatient quality of care measures for TIA, and ... Full text Link to item Cite

Temporal Trends and Factors Associated With Cardiac Rehabilitation Referral Among Patients Hospitalized With Heart Failure: Findings From Get With The Guidelines-Heart Failure Registry.

Journal Article J Am Coll Cardiol · August 25, 2015 BACKGROUND: Current guidelines recommend cardiac rehabilitation (CR) in medically stable outpatients with heart failure (HF); however, temporal trends and factors associated with CR referral among these patients in real-world practice are not entirely know ... Full text Link to item Cite

Acute Heart Failure and Atrial Fibrillation: Insights From the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) Trial.

Journal Article J Am Heart Assoc · August 24, 2015 BACKGROUND: Patients with acute heart failure (AHF) frequently have atrial fibrillation (AF), but how this affects patient-reported outcomes has not been well characterized. METHODS AND RESULTS: We examined dyspnea improvement and clinical outcomes in 7007 ... Full text Link to item Cite

Comparison of 2-Year Outcomes of Extended Criteria Cardiac Transplantation Versus Destination Left Ventricular Assist Device Therapy Using Continuous Flow.

Journal Article Am J Cardiol · August 15, 2015 Alternatives have emerged for patients ineligible for cardiac transplantation under standard criteria. The purpose of our study was to compare outcomes in patients ineligible for cardiac transplantation under standard criteria, treated either with extended ... Full text Link to item Cite

Association Between Comorbidities and Outcomes in Heart Failure Patients With and Without an Implantable Cardioverter-Defibrillator for Primary Prevention.

Journal Article J Am Heart Assoc · August 6, 2015 BACKGROUND: Implantable cardioverter-defibrillator (ICD) therapy is associated with improved outcomes in patients with heart failure (HF), but whether this association holds among older patients with multiple comorbid illnesses and worse HF burden remains ... Full text Open Access Link to item Cite

Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C.

Journal Article Hepatology · August 2015 UNLABELLED: Treatment for chronic hepatitis C virus (HCV) infection is evolving from interferon (IFN)-based therapy to direct-acting antiviral (DAA) agents, yet some safety concerns have arisen involving cardiac toxicity. In this study, we sought to better ... Full text Link to item Cite

Heart Failure in Non-Caucasians, Women, and Older Adults: A White Paper on Special Populations From the Heart Failure Society of America Guideline Committee.

Journal Article J Card Fail · August 2015 The presentation, natural history, clinical outcomes, and response to therapy in patients with heart failure differ in some ways across populations. Women, older adults, and non-Caucasian racial or ethnic groups compose a substantial proportion of the over ... Full text Link to item Cite

Worsening heart failure during hospitalization for acute heart failure: Insights from the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF).

Journal Article Am Heart J · August 2015 BACKGROUND: Despite initial in-hospital treatment of acute heart failure (HF), some patients experience worsening HF (WHF). There are limited data about the outcomes and characteristics of patients who experience in-hospital WHF. METHODS AND RESULTS: We as ... Full text Link to item Cite

Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure outcome models.

Journal Article Am Heart J · August 2015 BACKGROUND: Patients hospitalized for acute decompensated heart failure (ADHF) are at high risk for early mortality and rehospitalization. Risk stratification of ADHF using clinically available data on admission is increasingly important to integrate with ... Full text Link to item Cite

Diuretic response in acute heart failure-an analysis from ASCEND-HF.

Journal Article Am Heart J · August 2015 BACKGROUND: Diuretic unresponsiveness often occurs during hospital admission for acute heart failure (AHF) and is associated with adverse outcome. This study aims to investigate determinants, clinical outcome, and the effects of nesiritide on diuretic resp ... Full text Link to item Cite

Elevated Heart Rate in Patients with Heart Failure with Reduced Ejection Fraction: Associations with One-Year Survival and Costs

Conference Journal of Cardiac Failure · August 2015 Full text Cite

Novel Protein Glycan Inflammatory Biomarkers Predict Adverse Events in Heart Failure with Preserved Ejection Fraction

Conference Journal of Cardiac Failure · August 2015 Full text Cite

The Clinical Implications of Cardiac Troponin I Measured by an “Ultrasensitive” Assay in Acute Decompensated Heart Failure: Insights from ASCEND-HF

Conference Journal of Cardiac Failure · August 2015 Full text Cite

Elevated Total Bilirubin on Admission is a Marker of Worse 30- and 180-Day Outcomes for Patients With Acute HF: Insights From ASCEND-HF

Conference Journal of Cardiac Failure · August 2015 Full text Cite

Lack of Improvement in 30-day Readmission Rates for Patients Hospitalized with Heart Failure: Data from Get With The Guidelines-Heart Failure Registry

Conference Journal of Cardiac Failure · August 2015 Full text Cite

Trends in the Use of Guideline-based Therapies Among Dialysis Patients Hospitalized with Heart Failure: Findings from Get With The Guidelines-Heart Failure

Conference Journal of Cardiac Failure · August 2015 Full text Cite

Real world effectiveness of warfarin among ischemic stroke patients with atrial fibrillation: observational analysis from Patient-Centered Research into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) study.

Journal Article BMJ · July 31, 2015 OBJECTIVE: To examine the association between warfarin treatment and longitudinal outcomes after ischemic stroke in patients with atrial fibrillation in community practice. DESIGN: Observational study. SETTING: Hospitals (n = 1487) participating in the Get ... Full text Open Access Link to item Cite

Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure: Insights From Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARESS-HF).

Journal Article Circ Heart Fail · July 2015 BACKGROUND: Congestion is the most frequent cause for hospitalization in acute decompensated heart failure. Although decongestion is a major goal of acute therapy, it is unclear how the clinical components of congestion (eg, peripheral edema, orthopnea) co ... Full text Open Access Link to item Cite

Patient-Centered Research into Outcomes Stroke Patients Prefer and Effectiveness Research: Implementing the patient-driven research paradigm to aid decision making in stroke care.

Journal Article Am Heart J · July 2015 BACKGROUND: Stroke is common and costly, annually depriving the lives and well-being of 800,000 Americans. Despite demonstrated efficacy in clinical trials, questions remain about the safety and clinical effectiveness of various treatment options given pat ... Full text Link to item Cite

Novel Oral Anticoagulant Use Among Patients With Atrial Fibrillation Hospitalized With Ischemic Stroke or Transient Ischemic Attack.

Journal Article Circ Cardiovasc Qual Outcomes · July 2015 BACKGROUND: Novel oral anticoagulants (NOACs) have been shown to be at least as good as warfarin for preventing stroke or transient ischemic attack in patients with atrial fibrillation, yet diffusion of these therapies and patterns of use among atrial fibr ... Full text Link to item Cite

Assessing the Quality and Comparative Effectiveness of Team-Based Care for Heart Failure: Who, What, Where, When, and How.

Journal Article Heart Fail Clin · July 2015 Team-based or multidisciplinary care may be a potential way to positively impact outcomes for heart failure (HF) patients by improving clinical outcomes, managing patient symptoms, and reducing costs. The multidisciplinary team includes the HF cardiologist ... Full text Link to item Cite

Cluster-Randomized Trial of Personalized Site Performance Feedback in Get With The Guidelines-Heart Failure.

Journal Article Circ Cardiovasc Qual Outcomes · July 2015 BACKGROUND: There is significant variation in the delivery of evidence-based care for patients with heart failure (HF), but there is limited evidence defining the best methods to improve the quality of care. METHODS AND RESULTS: We performed a cluster-rand ... Full text Link to item Cite

The future of cardiovascular clinical research in North America and beyond-addressing challenges and leveraging opportunities through unique academic and grassroots collaborations.

Journal Article Am Heart J · June 2015 Recent developments have highlighted the challenges facing cardiovascular clinical research in global contemporary practice, particularly in North America, including shifting priorities for drug development targets, increasing regulatory requirements, and ... Full text Link to item Cite

Advanced (stage D) heart failure: a statement from the Heart Failure Society of America Guidelines Committee.

Journal Article J Card Fail · June 2015 We propose that stage D advanced heart failure be defined as the presence of progressive and/or persistent severe signs and symptoms of heart failure despite optimized medical, surgical, and device therapy. Importantly, the progressive decline should be pr ... Full text Link to item Cite

Does Age Influence Cardiac Resynchronization Therapy Use and Outcome?

Journal Article JACC Heart Fail · June 2015 OBJECTIVES: This study sought to describe the use of CRT-D and its association with survival for older patients. BACKGROUND: Many patients who receive cardiac resynchronization therapy with defibrillator (CRT-D) in practice are older than those included in ... Full text Link to item Cite

Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study.

Journal Article Circulation · May 19, 2015 BACKGROUND: Oxidative stress may contribute to heart failure (HF) progression. Inhibiting xanthine oxidase in hyperuricemic HF patients may improve outcomes. METHODS AND RESULTS: We randomly assigned 253 patients with symptomatic HF, left ventricular eject ... Full text Link to item Cite

Lack of impact of electronic health records on quality of care and outcomes for ischemic stroke.

Journal Article J Am Coll Cardiol · May 12, 2015 BACKGROUND: Electronic health records (EHRs) may be key tools for improving the quality of health care, particularly for conditions for which guidelines are rapidly evolving and timely care is critical, such as ischemic stroke. OBJECTIVES: The goal of this ... Full text Link to item Cite

Utility of socioeconomic status in predicting 30-day outcomes after heart failure hospitalization.

Journal Article Circ Heart Fail · May 2015 BACKGROUND: An individual's socioeconomic status (SES) is associated with health outcomes and mortality, yet it is unknown whether accounting for SES can improve risk-adjustment models for 30-day outcomes among Centers for Medicare & Medicaid Services bene ... Full text Link to item Cite

Heart rate at hospital discharge in patients with heart failure is associated with mortality and rehospitalization.

Journal Article J Am Heart Assoc · April 22, 2015 BACKGROUND: Whether heart rate upon discharge following hospitalization for heart failure is associated with long-term adverse outcomes and whether this association differs between patients with sinus rhythm (SR) and atrial fibrillation (AF) have not been ... Full text Link to item Cite

ACP Journal Club: pooled RCTs: β-blockers reduce mortality in heart failure patients with sinus rhythm but not in those with AF.

Journal Article Ann Intern Med · April 21, 2015 Full text Link to item Cite

Temporal trends for secondary prevention measures among patients hospitalized with coronary artery disease.

Journal Article Am J Med · April 2015 BACKGROUND: Prior studies have noted that in-hospital adherence to secondary prevention measures varied among patients undergoing coronary artery bypass graft surgery, percutaneous coronary revascularization, or no intervention. We sought to study contempo ... Full text Link to item Cite

Trends in endovascular therapy and clinical outcomes within the nationwide Get With The Guidelines-Stroke registry.

Journal Article Stroke · April 2015 BACKGROUND AND PURPOSE: We sought to determine hospital and patient characteristics associated with the use of endovascular therapy for acute ischemic stroke and to analyze trends in clinical outcome. METHODS: Data were from Get With The Guidelines-Stroke ... Full text Link to item Cite

Results of the Chronic Heart Failure Intervention to Improve MEdication Adherence study: A randomized intervention in high-risk patients.

Journal Article Am Heart J · April 2015 BACKGROUND: Poor adherence to evidence-based medications in heart failure (HF) is a major cause of avoidable hospitalizations, disability, and death. To test the feasibility of improving medication adherence, we performed a randomized proof-of-concept stud ... Full text Open Access Link to item Cite

Results of the chronic heart failure intervention to improve medication adherence study: A randomized intervention in high-risk patients

Journal Article American Heart Journal · April 1, 2015 Background Poor adherence to evidence-based medications in heart failure (HF) is a major cause of avoidable hospitalizations, disability, and death. To test the feasibility of improving medication adherence, we performed a randomized proof-of-concept study ... Full text Open Access Cite

Same-day discharge and risks of mortality and readmission after elective ICD placement for primary prevention.

Journal Article J Am Coll Cardiol · March 10, 2015 Full text Link to item Cite

Loop diuretic dose adjustments after a hospitalization for heart failure: insights from ASCEND-HF.

Conference Eur J Heart Fail · March 2015 AIMS: Loop diuretics are a cornerstone of heart failure (HF) treatment, but data regarding diuretic dose adjustments after a HF hospitalization and the association with subsequent outcomes are limited. This study was therefore conducted to determine these ... Full text Link to item Cite

Ventricular conduction and long-term heart failure outcomes and mortality in African Americans: insights from the Jackson Heart Study.

Journal Article Circ Heart Fail · March 2015 BACKGROUND: QRS prolongation is associated with adverse outcomes in mostly white populations, but its clinical significance is not well established for other groups. We investigated the association between QRS duration and mortality in African Americans. M ... Full text Open Access Link to item Cite

Correlation between peak expiratory flow rate and NT-proBNP in patients with acute heart failure. An analysis from ASCEND-HF trial.

Journal Article Int J Cardiol · March 1, 2015 Full text Link to item Cite

Implementation of management strategies for diabetes and hypertension: from local to global health in cardiovascular diseases.

Journal Article Glob Heart · March 2015 Diabetes and hypertension are chronic conditions that are growing in prevalence as major causal factors of cardiovascular disease (CVD). The need for chronic-illness surveillance, population-risk management, and successful treatment interventions are cruci ... Full text Link to item Cite

Transitions of care in heart failure: a scientific statement from the American Heart Association.

Journal Article Circ Heart Fail · March 2015 In patients with heart failure (HF), use of 30-day rehospitalization as a healthcare metric and increased pressure to provide value-based care compel healthcare providers to improve efficiency and to use an integrated care approach. Transition programs are ... Full text Link to item Cite